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Chapter 1 
General introduction 
General introduction 
Each stage in the clinical evaluation of an anti-tumor treatment has potential practical 
and ethical difficulties. In diseases for which there is no generally accepted 'standard 
treatment' a new scheme may be tried as the first treatment, providing the patient is 
fully informed. The situation is rather different where regimens with favorable responses 
for a particular disease already exist. In this setting, if a new regimen is to demonstrate 
to be of value, it would have to be more effective than the standard treatment. It is 
possible that potentially valuable regimens may be discarded. 
From the early period of radiotherapy, efforts have been made to obtain clinical 
information of a possible predictive value of the treatment for a given kind of tumor. 
There has been and is an obvious need to assist the physician in deciding on the plan of 
management of the individual patient. Questions asked are: should radiation alone be 
employed and if so, to what dose level; should radiation be combined with surgery 
and/or drugs; should radiation fractionation be accelerated, or hyperfractionated? 
However, there is a realization that efforts to evaluate the efficacy of new strategies of 
treatment are, almost certainly, being confounded by heterogeneity of tumors with 
reference to the tumor characteristic with which the new treatment is designed to deal. 
In the clinical situation, in trials of new treatment strategies, patients should be 
stratified not only on the basis of the clinically proven predictors but also on the basis 
of the physiological or other characteristics which defeat standard treatment. Such trials 
are time consuming due to the required number of patients in each experimental arm of 
the trial, and due to the time required to evaluate the treatment responses. For this 
reason model systems have been developed to study the treatment responses of (tumor) 
cells, and determine the effectiveness of a new treatment approach at the preclinical 
level. In this first chapter some in vivo and in vitro models presently used in 
radiobiology will be discussed. In chapter 2 the in vitro spheroid model will be described 
in greater detail before outlining the purposes of the present investigation. 
IN VIVO MODELS 
Murine and rat models have been used by many investigators in studies aimed at 
improving the radio- and chemotherapy of human cancer. Valuable information on the 
biology of solid tumors has thus been obtained. With the various animal tumor models 
available, data have been obtained on changes in cell cycle duration, fractions of 
quiescent cells, cell loss factors, fraction of hypoxic cells, reoxygenation rate, capillary 
blood flow, repair of radiation-induced damage (1). These phenomena have been studied 
with the aim to extrapolate the results to the human situation. It has been shown that 
this extrapolation presents serious problems since murine and rat tumors differ in many 
respects (cellular heterogeneity, growth rate) from human tumors (2,3). However, some 
of the draw-backs may be overcome by transplanting these tumors not in the flanks of 
the animal, as is the standard procedure, but in or near the organ from which the tumor 
originated. Krajewski et al. (4) implanted rat glioma cells under the dura mater of 
syngeneic rats. The growth pattern and invasion characteristics of these cells closely 
resembled those observed in the human situation. Kal and co-workers (5,6) transplanted 
rat lung tumor material into the lungs of syngeneic rats. Not only was the growth of 
lung implants slower than that of flank implants (5), being more comparable to lung 
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tumors in patients, but the sensitivity to chemotherapy of the two types of implants 
was also found to be different (6). 
Nevertheless, a simple experimental model for in vivo studies of human tumors 
may in some ways be preferable to rodent tumor systems. Recently, new and improved 
procedures for immuno-suppression of conventional mice and subsequent 
heterotransplantation of human tumors have been developed (7). For radiation studies 
these procedures were subsequently modified to obtain immuno-suppressed rats (8,9). In 
addition, congenitally athymic nude mice and rats have been shown to be useful as hosts 
for human tumor xenografts (10). No pretreatment of these animals is necessary, 
although the "take" rate of some tumors may be improved after whole-body irradiation 
or treatment with immuno-suppressive chemical agents (11). 
A major problem in studies of transplantable tumors, both of rodent and human 
origin, is that it requires a very large effort to investigate a sufficiently large number of 
tumors to evaluate. Although the implantation of human tumor xenografts in athymic 
or immuno-suppressed animals is reliable with regard to its accuracy for predicting the 
sensitivity to certain drugs (12), its expensive and time-consuming character will 
prevent individual patient testing. For this reason investigations have been mounted to 
develop in vitro models, which usually are cheaper and produce results within a short 
time-span. 
Barendsen and co-workers (13) have developed a number of different experimental 
tumors to compare their responsiveness to irradiation (14). The comparison of the 
radiation responses based on growth delay in vivo and on in vitro assays of 
clonogenicity showed that significant differences exist in responses to single and 
fractionated doses of radiation between these two assays. However, Slee et al. (15) 
compared an in vivo and an in vitro assay in 21 identical tumor specimens. Not 
surprisingly, major differences between the sensitivities as detected by the two assays 
were found (15). It must not be forgotten that assays that include disruption of the 
tumor's integrity also reflect the tumor cell's sensitivity to the disaggregation technique 
employed. This is reflected by the plating efficiency, that is less than 1% in many 
clonogenic assays. The sensitivity for disaggregation technique may vary between tumor 
types, or even between tumors of the same histological type, and perhaps is influenced 
by radiation dose. These considerations caution to compare different assays, and should 
encourage the use of assays that preserve tissue integrity. 
IN VITRO MODELS 
Most of the in vitro assays for human tumor material have been based upon the 
clonogenic stem cell assay introduced by Hamburger and Salmon (16). More recently 
several non-clonogenic assays have been developed. In radiotherapy the intrinsic cellular 
sensitivity is supposed to be significant in tumor response. 
The advantage of a clonogenic assay is that it is an accepted measure of cell 
survival. The human stem cell assay has been used extensively for drug and radiation 
testing and has the advantage that cloning of cells in soft agar is indicative of malignant 
cell growth. 
The stringent requirements of clonogenic assays, however, cannot usually be met in 
primary cultures from human tumors. The major problem is setting up an assay such 
that each colony arises from a single cell: large numbers of colonies arising from a 
clump of more than one cell results in too high an estimate of cell survival. Radiation 
experiments with primary human stem cell assays sometimes rendered radioresistant 
survival curve parameters that were biologically unlikely (17). Modifications of the 
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stem cell assay have been made to minimize the problem, but too many modifications 
tend to make an assay non-clonogenic. 
Rofstad et al. (18) presented radiation survival curves with exponential terminal 
slopes that were obtained with a modified Courtenay soft agar assay using human tumor 
cells. The problem of multiplicity due to small clumps was avoided by not performing 
assays if the cell suspensions contained doublets, and all cultures were screened after the 
first day for any clumps that might later be scored as colonies. This method may prove 
to be useful for drugs and radiation in clinical studies. However, the succes rate is not 
clear, and the number of cells required makes it inpractical to perform with biopsies. 
Non-clonogenic assays have common problems in that they are indirect measures of 
cell survival, therefore have to be validated against clonogenic assays, and they are 
usually accurate only under a defined range of conditions. These conditions that produce 
an accurate measure of cell survival are not always the same from one cell line to 
another, and especially not from one primary culture to another. Nonetheless, non-
clonogenic assays are important because they are designed to overcome the problems 
that often make clonogenic assays impossible. 
The MTT-assay as described by Carmichael et al. (19) is based upon the ability of 
living cells to reduce a tetrazolium salt (MTT) to an insoluable blue formazan product. 
Under the assumption that only living cells convert MIT to its cristalline form, cell 
killing is estimated by measuring the amount of blue material produced in treated 
cultures and comparing that value to controls. The presence in the starting population of 
cell clumps, dead cells, or abortive colonies will not influence the survival 
measurement. This assay yields comparable results to control and parallel clonogenic 
assays (19), and has probable potential as a method for screening new drugs. 
Due to the limited space available for cell growth in a multiwell plate the control 
cultures will reach a crowded state and slow their growth before treated cultures, which 
have more growth area per surviving cell due to cell killing. As a consequence, control 
and treated cultures have different rates of cell growth, producing fewer than expected 
total cells in control and low dose cultures which results in a "resistant" survival curve. 
Another in vitro model to test responses to radiation treatment currently undergoing 
extensive testing is the system developed by Baker et al. (20). In 24-well test plates that 
have had their surfaces coated with cell adhesion matrix (CAM) the attachment of cells 
and their growth is effectively promoted. Survival curves are established at different 
initial cell numbers and produce usuable data if they show a linear relationship between 
inoculated cell number and total growth. Treatments take place 24 hours after cultures 
are established, and the assay is terminated after a total of two weeks. The endpoint of 
the assay is the relative amount of crystal violet staining density in each culture, and 
experiments have shown that this value is directly related to the total cell number in 
each well. Therefore, this assay is based upon the relative two-week growth potential of 
cells that survive cytotoxic treatment. 
Similar to the MTT assay described before, this assay is subject to several problems 
that, unless properly controlled, will render the assay useless. Using a relationship 
between staining density and cell survival it is assumed that all surviving cells produce 
the same total number of progeny during the culture period. Especially after radiation 
treatment this assumption cannot be true under all conditions due to e.g. radiation-
induced division delay which is dose dependent. Only if several assumptions are true, 
than results will correspond with clonogenic cell survival. Since most of the factors 
required to be constant are dose dependent in radiation experiments, it remains uncertain 
whether non-clonogenic assays can provide an accurate estimate of clonogenic survival 
after radiation treatment. 
A model of intermediate complexity between monolayer culture systems and in vivo 
tumors for radiobiological studies was described by Sutherland and co-workers (21). As 
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an in vitro model it is easy to manipulate and offers a three-dimensional structure that 
resembles a-vascular micrometastases and cells in the vicinity of blood vessels. 

Chapter 2 
Multicellular tumor spheroids in 
radiotherapy research 
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Multicellular tumor spheroids io radiotherapy 
As a tool in the study of radiation responses of tumor cells, these cells can be cultured 
in the form of three-dimensional multicellular spheroids that simulate micrometastases 
of intervascular microregions of larger tumors (22,23). Experimentally induced 
aggregates of animal cells have been in use since the pioneering studies of Holtfreter 
(24). Systematic experiments were performed by Moscona (25) to assess the capacity of 
embryonic and malignant cells for reaggregation, proliferation, and differentiation. In 
particular, the invasive potential of melanoma cells was demonstrated in vitro (25). 
Studies on the response of cell aggregates to radiation therapy were initiated by 
Sutherland and co-workers (21,26,27). Because of the almost perfect spherical shape, the 
aggregates were termed "multicellular spheroids". Since cell survival curves obtained in 
radiation experiments either with aggregates or with solid tumors were similar (21,26), 
multicellular spheroids were henceforth considered to be in vitro models for mimicking 
basic biological properties of tumor cells in vivo. 
This chapter is focussed on recent publications on the use of spheroids in 
radiotherapy research. Reports older than four years are essentially referred to through 
previously published reviews (28,29). 
GROWTH OF SPHEROIDS 
Spheroids exhibit a histological structure similar to that of solid tumors. This holds for 
the distribution of vital and necrotic areas, and for the histologic appearance. It is a 
general finding that the degree of structural and functional differentiation in the primary 
tumor may be retained in spheroids rather than in conventional monolayer cultures. 
Spheroids have an outer layer of proliferating cells and an inside layer of mainly 
non-proliferating cells. In the central area of spheroids with diameters larger than 350-
500 μιη, there are often massive necrotic areas. This composition is similar to that of 
solid tumor nodules containing proliferating cells close to the capillaries, quiescent cells 
next to these and necrotic areas at larger distances. 
As the growth of spheroids progresses, the number of cells that are proliferating 
decreases, and the proportion of quiescent, non-proliferating cells, increases. When the 
cells become deprived of O2, glucose, and other substrates, and when toxic metabolic 
waste products accumulate, there are steep gradients in these metabolites, and cell death 
and necrosis will occur in the centers of the spheroids. The distance from the periphery 
of the spheroid at which necrosis occurs may vary from 50 to 300 μιη, depending on the 
cell type, and the concentrations of substrates in the tissue culture media (30). For most 
types of human tumor cells grown under optimal nutrient and oxygen conditions, the 
thickness of the rim of viable cells ranges from 100 to 220 μιη. 
CULTURING OF SPHEROIDS 
There are two main methods in use to grow spheroids in culture: spinner flask culture 
(21) and liquid overlay culture (31,32). The two techniques are often combined in that 
aggregates are induced in liquid overlay culture and transferred to spinner flasks for long 
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term culture. In the liquid overlay culture technique, the spheroids are cultured in a static 
medium above an agarose gel which prevents the attachment to the bottom of dishes. 
The spinner flask technique employs siliconated spinner flasks in which tumor cell 
aggregates are formed which subsequently grow as spheroids. The spinner flask is very 
suitable for the production of large amounts of similarly sized spheroids, whereas in 
liquid overlay, spheroids can be individually assessed for their response to treatment. 
However, not all types of tumor cells can grow as spheroids in liquid overlay or spinner 
flask culture. Also, the two techniques invoke different growth patterns in spheroids of 
the same origin and concommittant differences in oxygenation status (33). 
METHODS TO STUDY RADIATION RESPONSES IN SPHEROIDS 
1. Chnogenic assay of single cells. 
The response of a spheroid is a complex summation of the individual responses of cells 
that comprise a spheroid. Characterization of each individual cell of the population 
would give, after summation, the response of the spheroid as a whole. A number of 
problems arise, the foremost of which is the necessity to define the criteria of cell 
viability: histologic viability is feasible under some circumstances, but functional 
viability, usually assessed by proliferative potential, is mostly the endpoint of interest. 
A method for analyzing the response of individual cells of spheroids is to isolate 
them by preparing single cell suspensions. The most important problem with this 
method is the variability among different types of spheroids in terms of the degree and 
strength of intercellular adhesions. In some cases, especially from murine cell lines, 
spheroids can be easily disaggregated (21); with other cell lines, prolonged treatment 
with strong enzymatic cocktails produces little if any disaggregation (34). 
Easily obtained single cell suspensions from spheroids do not guarantee that cells 
recovered after the process of disaggregation are representative of the entire spheroid. For 
instance, the clonogenicity of V79 single cells obtained from spheroid^ is highly 
dependent upon trypsin concentration, trypsinization time, and the severity of 
mechanical forces (35). Also, the fraction of cells recovered after the trypsinization 
process varies with type of spheroid, ranging from as high as 80% in V79 (15) to as 
low as 20% in EMT6 cells (36). 
Even when single cell suspensions are easily obtained with high recovery, there are 
still potential artefacts induced by the methodology. By nature of the growth pattern of 
spheroids, a considerable number of cells will be quiescent, arrested in the G0 phase of 
the cell cycle. These cells would be expected to have a good capacity for repairing 
potentially lethal damage. Since the process of disaggregation and subsequent replating 
these cells in favorable growth conditions, is a stimulus to re-enter the cell cycle, this 
may compromise the cells' ability for this typ« of repair. Another complication is the 
potential redistribution of surviving cell populations. Cells bordering the necrotic 
region which would have died (irrespective of radiation treatment), may in fact be given 
a better chance to survive after disaggregation. Finally, the information obtained with 
clonogenicity assays is very selective. The net response is determined by the most 
sensitive subpopulation at high survival levels, and by the most resistant subpopulation 
at lower levels of survival. Circumvention of this problem requires cell separation and 
the following of each separate subpopulation of cells within the spheroid individually. 
The most reliable process of separation, fluorescence-activated cell sorting (37), is very 
slow, requires expensive equipment, runs the risk of contamination during sorting, and 
requires the use of potentially cytotoxic fluorescent agents. 
2. Spheroid сиге. 
A variation on the single-cell clonogenicity is "spheroid cure". Spheroids are observed 
either in liquid overlay culture and when no (re)growth occurs after radiation treatment 
they are termed cured (38). Alternatively, an entire spheroid is placed into standard tissue 
culture dishes and the ability of viable cells to migrate out of the spheroid and to 
proliferate is evaluated (34). In many respects, this is a very simple and straightforward 
technique, it does, however, also have limitations. 
The major difficulty of the spheroid cure assay is the necessity that any viable cell, 
even when located deep within the spheroid, must find its way to the surface of the 
spheroid, attach to the Petri-dish, and then proliferate. Or, in the case of the spheroid in 
liquid overlay, it may be that surviving cells are not in a position to proliferate and 
subsequently contribute to the volume increase of the spheroid. 
Another limitation follows from the nature of the spheroid: since the endpoint used 
is whether or not outgrowth of cells occurs, this endpoint will not discriminate between 
single or multiple cells outgrowing. Therefore, information can be obtained from this 
system only if treatment reduces survival probability to a level less than the inverse of 
the total number of cells. 
Nevertheless, spheroid cure is a relatively simple, powerful, and convenient 
technique. Results are usually expressed as the fraction of spheroids that are cured (i.e. 
'sterilized', equivalent to Tumor Cure Dose50 assays in animals). In a study on human 
melanoma spheroids, Poirreau-Schneider et al. (38) made a comparison between single 
cell clonogenicity and spheroid cure as observed in liquid overlay, and found a good 
correlation between the two endpoints. 
3. Spheroid growth delay. 
When spheroids are employed as an in vitro model of human tumors it is desirable to 
use endpoints comparable to those available in clinical medicine. Clinical data are based 
on subjective impressions of the radiotherapist as to whether or not the tumor shrinks 
in size. 
Measurement of the regrowth of spheroids after treatment is an easy endpoint for 
quantitative studies (38,39,40). However, regrowth includes a number of variables 
which have varying degrees of influence on growth rate of surviving cells. When no 
effects on the growth rate of surviving cells are observed, back-extrapolation of growth 
curves can lead to reasonable estimates of the surviving fraction. 
The major liability of regrowth delay is the fact that growth is determined primarily 
by the external proliferating cells. Treatment resulting in the killing of external cells 
will result in major growth delay, yet can leave internal cells untouched (41). To some 
extent this problem can be circumvented by the use of sufficiently small spheroids, 
consisting only of cells that are actively proliferating. 
Promising attempts have recently been made to correlate data from growth curves 
with data from single cell survival experiments, using calculation methods which allow 
comparisons to be made (42). 
SPHEROID RADIOSENSITIVITY AND TUMOR TYPE 
After the pioneering studies of Sutherland and Durand (25,26,27,28) the need for studies 
using spheroids from human origin invoked intensive research. In vitro radiosensitivity 
studies have received considerable impetus from recent evidence that cells derived from 
various human tumors differ markedly in their response to radiation. It has been reported 
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that radiosensitivity of human tumor cells in culture correlates with the "clinical 
radiocurability" of the tumor type concerned (43,44). These studies provide support for 
the concept that in vitro radiosensitivity studies may be able to provide clinically 
useful information. 
Rofstad and co-workers have provided important information on the radiosensitivity 
of spheroids initiated either from melanoma cell lines (45) or directly from human 
tumor material (46). Although radiosensitivity differed markedly within the group of 
melanomas, it was shown that spheroids exhibited radiation sensitivities similar to 
those of the parent xenograft and patient tumor (46). 
Similar to the in vitro studies on monolayer cells performed by Deacon et al. (47), it 
was shown by Wheldon et al. (48) that human neuroblastoma cells grown as spheroids 
are highly sensitive to irradiation. The radiation response of both neuroblastoma and 
melanoma spheroids was described by Evans et al. (49). They showed that spheroids 
from neuroblastoma origin grew faster and were more responsive to radiation than 
melanoma spheroids, thus establishing tumor-type dependent differences in the 
radiosensitivity of human tumor cells grown as spheroids. 
The radiosensitivity of a human colon carcinoma cell line grown as monolayers, 
spheroids and as xenografts in nude mice, was investigated by West and Sutherland (50). 
The observed unresponsive pattern to radiation was similar in spheroids and xenografts. 
They concluded that spheroids modelled the radiosensitivity of human colon carcinoma 
more accurately than monolayer cultures. 
Two human small cell lung cancer cell lines grown as spheroids were investigated 
by Duchesne and Peacock (51 ). Their most important observation was that, in the two 
lines studied, growth delay and clonogenic cell survival did not correlate well. 
Clonogenic survival was found preferable in that it more accurately reflected the 
radiation response pattern of human small cell lung cancer. 
A human ovarian carcinoma cell line grown as spheroids and its radiation responses 
was described by Rofstad and Sutherland (52). There were considerable similarities 
between spheroids and xenografts from the same cell line. The authors' conclusion is 
that spheroids from this cell line may be particular useful in the study of therapeutic 
consequences of partial hypoxia. 
CONTACT EFFECT AND RADIOSENSITIVITY OF SPHEROIDS 
Spheroids are held together by surface membrane microprojections, extracellular matrix, 
and a variety of cell-cell junctions (desmosomes, gap junctions). In some spheroids 
specialized junctions are rare, but when they are present, the most common junction is 
the desmosome. 
There is a positive correlation between lines of cancer cells that are electrically 
coupled and their resistance to ionizing radiation as small spheroids (53). This 'contact 
effect' was first demonstrated in small V79 hamster lung cells (54) and was subsequently 
shown for other cytotoxic agents such as heat (55) and adriamycin (56). A single contact 
effect is generally implied, the common denominator being that cells show an increased 
survival after radiation when grown as spheroids. Sometimes this takes the form of a 
wider shoulder on the survival curve, sometimes a slope modification has been reported. 
Traditionally, it has been assumed that the shoulder of the survival curve is related to 
cellular ability to repair sublethal damage (57), the terminal slope of the curve being 
indicative of inactivation rate. This implies different mediators of the contact effect in 
spheroids. A recent hypothesis is that the altered cell shape, associated with intercellular 
junctions, may stimulate transductions from cell membrane through cytoskeleton and 
nuclear matrix to the chromatin, thereby affecting DNA packaging (58). This concept, 
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along with a specific hypothesis of DNA loop sizes in cells in small spheroids 
compared with cells in monolayer cultures, has been proposed to explain decreased DNA 
damage in irradiated spheroids (59). If contact effect is a major modifier of radiation 
response, this exciting feature of the spheroid model can expand our knowledge of basic 
mechanisms of radiosensitivity and resistance. 
SPHEROID OXYGENATION AND RADIOSENSITIVITY 
One of the initial observations in the spheroid model system was the occurence of a 
central hypoxic region as spheroids developed and increased in size (60). Radiation-
resistant hypoxic cells have been demonstrated in most rodent tumors, and there is 
evidence for their existence in human tumors (61). Decreased radiation sensitivity begins 
to occur at а ρθ2 of less than 10 Torr. Such levels have actually been measured in many 
rodent and human tumors. Different rates and extents of reoxygenation, and therefore 
enhanced sensitization may occur during multifraction radiation therapy. 
The relation of reoxygenation to changes induced in tumor cell oxygen 
consumption, possible migration of hypoxic cells, or other characteristics of radiation 
related phenomena, still have to be elucidated. Information in this respect may be 
obtained from spheroids. A radiation-resistant hypoxic fraction in spheroids of both 
murine (62,63) and human origin (64) has been demonstrated. When spheroids are 
subjected to fractionated doses of radiation, simulating radiotherapy, reoxygenation 
occurs that demonstrates the importance of decreased cellular respiration (65). However, 
this reoxygenation was demonstrated using clonogenic survival as measure for radiation 
response. 
Surprisingly, this reoxygenation seems to be a radiobiological, rather than a 
physiological process, in that no actual increase of oxygen tension could be established 
during and after fractionated irradiation (66). Either reoxygenation is a process that 
eludes direct рОз measurements with micro-electrodes, or hypoxic cells influence tumor 
control in a different manner than by oxygen availability alone. 
From the literature there are strong indications that radiobiological reoxygenation 
occurs after very high radiation doses in many types of experimental tumors transplanted 
in mice (67). It is not clear to what extent hypoxic cells exert a threat to succesful 
radiotherapy of human tumors, and it is therefore not clear whether reoxygenation occurs 
and is sufficient, during conventional fractionated treatment, to prevent such hypoxic 
cells from influencing tumor control (68). 
Sensitizing agents that enhance the efficiency of radiation treatment are mostly 
directed at increasing the oxygenation status of tumor cells (69). Improvement of tumor 
oxygenation can be achieved either through the inhibition of cellular respiration (65) or 
by increasing the oxygen delivery to the tumor tissue. An exciting new approach to the 
latter is the use of TCDO (tetrachlorodecaoxide), which decays into "physiologicar 
products, that is, into oxygen and chloride ions. In spheroids this product increases the 
oxygen availability and ρθ2(69). Radiosensitization and radioprotection brought about 
by manipulation of cellular thiol content through chemical agents has also been 
demonstrated in the spheroid system (70). The clinical feasability of this approach in a 
clinical setting still has to be established. 
REPAIR OF RADIATION DAMAGE IN SPHEROIDS 
Cell survival is usually measured by irradiating cells and immediately inducing them to 
proliferate so that the survivors form colonies. If at the time of irradiation the cells are 
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out of the cell cycle, i.e. in a nonproliferative state, cells can be induced into 
proliferation at any time after the irradiation. If there is such a time delay, repair of 
potentially lethal damage (PLD) is likely to occur. This process stops when the cells are 
induced into cycle, by induction of proliferation to form colonies. Repair of PLD 
increases the level of survival. 
The existence of nonproli f erating or quiescent cells in spheroids is one of the most 
widely accepted concepts in its growth kinetics (37). Both in murine (71) and in human 
tumor spheroids (72) it has been shown that quiescent cells are more radiosensitive than 
proliferating cells from the same spheroids, when plated directly after irradiation. If 
quiescent cell populations are the source for renewed growth after cancer therapy (73), it 
is most probably the repair of PLD that is responsible for this phenomenon. 
Recovery from PLD of noncycling cells in 9L rat gliosarcoma spheroids and 
monolayers was described by Rodriguez et al. (74). They showed that the PLD repair 
capacity of 9L cells was equal in confluent monolayers and spheroids. However, 
spheroid cells were more resistant than monolayer cells. The authors conclude that the 
difference in time to recruit cells into the cell cycle is responsible for this difference in 
radioresistancy. 
Due to the difficulties in obtaining single cell suspensions for clonogenic survival 
(discussed in an earlier part of this chapter), PLD has been studied in spheroids of 
human origin only indirectly. Weichselbaum et al. (75) studied the differences in repair 
of PLD in human melanoma and breast carcinoma cell lines and correlated this repair 
capacity with responses to fractionated radiotherapy of the same lines grown as 
spheroids. They concluded that repair of PLD in spheroids constituted a considerable 
factor in the differential radiation responses of cell lines derived from different tumor 
types. 
The amount of radiation damage repair seems to vary from one cell type to another. 
Recovery from radiation damage is an important process in radiotherapy which applies 
to the majority of present-day regimes of radiotherapy. After a dose of radiation it is 
supposed that a cell may remain undamaged, may be irrepairably damaged, or may 
accumulate ionizing events in some of its targets (57). 
In this model this type of injury, sublethal damage (SLD) can either become lethal, 
or may be repaired, and a cell can thereby remain clonogenic. The time course and the 
extent of the repair of SLD are studied by delivering a second dose at various time 
intervals after an initial radiation dose and measuring the radiation dependent endpoint 
(split-dose recovery). There is a decrease in the effectiveness of split-dose irradiation as 
compared to the single dose, which is said to be due to repair of SLD (76). The 
differential repair capacity of normal and tumorous tissues is the rationale for 
fractionating radiation treatment in the clinical setting. 
In spheroids of murine cell lines repair of SLD has been extensively studied (28,77). 
For V79 hamster fibroblast spheroids it has been shown that repair of SLD was larger 
in spheroids than in conventional monolayer cultures (78). Recovery of split-dose 
irradiation was also demonstrated in 9L rat brain tumor spheroids (79). For relatively 
short times, recovery probably resulted from repair processes, but for longer times 
recovery also appeared to depend on redistribution in the cell cycle phases and on effects 
induced by repopulation of surviving cells. The latter was also ascribed by Durand (77) 
as being a major determinant of spheroid response to multifraction irradiation. 
Very limited data are available for spheroids from human tumor cell lines. Wheldon 
et al. reported on the split-dose recovery in spheroids of a human neuroblastoma cell 
line (80). The splitting of a radiation dose had no sparing effect for spheroids from this 
cell line, from which the authors concluded that neuroblastoma as a group of tumors 
might be amenable for fractionated radiation regimes (81 ). 
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OBJECTIVES OF THE PRESENT STUDY 
Radiation responses of spheroids show a strong heterogeneity with regard to the type of 
cell line from which they were derived. Spheroids from murine cell lines are very 
convenient models for the study of radiation responses in that they are easily 
disaggregated for clonogenic assays. However, recent evidence regarding the tumor type 
dependent differences in radiosensitivity of human tumor cells in vitro as monolayers 
(43,44) make it imperative that studies on the radiation responses in spheroids are 
performed with human cell lines (82). 
The objectives of the present study are 1) to establish factors that determine why 
some human tumor cell lines form growing spheroids while others don't; 2) to elucidate 
the tumor type dependency of human tumor cell lines when grown as spheroids; 3) to 
study the influence of other factors than tumor type, such as oxygenation status, contact 
effect, repair of sublethal damage, on the radiation responses of spheroids; and 4) to 
determine the influence of contact effect, growth rate and the use of cytostatic agents on 
sublethal damage repair. 
This chapter was based on: 
J.H.M. Schwachöfer: Multicellular tumor spheroids in radiotherapy research (review). 
Anticancer Res 10: 963-970, 1990. 
Chapter 3 
Materials and Methods 
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Materials and methods 
The study described in this thesis comprises experiments in which the same materials 
and methods were used. These materials and methods are described in this chapter. Two 
main sections can be distinguished; an in Wiropart and an in vivo section. 
In vitro studies 
Human tumor cell lines 
All cell lines used in this study were originally derived from human tumors. Table 3.1 
lists their codes, origin, reference, and monolayer culture doubling times. Tumor cells 
were maintained as monolayers in RPMI 1640 with 10% foetal bovine serum 
supplemented with 2 mM L-glutamin/ml, 100 IU penicillin, and 100 μg 
streptomycin/ml (Gibco Ltd, Paisley, Scotland). 
Cells were incubated in 7.5% CO2 at 37° С and 100% humidity and were 
subcultured once a week after dissociation with 0.25% trypsin (Difco Co., Detroit, MI, 
USA)/0.025% EDTA (Merck AG, Darmstadt, FRG) in a buffered salt solution. Cells 
were routinely tested for mycoplasma contamination. 
Tabic 3.1. Tumor cell line code, origin reference, and monolayer culture doubling lime of 
five human tumor cell lines. 
Cell line 
code 
BRO 
HN-1 
LAN-1 
NB-100 
NCI-H125 
Origin 
melanoma 
SCC* tongue 
neuroblastoma 
neuroblastoma 
lung adenocarcinoma 
Reference Monolayer culture doubling time 
Lockshin (83) 
Easty (84) 
Seeger (85) 
Schlesinger (86) 
Carney (87) 
(day + SE) 
1.5 + 0.1 
2.0 + 0.1 
2.6 + 0.3 
2.2 + 0.2 
1.9 + 0.1 
squamous cell carcinoma 
Culture of spheroids 
Single cell suspensions were obtained by trypsinization of monolayer cultures; 1x10^ 
cells were seeded in 60-mm Petri dishes coated with 1% agarose (BDH Chemicals, 
Poole, England), and incubated in a humid atmosphere with 7.5% CC^at 37° C. After 
four days small spheroids had developed which could be harvested individually using a 
Pasteur pipette. Spheroids with the desired diameter, depending upon the type of 
experiment, were selected and transferred to individual wells in 24-well test plates 
(Costar Cambridge, MA, USA) coated with 1% agarose. The plates were incubated as 
above with weekly replenishment of fresh medium. 
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Monolayer culture 
Cell cultures were harvested from exponentially growing cultures by trypsinization 
(same conditions as described under heading Human tumor cell lines). Cells were washed 
by centrifugation and resuspension, counted, diluted and plated in 6-well test plates 
(Costar, Cambridge, MA, USA). For survival determinations six wells (0 35 mm) of 
one test plate per radiation dose were inoculated with 1,000 - 10,000 cells in 2 ml 
medium. The cell number depended upon radiation dose. After allowing four hours for 
cell attachment, cells were irradiated. 
When plateau phase cells were used for determination of potentially lethal damage 
repair, cells were irradiated as monolayers. Cells were grown to confluence in 25 cm^ 
culture flasks (Nunc AS, Kastrup, Denmark) without medium replenishment, after 
which irradiation was performed. Cells were plated either directly after irradiation, or 
were kept for a period of time in a non-proliferative state after radiation procedure had 
been completed. Confirmation of correct proliferative status of cells was performed by 
flow cytometric evaluation of samples from cell suspensions obtained prior to 
experimental procedures. Cells were released by replating them at lower densities 
( 1,000-10,000 cells) in each of 6 wells of 6-well test plates. 
Irradiation procedures 
The required doses of radiation were administered using a 18 MV photon beam from a 
linear accelerator (CGR, Bue, France) at a dose rate of 2 Gy/min. Test plates were placed 
on a wax build-up to ensure homogeneous energy deposition within each well. For this 
purpose only 24-well test plates manufactured by Costar (Cambridge MA, USA) could 
be used, since these test plates have no closing bottom jointly closing all 24 wells. 
Control plates were removed from the incubator for the same period of time, but were 
not irradiated. 
In the studies on radiation induced DNA damage and DNA repair irradiations were 
carried out on ice using 250 KV X-rays from a Siemens Stabil ¡pan (Siemens AG, 
Erlangen, F.R.G.) at a dose rate of 47.8 cGy/min. 
Estimation of response to radiation 
The growth of spheroids on test plates was determined twice weekly by measuring the 
diameter of individual spheroids using a calibrated scale in the eyepiece of an inverted 
microscope. The volumes were then calculated on the assumption of spherical 
geometry. Spheroid growth curves were constructed plotting volume/initial volume as a 
function of time after treatment. 
The growth delay was determined by calculating the difference in time between 
irradiated and control spheroids necessary to reach a fixed number of times the initial 
treatment volume. This number differed in the various experiments performed during 
this study. When comparing the five different tumor lines, the data were analyzed using 
the exponential relationship TJ/TQ = eED where TD is time (day) to obtain five times the 
volume at time of irradiation, after dose D (Gy), TQ is the time (day) for unirradiated 
spheroids to fulfill this requirement, and g is a delay constant (Gy" 1 ). Specific growth 
delay (SGD) was used in some experiments, and was calculated as: SGD = growth 
delay/Vd where Vd is the volume doubling time of untreated spheroids. 
Cell survival estimates could be derived from the growth curves on the basis of the 
following assumptions (48): (a) the number of spheroid regenerating units (SRU) 
within a spheroid at the time of irradiation is proportional to its volume at that time; 
24 
(b) the growth rate of control and the growth rate after irradiation can be fitted by a 
common best slope; (c) the exponential part of the growth curves obtained can be 
approximated by a single exponential function. The extrapolated volume at zero time is 
indicative of the relative number of SRU and, therefore, the surviving fraction of SRU 
after a given dose. A decision was made as to which range of time points of a regrowth 
curve constituted exponential growth. A common best slope for all the growth curves in 
an experiment was obtained using a minimum least square method (88). The back-
extrapolates of these curve-fits for the different doses gave the surviving fractions of 
SRU. This procedure has been shown to give values of surviving fraction comparable to 
those for clonogenic cells (42). The surviving fraction was plotted as a function of 
radiation dose and a single-hit, multitarget model (88) was applied to the data. The 
program calculated values for the reciprocal of the final exponential slope (DQ) of the 
survival curve and its extrapolation number (N). 
In one series of experiments spheroids were irradiated at 37° С and trypsinized with 
0.25% trypsin/0.025 EDTA in buffered salt solution. Cells were washed by 
centri fugation and resuspension, counted, diluted and plated in 35 mm Petri dishes. Per 
radiation dose 1,000 - 10,000 cells in 2 ml complete medium were inoculated in each of 
three dishes. The number of cells depended on the radiation dose. Fixation and counting 
of colonies was as descibed under monolayer culture procedures. 
Spheroids were considered to have been controlled or "cured" if they failed to regrow 
(i.e. to increase in volume) during the 5-6 week observation period following the 
irradiation. The percentage cured was calculated relative to the total number of spheroids 
originally present in the treatment group. The spheroid control dose50 (SCD50) was 
defined on the analogy of the tumor control doseso (TCD50) assay. This point is 
reached when the fraction of surviving clonogenic cells per tumor is equal to ln2 or 
0.693 cell (89). Probit analysis of the results in the different dose groups gave a dose of 
radiation necessary to sterilize 50% of the spheroids. Statistical analysis for differences 
in the SCD50 values was performed as described by Litchfield and Wilcoxon (90). 
Quantification of sublethal damage repair 
A "dose repaired" was calculated from the growth delay curves derived for the different 
groups of spheroids and from the survival curves for both monolayers and spheroids. 
The dose related repair capacity, as expressed by this dose repaired, is defined as the 
difference between a total dose administered in two equal fractions and the single dose 
required to achieve the same biological effect (iso-effect calculation). The "dose repaired" 
was determined as function of total dose using the fitted curves. 
An alternative approach to describe the repair data was to calculate the recoveiy ratio, 
RR, from the growth delay and the cell survival data. In the LQ-model (91) this ratio is 
defined as the ratio of surviving fractions after a total dose D, given in either single or 
split-dose regimens. In the LQ-equation the surviving fraction after a single dose (SF3) 
is described by (see Figure 3.1): 
SF3- exp -{a(2Di) + ß(2Di)2 } = exp -(2aDi + 4 ßDi2), 
the surviving fraction after a split dose by: 
SF2- (SFi)2 = (exp -(aDi + ßDi2}2 - exp -(2aDi + 2 ßDi2) 
25 
SF2 atp-(2aDi + 2ßDi2) 
Recovery ratio, RR- = = exp-(2o£)i + 2ßDi2) + (2aDi + 4 PD]2) 
SF3 atp-(2aDi + 4PDi2) 
in RR= гро2 
In analogy to the determination of RR from surviving fractions, the RR was deduced 
from the growth delay values after split and single doses. 
Figure 3.1. Survival curves fitted to the linear quadratic equation, depicting the 
principle of the recovery ratio (RR) after single dose (SFl, SF3) and split (SF2) dose 
irradiation. 
Flow cytometry 
For DNA measurements, cell suspensions were obtained from spheroids or monolayer 
cultures by trypsinization. Cells were fixed in 100% ethanol and were stained with 
isotonic propidium iodide (Calbiochem, San Diego, CA, USA) (0.02 mg/ml)/RNase 
(Sigma Co, St. Louis, MO, USA) (0.1 mg/ml). These specimens were analyzed for 
DNA content using a flow cytometer (Ortho Diagnostics Systems Inc., Cytofluorograf 
System 3 OH). The percentage of cells in the individual phase of cell cycle was 
ascertained from the fluorecence data according to Egmond and Hillen (92). 
Detection of DNA damage 
The fluorometric analysis of DNA unwinding (FADU) (93) was used to measure DNA 
strand breaks. This method detects frank single strand breaks, double strand breaks and 
alkali labile damage. Briefly, control and irradiated cells were diluted in an isotonic 
solution, and distributed in three sets of three tubes, each set designated as F
m a
x , F
m
i
n
, 
and Ttest· Pilot studies had proved that the optimal time for alkali unwinding was 30 
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min at 0° С, followed by 60 min at 15° С, to allow partial unwinding (pH 12.0-12.6). 
Fmax contained double stranded DNA not sheared and never exposed to denaturing pH. 
Among the three sets of tubes, this set was the one that gave maximal fluorescence 
yield when in the presence of ethidum bromide (EB), a fluorescent dye binding specific 
to duplex DNA. The Ftest tubes contained unsheared, alkali-denatured double stranded 
DNA. The Fmjn tubes contained DNA sheared by sonification for 30 sec. After the 
same treatment as the Ftest tubes, total DNA unwinding was achieved. Among the three 
sets of tubes, these are the ones that gave the minimal fluorescence yield when in the 
presence of EB. 
To minimize mechanical shearing of DNA, the precautions described by Bimboim 
and Jevcak (93) were strictly followed, i.e. no light exposure, gentle addition of 
solutions and handling of the tubes. In spite of these precautions, variabilities in the 
frequencies of strand breaks in non-irradiated samples was still observed between 
experiments. After neutralization of the pH of the solution in tubes F
m a
x , F
m
in> and 
Ttest» ethidium bromide (Sigma Co, St. Louis, MO, USA) was added to all tubes. 
Relative fluorescence intensities were read at room temperature in a spectrofluorimeter 
operating at 520 nm (excitation) and 590 nm (emission). The percentage DNA 
remaining double stranded after alkali treatment was calculated as: D = 100% χ ( Р ^ -
F
minV( Fmax - Fmin)> where F t e s t , F m a x , and F m i n are fluorescence intensities of the 
respective tubes with the same names, each estimated in triplicate. The extent of DNA 
damage was expressed as QD = 100(log DQ - log Ц), where subscripts 0 and i represent 
nonirradiated and irradiated samples. The rejoining process of the X-ray induced strand 
breaks was studied by incubating control or irradiated cells in culture at 37° С for 
different periods before FADU assay. Results were expressed as percentage of initial 
damage remaining after various time periods. 
Oxgen tension measurements 
The partial oxygen tension was measured polarographically with microelectrodes as 
described by Baumgärtel (94). The active measuring element was a platinum wire 
conically etched down to tip diameters between 0.1 and 0.5 μπι. The electrode shaft 
consisted of lead-free melting-glass, which was fused to the tip of the platinum cathode 
over a length of 25 mm giving a final tip diameter of 2-3 μπι. The tip was covered with 
a polystyrol membrane. The anode consisted of a calomel electrode. There is a linear 
relation between current and рЮг: at a voltage of 700 mV and а рэОг of 140 Torr these 
electrodes gave a current value of 0.2-1.1 nA and at а рОг of 0 Torr 0.001-0.005 nA. 
Spheroids were transferred from the 24-well test plates to a perfusion chamber as 
described in detail elsewhere (95). A buffered salt solution without serum but with 
glucose was circulating (10 ml/min) through the perfusion chamber. The flow rate of 
the medium was highest in the upper part of the chamber while the flow was close to 
zero near the bottom. The spheroids were positioned at the bottom of the chamber. The 
Polarographie microelectrode was manoeuvred in prasition with the aid of two 
independent optical systems. One system existed of a lOx microscope objective 
connected to a TV-system. The other system was a stereo microscope. By using these 
two independent systems working along different axes, it was possible to obtain an 
accurate p>ositioning of the electrode in relation to the spheroid. The electrode was passed 
along an axis through the centre of the spheroid and was moved stepwise electronically 
by a nano-stepping microdrive (WSE-electronics, Heidelberg, FRG) towards the centre 
of the spheroid. The first contact of the electrode with the spheroid at the surface was 
determined by the optical systems. Oxygen gradients were constructed from the partial 
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tension values inside the spheroid (measured by the electrode) and the depth of the 
measuring point (given by the microdrive) (95). 
Calculation of oxygen consumption. 
The methods used to calculate oxygen consumption from oxygen tension profiles have 
been described elsewhere (96). In short: assuming values for oxygen diffusion coefficent 
and solubility coefficent in cells reported by Grote et al. (97), the oxygen tension 
profiles measured inside of individual spheroids were fitted to the adapted Henry's law: 
P(r) = Po - сь . (R2 - Γ2) 
ó . D . a 
P(r): partial oxygen tension in r 
Po: partial oxygen tension at surface of spheroid 
D: oxygen diffusion coefficient 
a: oxygen solubility coefficient 
r: distance from centre 
R: radius of spheroid 
The factor V02 represents the oxygen consumption expressed as ml OyiOO g per min. 
As a measure for the goodnes of fit the partial oxygen tension at the spheroid surface 
predicted by the calculation method was compared to the measured value. The deviation 
of the predicted value was less than 2%, indicating that the mathematical model fitted to 
the actual data. 
Spheroid-forming capacity of human tumor cell lines 
Lung cancer cell lines 
Small cell lung cancer cell lines can be subdivided into two major categories: classic 
and variant cell lines. In contrast to classic cell lines, variant cell lines exhibit a much 
looser morphology in vitro, a higher cloning efficiency, faster doubling times and are 
less radiosensitive (98). 
NCI-H69 and NCI-H449 were established by Camey et al. (87) and are of the classic 
type. NCI-H69 was obtained from pleural effusion of a male patient and NCI-H449 
from the bone marrow of a female patient. NL-SCLC2, also of the classic type, was 
established by Broers and co-workers (99) from a pleural effusion. Cell line NL-SCLC2 
grows in clusters of cells floating in the medium. 
NCI-H82 and NCI-H524 are small cell lung cancer lines of the variant type described 
by Camey et al. (87). NCI-H82 has been established from the lymph node of a male 
patient. 
NCI-H23 and NCI-H125 are adenocarcinomas of the lung, both established by 
Camey et al. (87) from biopsy material. 
Bladder cancer cell lines 
The T24 cell line was derived from a female patient with grade II bladder carcinoma 
and was established by Bubenik et al. (100). The 647V cell line was established by 
Elliott and co-workers (101) from a primary transient cell carcinoma grade II from the 
bladder. The VM-CUB-2 cell line was described by Fogh (102) as a transient cell 
carcinoma of the bladder derived from a lymph node metastasis. The 5637 cell line was 
established from a primary transient cell carcinoma of the bladder ( 102). Cell lines were 
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kindly donated by Dr. R. van Moorselaar from the department of Urology at our 
hospital. 
Liquid overlay culture 
For initiation of aggregates 3 different media were chosen: RPMI 1640, Ham's Fl 2 
and Dulbecco's Minimal Essential Medium (Gibco Ltd, Paisley, England). Each was 
supplemented with either 10% or 20% foetal bovine serum (Gibco Ltd, Paisley, 
England). The same batch of serum was used during each series of experiments. All 
media were further supplemented with 100 IU penicillin/ml, 100 pg streptomycin/ml 
and 2 mM L-glutamine (Gibco Ltd, Paisley, England). 
Spheroid forming capacity was classified after Carlsson et al. (10): Category I 
consisted of single cells and small clumps of cells. Category II were flat aggregates of 
cells, 2 cell-layers thick, the usual growth pattern of small cell lung cancer cell lines. 
Category III were spherical aggregates (spheroids) with clumps and single cells. 
Category IV consisted of irregularly formed aggregates like those in category II but of 
much larger dimensions, single cells and cell clumps. 
Cell viability 
Aggregates were dissociated by trypsinization for 10 min (0.25%trypsin/0.025% 
EDTA) in a phosphate buffered salt solution followed by vigorous pipetting. The single 
cells obtained were assessed for viability by trypan blue (0.4%) exclusion and counted in 
a hemocytometer. 
Morphology 
Sections for light microscopy were obtained by washing the spheroids twice in 
phosphate buffered physiological saline (PBS) and fixing in a 4% glutaraldehyde-based 
fixative for 1-3 h. The spheroids were rinsed for 20 seconds, and embedded in epoxy 
resin, l-pm sections were cut using an ultra-microtome and stained with toluidine blue. 
Intermediate filament expression 
The procedures for the indirect immunofluorescence have been described elsewhere 
(98). In short, cells were cultured on glass coverslips for 1-2 days and fixed by briefly 
dipping in methanol (-20° C) and acetone. Cells were incubated with the primary anti-
body for 30-45 min, washed and incubated with either fluorescein isothiocyanate 
(FITC)-conjugated rabbit anti-mouse IgG (1:25, Nordic, Tilburg, The Netherlands) or 
FITC-conjugated goat anti-rabbit IgG (1:25, Nordic) for 30-45 min. Primary antibodies 
used in this study were as follows: RCK102, which recognizes cytokeratins (CKs) 5 and 
8, and as a result stains virtually all epithelial tissues; RCK105 reacting only with CK 
7, while RCK is monospecific for CK 18. Antibody 1C7 reacts with non-comifying 
squamous epithelia. 6B10 recognizes only CK 4. RKSE60 recognizes CK 10. The 
monoclonal antibody RV202 reacts with mesenchymal cells and recognizes vimentin. 
Antibodies RCK102, RCK105, RKSE60, 6B10, and 1C7 are available from 
Eurodiagnostics BV (Apeldoorn, The Netherlands). 
Cytotoxic drugs 
Cisplatin and carboplatin were both obtained from Bristol-Myers (Weesp, The 
Netherlands). Carboplatin was obtained as a lyophylized powder and was stored in dark 
bottles at 4° C. Prior to use the powder was dissolved in buffered saline solution and 
diluted to the desired concentrations in tissue culture medium. Cisplatin was obtained as 
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a 1 mg/ml solution and was stored at room temperature in a dark environment. 
Spheroids were exposed to drugs for 1, 4, or 24 h in Petri-dishes under standard tissue 
culture conditions. Subsequently spheroids were transferred to universale and the drug 
was rinsed off. A high (5-20 μg/ml) and a low (0.01-1.0 μg/ml) dose range were used in 
the comparative study. In the study using combinations of both drugs with radiation for 
each of the drugs one concentration was used. 
Antimetabolic assay 
The antimetabolic assay used in this study was previously used to test drug efficacies in 
tumor slices (103) and was adopted for use with spheroids. 
During the last hour of drug incubation PH]-thymidine was added to the Petri-dishes 
to a final concentration of 1 pCi/ml. Spheroids were then washed 3 times in an isotonic 
solution of unlabelled thymidine for 1 h at 4° С and subsequently dissolved in Luma 
Solve (Lumac Systems AG, Basel, Switzerland). The level of radioactivity incorporated 
was measured in a LKB81000 Liquid Scintillation Counter. Averages of twelve 
spheroids per measuring point were calculated. The cpm values of the PH]-thymidine 
incorporation measured in the control spheroids were set at 100%. The effects of the 
drugs were expressed as percentages of the control. 
In vivo experiments 
Experimental Animals 
Nude mice 
The animals used in these experiments were 6-9 week-old congenitally athymic nude 
mice with CD-I background (Charles River WigaGmbH, Sulzfeld, FRG). The mice 
were kept under standardized conventional conditions (Makrolon cages, 27° С room 
temperature, 50% relative humidity, autoclaved bedding) in a separate room especially 
contolled against infections. A heavily irradiated diet (1210, Hope Farms, Woerden, The 
Netherlands ) and acidified water (pH 2-3) free of antibiotics were given ad libitum. 
Immunosuppressed mts 
Three-month-old male Wistar rats (200 g + 5%) of the outbred strain Cpd:WU 
(Institute of Laboratory Animals TNO, Zeist, The Netherlands) were treated with 
cyclophosphamide (i.p., 10 mg/kg) on four subsequent days, followed by a total 
lymphoid irradiation of 9 Gy. Four days after irradiation fragments of approximately 2 χ 
2 x 2 mm 3 were implanted subcutaneously in one of the flanks of the animals. Daily 
Cyclosporin A (15 mg/kg) dissolved in olive oil was administered orally to maintain 
the state of immunosuppression (104). Animals were kept in a laminar flow cabinet 
(Clean Air, Woerden, The Netherlands) on the same food and water conditions as the 
mice. 
Tumor xenografts 
All four tumor lines originated from in vitro human tumor cell lines of which the 
characteristics and references are listed in Table 3.1. From neuroblastoma line LAN-1 no 
xenografts were obtained. Experiments in nude mice were performed after four passages 
in the immunedeficient animals. 
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Since it is possible that host versus tumor responses contribute to the radiation 
responses (105) growth rates of tumor cells growing as xenografts in both immune 
deficient nude mice and immunosuppressed Wistar rats were compared. 
Tumor irradiation 
Graded doses of radiation to tumor xenografts in nude mice were administered with a 
13 MeV electron beam of a linear accelerator (COR, Bue, France) with a skin dose of at 
least 90%. Due to the use of electrons, the variation of the dose across the tumor is less 
than 5%. Proper shielding with lead slabs (thickness 7 mm) reduced the outside of the 
irradiation portal to a negligible value. 7 to 8 animals per radiation dose were treated 
while anaesthetized with a modified semiclosed Enflurane-oxygen system (106). 
Assessment of tumor response 
Xenograft dimensions were determined twice weekly by measurement with Vernier 
callipers in three dimensions. Estimates of tumor volume were obtained by: V = л(а . b 
. c)/6, where a, b, and с were xenograft dimensions. No correction for skin thickness 
was made. Tumor growth curves were constructed by plotting volume/initial volume as 
a function of time after treatment. 
Growth delay for each experimental group was determined by calculating the 
difference between irradiated and control tumors in time to reach five times the initial 
volume. The data were analyzed using the exponential relationship TJ/TQ = eßD where 
Tß is time (day) to obtain two times the volume at time of irradiation, after dose D 
(Gy), TQ is the time (day) for unirradiated xenografts to fulfill this requirement, and g is 
a delay constant (Gy1). 
The tumor control doseso assay was used to calculate the dose necessary to control 
50% of the irradiated xenografts. A tumor was considered to have been cured if no 
regrowth had occurred during a sufficiently long period (10 times the volume doubling 
time) after which the xenograft was not distinguishable. The percentage cured was 
calculated as the fraction non-regrowing tumors relative to the total number of 
xenografts originally present in the treatment group. Probit analysis of the results in the 
different dose groups gave the dose necessary to sterilize 50% of the tumors. Statistical 
analysis for differences in TCD50-values was performed using the methods described by 
Litchfield and Wilcoxon ( 90). 
Chapter 4 
Growth and culture conditions of 
multicellular tumor spheroids of human 
tumor cell lines 
Growth and culture conditions of multicellular tumor 
spheroids of human tumor cell lines 
A B S T R A C T 
Aggregates of human tumor cells are widely used in experimental studies on tumor responses 
to treatment Only a limited number of human tumor cell lines are capable of forming 
spheroids The cellular characteristics of 7 lung cancer and 4 bladder cancer cell lines are 
described with respect to their spheroid forming capaaty Comparisons were made with four 
reference lines known for their propensity to form growing aggregates Spherical aggregates 
were formed by one bladder and one lung cancer cell Ime, of which only the latter exhibited 
growth Cellular factors influencing the ability of spheroids to increase in volume after 
spherical aggregation are not yet defined Viability and clonogemcity of cells in aggregates 
are not the déterminant of growth capacity 
The growth rate of cell lines that exhibited growth is determined by tissue culture conditions 
and additives Type of medium, percentage of foetal bovine serum and glucose concentration 
influenced the growth rate of spheroids Since the response to radiation may be influenced by 
the growth rate of the tumors, manipulation of tissue culture medium composiUon offers the 
possibility of testing the influence of growth rate on the radiation response of one type of 
spheroids 
The 3-dimensional culture of human tumor spheroids under standardized medium condiUons 
may reveal information on specific biological parameters that could be masked in serum-
supplemented media Spheroids denved from human tumor cells are growth retarded in media 
free of scrum Ex-cytc is a substance denved from human blood that can be used to improve 
growth in tissue culture The growth of spheroids from four different human tumor cell lines 
was studied when grown m medium free of scrum, medium supplemented with varying 
concentrations Ex-cytc, and medium supplemented with foetal calf serum (PCS) Growth rate, 
growth enhancement, clonogemcity and cell cycle distribution were the parameters used for 
comparisons 
The four cell lines showed different growth rates in serum-free medium, which were increased 
to different extents when Ex-cytc or PCS were added The growth enhancing effect induced by 
Ex-cyte was not concentration dependent The clonogemcity of cells grown as spheroids in 
serum-free medium was lower than in spheroids grown m supplemented media There was no 
difference in clonogemcity between the differently supplemented media All four the cell 
lines responded to growth in serum-free medium with a drop in the S-phasc and G2M-phase 
The work desenbed here provides a novel approach to the study of human tumor cells m three-
dimensional culture under defined conditions The human scrum derived substance Ex-cyte 
provides a method to obtain information on specific biological parameters that could be 
masked in serum-supplcmenlcd media 
INTRODUCTION 
Experimentally induced aggregates of animal cells have been widely used in biological 
research for many years. Studies on the response of V79-171 hamster lung cell 
aggregates to radiation treatment were initiated by Sutherland and coworkers (21,26,27), 
who showed that cell survival curves obtained were similar when obtained either with 
aggregates or with solid tumors (27). Because of their almost perfect spherical shape, 
the aggregates were termed "multiceli spheroids" which resembled the nodular structures 
observed in C3H mouse mammary carcinomas (107) or in several types of human 
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tumors (88). Multicellular tumor spheroids were henceforth considered in vitro tumor 
models for mimicking basic biological properties of cancer cells in vivo. 
Spheroids provide a model with interesting features such as 'contact resistance' (53), 
the availability of a variety of endpoints to study responses to radiation treatment (38), 
and the development of kinetic and metabolic heterogeneity (37). Heterogeneity in 
tumors may develop because of intrinsic genetic mutations, and/or extrinsic cellular 
environments, which may alter metabolic functions, and consequently, responses to 
therapy (109). The dynamic nature of both nutritive blood supply and the cellular 
utilization of critical metabolites are both important for determining cellular 
environments in tumor microregions (110). 
For several types of tumor cell lines, spheroid models have been established, e.g. 
neuroblastoma (44), melanoma (45) and glioma (111). Two groups with 
radiotherapeutic interest have so far yielded only few results with respect to aggregate 
forming ability: spheroids of only two small-cell lung cancer lines (51) and one bladder 
cancer cell line (112) have been described. 
In this chapter work will be described with the aim to determine whether several 
lung and bladder cancer cell lines (see Table 4.1) were capable of forming aggregates, 
and to correlate this capacity with the expression of intermediate filaments, which 
constitute part of the cytoskeleton of eukaryotic cells. Comparisons were made with 
two neuroblastoma cell lines (NB-100 and LAN-1) with known capacities to form and 
grow as spheroids, and with two cell lines of which the ability to form spheroids was 
established at our institute: one squamous cell carcinoma line of the oral tongue and one 
melanoma cell line. Since the growth rate of tumors may influence the radiation 
response, the manipulation of growth rate of spheroids by tissue culture medium 
composition has been studied. Ideally, tissue culture conditions should mimic the in 
vivo situation as much as possible. Addition of different sources of serum to the 
medium may as such be advantageous, but precludes control with chemical 
environment. The growth of spheroids in serum-free medium may reveal information on 
specific biological parameters that could be suppressed or masked in serum-
supplemented media (113,114). Most spheroids are growth-retarded in media that are free 
of serum (115). Ex-cyte IV is a substance derived from human blood, that can be used as 
an additive for the growth of a pupal-ovarian cell line (116). In this study the growth of 
human tumor cell lines of different origin in medium with varying concentrations of 
glucose, serum, and Ex-cyte is described. 
RESULTS 
Using the various techniques described in chapter 3, the following results were obtained. 
Formation and growth of aggregates 
Aggregation patterns are classified according to 4 categories as indicated in Materials and 
Methods. The results of the spheroid formation studies are given in Table 4.1. The two 
neuroblastoma lines were included for comparative purposes, since their capacity to 
form growing spheroids had previously been reported (49). The other two reference lines 
were known by the author for their propensity to form spheroids. 
Large variations in the aggregation pattern were seen among and within the different 
cell types. As a general rule, if aggregation in one type of medium was exhibited, then 
the cells aggregated also in other media. The only exception to this rule was the LAN-1 
neuroblastoma cell line, which formed spheroids only in Ham's Fl 2 + 20% FCS, and 
category IV aggregates in two media when supplemented with 20% FCS. 
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Table 4.1 Spheroid formation patterns for different types of human tumor cells in different 
culture media 
Cell line Tumor of origin Spheroid formation pattern 
А В С D E F 
NCI-H69 
NCI-H449 
NL-SCLC2 
NCI-H82 
NCI-H524 
NC1-H23 
NCI-H125 
T24 
647V 
VM-CUB-2 
5637 
NB-100 
LAN-1 
BRO 
HN-1 
SCLC1, classic type 
SCLC1, classic type 
SCLC1, classic type 
SCLC1, variant type 
SCLC1, variant type 
adenocarcinoma lung 
adenocarcinoma lung 
care unnaiy bladder 
ТСС
2
 unnary bladder 
TCC2 unnary bladder 
TCC2 unnary bladder 
neuroblastoma 
neuroblastoma 
melanoma 
SCC3 oral tongue 
II 
I 
II 
II 
II 
I 
III 
II 
I 
I 
III 
III 
I 
III 
HI 
IV 
IV 
II 
II 
IV 
II 
IV 
II 
II 
II 
III 
IV 
IV 
IV 
III 
II 
II 
II 
II 
II 
I 
HI 
II 
I 
I 
HI 
III 
I 
HI 
HI 
II 
IV 
II 
II 
IV 
II 
IV 
II 
II 
II 
III 
IV 
III 
IV 
IV 
II 
II 
II 
II 
II 
I 
HI 
II 
I 
I 
III 
IV 
II 
HI 
III 
II 
II 
II 
II 
II 
II 
IV 
II 
II 
I 
III 
III 
IV 
IV 
IV 
small cell lung cancer, transient cell carcinoma, squamous cell carcinoma 
Formation categories as indicated in Materials and Methods 
Culture media A, RPMI 1640+ 10% FCS, B, RPMI 1640 + 20% FCS, C, Ham's F12 + 10% 
FCS, D, Ham's Fl2 + 20% FCS, E, Dulbccco's MEM + 10% FCS, F, Dulbccco's MEM + 20% 
FCS 
volume -ΙΟ6 μπι3] 
5 10 IS 20 25 30 t i r re Idaysl 
F i g u r e 4 . 1 . Growth curves of spheroids from five different human tumor cell lines. 
Each point represents the average ± SD of at least 20 spheroids 
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Representative growth curves are shown in Figure 4.1. A correlation between the 
respective volume doubling times in monolayer and spheroid culture was not observed. 
Cell lines with short population doubling times did not necessarily have short volume 
doubling times when growing as spheroids. 
Of the 11 tested tumor cell lines, only one produced growing spheroids (NCI-H125), 
and one (5637) produced spheroids that did not grow. 
Cell viability and clonogenicity 
The tests of the cell viability by trypan blue exclusion and clonogenicity are given in 
Table 4.2. There is no indication of differences in viability between cells in newly 
formed spherical aggregates. Results from clonogenicity testing showed no distinct 
pattern: the highest plating efficiencies are found in NB-100 cell line (9.0%) with 
Table 4.2. Cell viability and clongenicity of spherical aggregates newly formed in liquid 
overlay. 
Cell line: Cell type Spheroid diameter Viability Clonogenicity 
(μΐϋ) (%) (%) 
average ' + SD average2 + SD 
NB-100 
LAN-1 
BRO 
HN-1 
NCI-H125 
5637 
neuroblastoma 
neuroblastoma 
melanoma 
SCC 3 oral tongue 
adenocarcinoma 
of the lung 
TCC3 urinary 
258 + 33 
245 + 45 
185 + 30 
115 + 27 
135 + 20 
160 + 27 
97 
97 
9 8 
100 
99 
86 
9.0 + 1.0 
1.5 + 0.3 
2.3 + 1.2 
1.8 + 0.2 
3.2 + 1.1 
4.1 + 1.4 
' : average of at least 15 aggregates, 2 : average of 6 replicates, 3 : squamous cell carcinoma, 
4
: transient cell carcinoma. 
growing spheroids, and in cell line 5637 (4.1%) with spheroids that did not increase in 
volume. The diameters of aggregates from both neuroblastoma lines are considerably 
larger than those of the other cell lines, with no consequences for either viability or 
clonogenicity. 
Influence of culture medium on growth of aggregates 
The ability to aggregate is independent of the type of medium in which the single cell 
suspensions are inoculated, however, once the aggregates are growing the type of 
medium becomes important: Figure 4.2 shows that the growth in Ham's F12 of LAN-1 
spheroids is slower (volume doubling time 5.4 days) than in RPMI1640 (volume 
doubling time 4.0 days). 
Another factor of importance are the supplements to the medium, such as the 
percentage FCS. Figure 4.3 shows growth curves of BRO and NB-100 spheroids 
growing in RPMn640 with either 10% or 20% FCS. The difference is more 
pronounced for BRO (volume doubling time decreases from 3.8 to 2.1 days) if the 
percentage of FCS is doubled. In NB-100 this decrease is less drastic (from 4.4 to 3.6 
days). 
Figure 4.4 shows the growth curves of NB-100 spheroids in RPMI1640 + 10% 
FCS + 500 or 1000 μg glucose/1. The addition of glucose to the culture medium 
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enhances the growth rate of spheroids; the difference between 500 and 1000 μg 
glucose/1, however, is not significant. 
volume M 0 6 μπι3) 
volume М О 6 ц т э ) -
1000-
100 
10 15 20 25 30 
time (days) 
Figure 4.2. Growth curves ofLAN-l 
neuroblastoma spheroids growing in two 
types of culture medium, RPMI1640 
and Ham's Fl 2 with same percentage 
of FCS. Each point represents the 
average ± SD of at least 20 spheroids. 
Figure 4.3. Growth curves of BRO mela­
noma and NB-100 neuroblastoma spheroids 
growing in RPMI1640 supplemented with 
either 10% or 20% FCS. Each point repres-
represents the average ± SD of at least 20 
spheroids. 
Tabic 4.3. Volume doubling time of four human tumor cell lines when grown in serum-free 
medium. Growth enhancement factor when different concentrations of Ex-cyte or 10% foetal 
calf serum (FCS) were added. 
Cell line 
BRO 
HN-1 
NB-100 
NCI-H125 
Volume 
doubling 
urne (day) 
(control) 
11.9 
9.9 
5.0 
19.0 
25 μg/ml 
Ex-cyte 
2.4 
1.2 
1.2 
1.0 
Growth Enhancement Factor 
50 μg/ml 
Ex-cyte 
3.8 
4.0 
1.9 
1.3 
100 μg/ml 
Ex-cyte 
6.0 
5.0 
2.5 
2.4 
10% 
FCS 
4.8 
5.8 
2.8 
4.2 
Figure 4.5 shows the growth curves obtained for BRO human melanoma spheroids after 
addition of different concentrations of Ex-cyte. All cell lines examined formed spheroids 
in serum supplemented medium, and could be propagated in serum-free medium. The 
volume doubling times that were thus obtained are listed in Table 4.3. The growth rate 
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ranges from 5.0 days for NB-100 neuroblastoma to 19.0 days for NCI-H125 lung 
adenocarcinoma spheroids. 
Addition of increasing concentrations of Ex-cyte increased the growth rate to different 
extents. Growth enhancement factors (GEF), defined as volume doubling time in serum-
free medium divided by volume doubling time in supplemented medium, after adding 
Ex-cyte of FCS to the medium are summarized in Table 4.3. In NCI-H125 the growth 
increase induced by adding Ex-cyte to the culture medium was the lowest (1.0-2.44. 
FCS gave a GEF increase of 4.2 in this cell line. In NB-100 spheroids a similar GEF 
could be reached (2.5), which in these spheroids was comparable to the effect of 10% 
FCS (GEF= 2.8). In BRO melanoma and HN-1 squamous cell carcinoma spheroids the 
growth rate was increased by a factor of approximately 5. In BRO the GEF induced by 
100 ц§/т1 Ex-cyte was in excess of the increase induced by 10% FCS. 
The clonogenicity of cells grown as spheroids and dispersed when the volume had 
increased to three times the initial volume, after culture in differently supplemented 
tissue culture medium is listed in Table 4.4. The clonogenicity is decreased in serum-
free medium when compared to supplemented media. No differences were observed 
between the media that were supplemented with varying concentrations Ex-cyte or 10% 
FCS. The absolute clonogenicity of cells from spheroids of the four cell lines differed 
considerably, but there was no relation to growth rates. 
The percentage of cells in the different stages of the cell cycle is shown in Table 4.4. 
In general, the fastest growing, NB-100 neuroblastoma, spheroids had a larger 
percentage of cells in the S and G2M-phase of the cell cycle, as compared to the slower 
growing spheroids. All four the cell lines responded to growth in serum-free medium 
with a drop in the S and G2M-phase. The different supplementations had no effect on 
the cell cycle distribution of any of the four cell lines. 
volume (. 1 0 6 ц т э ) -
.ΙΟΟΟμς glucose/l) 
. 5ΰ0μς glucose/l) 
flRPMI 1640. 
ІО . FCS 
5 10 15 20 timeldays) 
Figure 4.4. Growth curves of NB-100 
neuroblastoma spheroids growing in 
RPMI1640 supplemented with either 
500 or 1000 μg/l glucose. Each point 
represents the average ± SD of at 
least 20 spheroids. 
Figure 4.5. Growth curves of BRO mela­
noma spheroids growing in serum-free 
medium (SF-X)) supplemented with either 
10% FCS or graded concentrations of 
of Ex-cyte. Each point represents the 
average + SD of at least 20 spheroids 
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Table 4.4. Clonogenicity of cells from dispersed spheroids and flow cytometric DNA 
measurements of spheroids grown in serum-free medium (control), medium supplemented with 
varying concentrations of Ex-cyte, or 10% foetal calf serum (PCS)'). 
Cell line Medium Clonogenicity Cell cycle phases 
type (%) GI (%) S (%) G2M(%) 
average + SD average average average 
+ SD + SD + SD 
control 
25 μg/ml Excytc 
50 μg/ml 
100 μg/ml 
10% PCS 
control 
25 μg/ml Excyte 
50 μg/ml 
100 μg/ml 
10% PCS 
control 
25 μg/ml Excyte 
50 μg/ml 
100 μg/ml 
10% PCS 
control 
25 μ£/πι1 Excyte 
50 μg/ml 
100 μg/ml 
10% PCS 
9.0 + 1.1 
15.3 + 1.9 
14.2 + 2.0 
18.2 + 3.1 
17.5 + 2 . 7 
1.8 + 0 . 2 
3.2 + 0.9 
5.2 + 1.1 
4.3 + 0.8 
4.2 + 0.9 
3.5 + 1.3 
7.8 + 2.1 
7.9 + 2.1 
7.7 + 1.8 
7.7 + 2.3 
2.3 + 1.1 
4.1 + 1.0 
4.3 + 1.1 
4.1 + 1.1 
4.2 + 1.2 
85.0 + 2.4 
58.4 + 1.8 
56.9 + 2.4 
56.5 + 4 . 5 
57.3 + 5.1 
84.3 + 4 . 0 
60.2 + 1.6 
67.0 + 5.5 
63.2 + 3.7 
66.8 + 2.7 
70.5 + 4.5 
64.5 + 0.8 
67.4 + 5.6 
65.5 + 2.5 
64.7 + 4.2 
82.3 + 4.2 
68.2 + 3.4 
67.1 + 6 . 7 
66.9 + 4.9 
64.2 + 3.3 
7.5 + 2 . 0 
23.1 + 0.9 
24.2 + 1.9 
24.3 + 2.4 
22.3 + 4.1 
9.1 + 1.7 
19.7 + 1.5 
18.9 + 5.2 
18.7 + 4 . 2 
17.1 + 2 . 9 
15.5 + 2.5 
22.3 + 0.9 
18.7+ 5.0 
17.5+ 3.9 
2 2 . 1 + 2 . 1 
8.9 + 1.3 
14.3 + 2.8 
15.5 + 3.1 
16.9 + 2 . 3 
18.1 + 5.2 
7.5+1.8 
18.1+1.2 
20.7+2.2 
19.8+2.7 
19.2+3.6 
7.1+ 1.2 
20.7+ 1.7 
14.1+2.4 
16.6+4.1 
1 5 . 4 + 2 . 2 
14.0+4.6 
13.0+.0.9 
14.1 ±_ 1.8 
17.2 i 2.3 
12.8 + 1.2 
7.8 + 1.0 
16.6 + 1 . 6 
16.5 + 4 . 3 
16.5 + 2 . 9 
18.0 + 4.3 
' ' more than 20,000 cells were analyzed 
Intermediate filament expression 
The expression patterns of cytokeratins (CKs) and vimentin in human tumor cell lines 
as detected with immunocytochemical techniques are shown in Table 4.5. Antibodies 
1C7 (CK13) and RKSE60 (CK10) were negative for all cell lines. 
The expression of vimentin is shown by all reference lines, not by the small cell 
lung cancer lines of the variant type, only part of the cells expressed vimentin, and only 
one bladder carcinoma line. 
DISCUSSION 
The capacity to form growing spheroids is not a general property of human tumor cells 
in culture, and attempts to form spheroids from lung and bladder cancer cell lines have 
but seldom been succesful (51,112). In this study, 11 cell lines were tested for their 
ability to form spherical aggregates. Two cell lines, NCI-H125 and 5637, were found to 
BRO 
HN-1 
NB-100 
NCI-H125 
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form spherical aggregates (Table 4.1) but only 1 (NCI-H125) exhibited growth (Table 
4.2). The viability of the cells in both growing and non-growing spheroids did not differ 
directly after initiation, and clonogenicity also did not show a general pattern. In 
addition, aggregates with similar diameter like NB-100 and LAN-1 contain different 
numbers of clonogenic cells, but exhibit similar growth rates; this seems to indicate 
that the growth of spheroids is only partly determined by the number of clonogenic 
cells. Since it is generally accepted that tumors after treatment are able to regrow from a 
single clonogenic cell (89), and since these cells are present in aggregates that exhibited 
no growth, it is possible that the growth of these cells is determined by factors that are 
not present in all spherical aggregates. 
It has been shown that responses to radiation and cytostatic treatment in vivo depend 
to a great extent on the growth rate of tumors (37). Since the volume doubling time of 
spheroids in vitro can be manipulated, they are ideal models for the study of tumor 
responses to chemo- and radiotherapy in vitro. Results from studies on the radiation 
responses of spheroids growing with different growth rates will be reported upon in this 
thesis. 
Four cell lines studied here were able to form and grow as spheroids in serum-free 
medium, which indicates that certain factors not present are limiting for growth of 
human tumor cells in 3-dimensional culture. The succesful propagation of human tumor 
spheroids in medium supplemented with Ex-cyte, reflects the greater complexity of this 
medium-type, and indicates that albumin and trace elements may be essential 
components. 
The wide range in volume doubling times (5.0-19.0 days) expressed by the four cell 
lines when spheroids were grown in serum-free medium, indicates that the dependence 
on nutrients for optimal growth is different for each line. Nevertheless, the growth rate 
of the slowest growing spheroids (NCI-H125) is affected to the same extent by the 
addition of serum (GEF= 4.2), as the faster growing spheroids (GEF= 4.8 and 5.8 for 
BRO and HN-1, respectively). 
The clonogencity of cells grown in spheroids was increased when serum-free medium 
was supplemented with either Ex-cyte or FCS. This indicates that the growth rate of 
clonogenic cells was not proportional to the growth rate of the non-clonogenic cells in 
spheroids. This is in agreement with results from spheroids grown in different 
concentrations of glucose (62) and with the results obtained in this study with spheroids 
dispersed directly after initiation. 
Cell cycle distributions based on DNA analysis of flow cytometric data showed that 
the fastest growing spheroid types had a higher fraction of S-phase and G2M-phase 
cells. This is in good agreement with the results reported by Yuhas and Li (117), who 
reported the growth fraction of spheroids to be the major determinant of their growth 
rates. Surprisingly, the addition of different concentrations of Ex-cyte or 10% FCS did 
not have an effect on the cell cycle distribution when inter-compared, although the 
growth rates in different concentrations of Ex-cyte were significantly different. One 
might speculate whether the reduced growth rate observed for spheroids grown in serum-
free medium is caused by an increased shedding of mitotic cells from the spheroids 
propagated in serum-free medium (118), or whether this phenomenon is caused by an 
increased cellular doubling time. When during tissue culture the medium was changed 
once a week, shedded cells were collected and counted in a hemacytometer, and no 
differences were found in the number of shedded cells when spheroids were cultured under 
various conditions (data not shown). This indicates that the latter explanation is the 
most plausible. 
Intermediate Filaments in eukaryotic cells constitute a considerable part of the 
cytoskeleton in addition to microfilaments and microtubules. A constituent of 
intermediate filaments is vimentin, which seems to be characteristic of cells of 
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mesenchymal origin, but is also expressed by many cells in culture and can be present 
in addition to specific tissue filaments, suggesting that vimentin filaments are produced 
in culture conditions (119). A role for vimentin in cell anchorage has been suggested 
(120). In this study it was found that vimentin was not expressed by tumor cells that did 
not show spheroid formation of category III or IV. It seems that the absence of 
expression of vimentin can be used as an indication for the spheroid forming ability of a 
cell line. The growing ability of spherical aggregates, however, is probably determined 
by other factors. 
Table 4.5. Expression of intermediate filaments in human tumor cell lines as detected by 
immunocytochemical techniques. 
Cell line RCK102 RCK105 RCK106 6B10 RV202 
CK 5+8 CK.7 CK18 CK4 vimentin 
NB-100 
LAN-1 
BRO 
HN-1 
NCI-H69 
Να-Η449 
NL-SCLC2 
NCI-H82 
NCI-H524 
NCI-H23 
NCI-H125 
T24 
647V 
VM-CUB-2 
5637 
-
. 
-
+ 
+ 
+ 
+ + 
. 
-
+/-
+ + 
+/-
ND 
+ + 
+ 
-
. 
-
-
_ 
+/-
-
. 
-
s.c. 
+ + 
+ + 
++ 
+ + 
+ + 
. 
. 
. 
+ 
+/-
+ 
+ + 
. 
-
+/-
++ 
++ 
++ 
+ + 
+ + 
-
-
-
-
_ 
-
-
-
-
-
-
_ 
-
-
+ + 
+ 
+/-
+ + 
+ + 
_ 
. 
-
+/-
+/-
+ + 
+ 
_ 
. 
-
+ + 
-, no reaction in any cell; s.c, weak to strong staining reaction in some cells; +/-, 
reactivity in part of the cells (10-90%); +, reactivity in more than 90% of all 
cells; ++, strong reactivity in all eels. ND: not done. 
There are two general morphological characteristics of spheroids that could be 
established: 1) the presence of central degenerative cores (see Fig. 4.6), and 2) a 
morphology similar to the in vivo counterparts of the same cell type (Fig. 4.6, panels 
F and G). There exist large variations in morphology among the different tumor types 
(121) and even between different regions within the same tumor (122), due to differences 
in vascularization and hence supply of oxygen and nutrients (123). Since availability of 
nutrients and oxygen in a spheroid is limited by diffusion from the medium, depending 
on the cellular composition within the spheroid, it seems logical that the thickness of 
the viable cells rim, which depends on availability of oxygen and nutrients, should 
remain constant, independent of spheroid size. 
Unfortunately only a limited number of human tumor cell lines produce spheroids, 
as is shown by this study. The expression of vimentin may indicate the capacity of a 
cell line to aggregate to spheroids. Whether growth of the aggregates is exhibited 
remains a process of trial and error. Limited data from radiation studies where in viiro 
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spheroids were used are available. The use of different tumor types growing as spheroids 
may be helpful in elucidating the role of different factors in the curability of tumors and 
could then be of direct therapeutic relevance. 
Figure 4.6. Small (± 200 цт) almost solid spheroid from LAN-1 neuroblastoma cell 
line (panel A), intermediate spheroid (±375 pm) from LAN-1 cell line with small 
central necrosis (panel B) and large (+ 800 pm) spheroid f ют LAN-1 cell line with 
large necrotic center (panel C). Section from a HN-1 squamous cell carcinoma spheroid 
with spontaneous giant cells (panel D) and lung adenocarcinoma NCI-H125 spheroid 
with clear adenoid configuration (panel E). Sections from NB-100 neuroblastoma cell 
line spheroid (panel F) and in vivo xenograft from same cell line (panel G)) 
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Chapter 5 
Radiosensitivity of different human tumor 
cell lines grown as xenografts and as 
spheroids 
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Radioseositivity of different human tumor cell lines grown 
as xenografts and as spheroids 
ABSTRACT 
Five human tumor cell lines were grown as multicellular tumor spheroids іл vitro and as 
xenografts in vivo to determine whether tumor cells, derived from human tumors, grown in 
these two mode] systems would show tumor-type dependent differences in response to single-
dose irradiation, and whether these differences paralleled clinical behavior. Spheroids and 
xenografts from neuroblastoma, lung adenocarcinoma, melanoma and squamous cell 
carcinoma of the oral tongue, were studied in terms of growth delay, calculated cell survival 
(spheroids only), and control doseso (TCD50 and SCD50). Growth delay and cell survival 
analysis for the tumor cell lines studied showed sensitivities that correlated well with clinical 
behavior of the tumor types of origin. The cure dose for the melanoma line deviated from the 
general pattern, similar to other reports on melanomas. The xenografts were grown and 
irradiated in immunodeficient animals. To exclude an immunorcaction of the host in the 
radiation response of the tumor xenografts, the tumor lines were tested for their growth in 
immunosuppressed Wistar rats. No differences in growth rate of xenografts either in 
immunodeficient mice or in immunosuppressed rats were observed. Both growth delay and 
local tumor control as expressed by cure correlated well with clinical behavior of the tumor 
types of origin. This study demonstrates that radiosensitivity of human tumor cell lines can 
be evaluated in terms of growth delay, calculated cell survival, and spheroid control dose50 
when grown as multicellular tumor spheroids, and in terms of growth delay and tumor control 
dosejo when grown as xenografts. The radiosensitivity established from the ш vivo 
evaluations parallels clinical behavior, thus offering a tool for analysis of human tumor 
radiosensitivity of histologically different tumors. The sensitivity established from the in 
vitro determinations parallels clinical behavior and correlates well with the in vivo studies, 
thus offering an unique tool for the in vitro analysis of human radiosensitivity. 
I N T R O D U C T I O N 
Clinical investigations have shown the response to radio- and chemotherapy of human 
tumors to differ significantly among individual patients. Whereas the resistance of 
certain types of human tumors to conventional radiation therapy is clear, the 
understanding of the biological basis for the observed differences is still unexplained. 
Treatment responses can depend upon histological type and differentiation status. The 
best known classification of the radiosensitivity of different tumor histologic types was 
that of Paterson (124), who divided all tumors in three groups: radiosensitive, tumors of 
intermediate radiosensitivity, and radioresistant. Classifications of this type are still 
valid; as a class, it is indisputable that melanomas are more radioresistant than 
lymphomas. 
Murine and rat tumors have been used by many investigators (1,5,14,125,126,127) 
in studies aimed at improving the radiotherapy of human cancer. Valuable information 
on the biology of solid tumors has thus been obtained. However, it has not been 
possible to explain the underlying mechanisms for inter-tumor differences in response to 
radiotherapy. 
A simple experimental model for in vivo studies of human tumors may in some 
ways be preferable to rodent tumor systems. Recently, new and improved procedures for 
immuno-suppresssion of conventional Wistar rats and subsequent heterotransplantation 
of human tumors have been developed (104). In addition, congenitally athymic mice 
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have been shown to be useful as hosts for human tumor xenografts (128,129). No 
pretreatment of these mice is necessary, although the 'take' of some, especially primary, 
tumors may be improved by immuno-suppressive pretreatment. 
In vi'froradiosensitivity studies have gained considerable impetus from evidence that 
cell lines differ markedly in their response to radiation. The observed clinical curability 
of a certain tumor type can be correlated with intrinsic radiosensitivity in vitro (44,130), 
the capacity to repair radiation induced damage (75) and radiation response when grown 
as multicellular tumor spheroids (MTS) (49). 
Spheroids provide an in vitro model of intermediate complexity between monolayer 
cultures and in vivo tumors (21), with characteristics that make them an interesting 
model of small solid tumors. These factors include the expression of contact resistance 
(131), the development of kinetic and metabolic heterogeneity (37), and the availability 
of a variety of end-points of response to treatment (38). 
The question to be considered is whether xenografts and spheroids will behave 
uniformely to radiation treament or whether behavior will depend on the tumor of 
origin. Several studies have reported on the single-dose radiosensitivity of human tumor 
cells grown as xenografts, and included different histological types of tumors. Steel 
(132) has summarized the data in a recent review from which two interesting 
conclusions can be drawn. Firstly, the radiation response varies considerably among 
xenografts. Secondly, there is some evidence that the radiation response correlates with 
the clinical radioresponsiveness of tumors of corresponding histology. 
Several reports have have now appeared on the single-dose radiosensitivity of two 
types of human tumor cells grown as spheroids. Either neuroblastoma (47,48), 
melanoma (46) or both (49) were used in these studies, showing a good correlation with 
clinical behavior of both tumor types. In this chapter the radiosensitivity of five human 
tumor spheroid lines of different origin, namely, neuroblastoma, lung adenocarcinoma, 
melanoma and squamous cell carcinoma of the tongue, is described. Radiation response 
of 250 μηι ( ± 8 μπι, SE) spheroids was quantified in terms of growth delay, calculated 
cell survival and spheroid cure rate. Radiation response of 7-10 mm xenografts was 
quantified in terms of growth delay and tumor cure. 
RESULTS 
Using the various techniques described in chapter 3 the following results were obtained. 
Regrowth curves following treatment 
Table 5.1 shows the baseline growth data of each of the five cell lines growing as both 
spheroids and xenografts. Volume doubling times for spheroids vary from 1.7 d for the 
neuroblastoma line NB-100, to 3.7 d for the lung adenocarcinoma Une NC1-H125. For 
xenografts the volume doubling times vary from 2.9 d for NB-100 to 11.1 d for the 
squamous cell carcinoma cell line HN-1. There is no relationship between the 
monolayer culture doubling times and the respective volume doubling times when 
tumor cells are grown as spheroids and xenografts. Figures 5.1 and 5.2 are growth 
curves for BRO melanoma spheroids and xenografts, respectively, constructed by 
plotting volume/initial volume as function of time after treatment. The growth curves 
of the two different models indicate different sensitivity for radiation. Whereas a single 
dose of only 10 Gy causes a static phase in the growth of the BRO spheroids, a similar 
growth delay in xenografts requires a dose of 90 Gy. 
In all five the tumor lines a similar pattern of responses could be observed; a dose 
dependent lag period, in which size remained constant, followed by a period of regrowth 
with similar growth rates as control spheroids and xenografts. 
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Figure 5.1 Growth curves of BRO mela­
noma spheroids after irradiation with single 
doses of 18 MVXrays. The Y axis repres­
ents the relative volume, plotted as 
volume/initial volume. Each point 
represents the average volume ± SE of at 
least ten spheroids. 
Time (day) 
Figure 5.2 Growth curves after irra­
diation of human melanoma BRO 
grown as xenografts in nude mice. 
Each point represents the average 
volume + SE of at least five xeno­
grafts. Dots: untreated controls; 
circles: 20 Gy; closed squares: 40 Gy; 
open squares: 70 Gy; triangles: 80 Gy 
Figure 5.3 shows the growth curves for unirradiated xenografts of three human tumor 
lines when grown as xenografts in both immunodeficient mice (open symbols) and in 
immunosuppressed rats (closed symbols). There is no significant difference in volume 
doubling time when these cells were grown in two animal models for HN-1 and BRO, 
indicating that there is no contribution of immune response in the mouse model. For 
NB-100 the growth was even more rapid in the immunodeficient mice than in immuno 
suppressed rats. 
Figure 5.4 shows the time period to obtain a 5-fold of the volume at time of 
irradiation TD, as a function of dose for spheroids (panel A), and the time period to 
obtain a 2-fold of the volume for xenografts (panel B). The lines are the best fit for all 
data points described by TJ/TQ = e«0. Table 5.1 summarizes the estimated growth delay 
constant for the tumor lines studied when grown as spheroids and xenografts. Based on 
this parameter in spheroids as well as in xenografts, the melanoma BRO and the lung 
adenocarcinoma NCI-H125 are the least sensitive to radiation, whereas the 
neuroblastomas NB-100 and LAN-1 and the squamous cell carcinoma HN-1 are equally 
sensitive as spheroids. The first and the latter are also equally sensitive as xenografts. 
Estimation of cell survival 
The regrowth curves for spheroids showed a return to parallelism with control growth 
curves and therefore satisfied the condition for estimation of cell survival by back-
extrapolation of regrowth curves. Estimates of cell survival were fitted according the 
multitarget model and Do-values for each spheroid line were obtained. As has been 
shown previously (22) the values for the extrapolation number N, obtained with this 
method, are commonly higher than those for clonogenic cells. This was also noted in 
this study, and could occur because of the relatively high doses, usually in excess of 3 
Gy. This tended to increase the size of the shoulder region, and hence the extrapolation 
number. For comparisons of radiosensitivity of the five lines the extrapolation numbers 
were discarded. The results of the analysis of back-extrapolated growth curves are 
summarized in Table 5.1. Based on this parameter the most radiosensitive tumor lines 
are the neuroblastoma line NB-100, squamous cell carcinoma line HN-1, and the other 
neuroblastoma line LAN-1. The least sensitive lines are the melanoma line BRO and 
lung adenocarcinoma NCI-HI 25. 
Determination ofSCDjo and ТСО
я 
Figure 5.5 shows the percentage cured spheroids (panel A) and xenografts (panel B) as a 
function of total dose for each cell line. Results of SCDSQ and TCD50 calculations are 
presented in Table 5.1. Using this endpoint in spheroids, the melanoma seems to be the 
most sensitive (SCDso = 5.6 Gy), and the lung adenocarcinoma line the least sensitive 
(SCD50= 9.3 Gy). In xenografts, this endpoints indicates the NB-100 neuroblastoma to 
be the most sensitive ( T C D ^ 39 Gy), and the lung adenocarcinoma line NCI-H125 the 
least sensitive ( T C D ^ 74 Gy). 
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Figure 5.3. Growth curves for three human tumor lines grown as xenografts in 
immunodeficient mice, open symbols, or in immunosppressed rats, closed symbols. 
Circles: neuroblastoma NB-100; squares: melanoma BRO; triangles: squamous cell 
carcinoma HN-1. 
DISCUSSION 
This study was performed to determine whether spheroids and xenografts derived from 
different types of human tumor lines would show tumor-type dependent differences in 
response to single-dose irradiation, whether these differences paralleled clinical behavior, 
and whether the ranking in spheroids correlated with xenografts. The curability of 
malignant tumors is related both to local control and to the development of metastatic 
disease. In this study radiocurability is defined in terms of the ease of local control. 
Especially when local control is used as an endpoint, immune responses by the host 
may be a potential source of artefacts in therapeutic studies of xenografts (105). For this 
reason we compared the growth of the human tumor lines used in this study when 
grown as xenografts in an immunedeficient model and an immunosuppressed model. 
There were no differences in growth rates in the two models, nor was the "take" higher 
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in the immunesuppressed model, excluding the possible contribution of immune 
defences in the radiation responses. 
Tumor growth delay is a conventional endpoint for evaluating radioresponsiveness of 
most human tumor xenografts. This endpoint is easy to use in practice, and 
discriminates adequately between the effect of different treatment doses for a given 
xenograft line (133). However, there is no generally accepted way of analyzing growth 
delay data in order to compare the treatment sensitivity of different xenograft lines. We 
chose the growth delay constant as described in Materials and Methods section, since 
this parameter was previously used for comparing radiosensitivity of the cell lines used 
in this study (49). 
The four tumor lines used were derived from tumor types considered to be of different 
radiocurability. From a tumor type considered locally radiocurable (neuroblastoma lines 
NB-100 and LAN-1), from two tumor types considered not clinically radiocurable (lung 
adenocarcinoma NCI-H125 and melanoma BRO), and a line derived from a tumor 
generally considered of intermediate radiocurability locally, a squamous cell carcinoma 
of the oral tongue (HN-1). 
Table 5.1. Radiosensitivity of human tumor lines grown as spheroids and as xenografts, 
expressed as growth delay constant, control dose (SCD50 and TCD50) and DQ for spheroids. 
Tumor 
line 
NB-100 
HN-1 
LAN-1 
BRO 
NCI-H125 
Volume 
doubling 
1.7 
2.1 
2.4 
3.6 
3.7 
SPHEROIDS 
g' + SE 
(Of1) 
time (day) 
0.18 + 0.02 
0.24 + 0.09 
0.16 + 0.04 
0.09 + 0.04 
0.10 + 0.02 
D o ± S E 
(ОЙ 
0.9 + 0.2 
1.0 + 0.1 
1.3 + 0.2 
3.6 + 0.1 
2.6 + 0.3 
SCD502 
+ SD (Oy) 
8.3 + 0.5 
6.3 + 0.4 
7.5 + 0.5 
5.6 + 0.4 
9.3 + 0 . 5 
XENOGRAFTS 
Volume gl + SE T C D ^ 
doubling (Gy-1) +SD(Gy) 
2.9 
11.1 
n.d. 
3.2 
10.3 
time (day) 
0.11 + 0.03 39 + 7 
0.09 + 0.02 4 7 + 6 
n.d. n.d. 
0.05 + 0.02 6 8 + 8 
0.03 + 0.02 74 + 7 
': growth delay constant, see Materials and Methods section. 
2
: Dose to sterilize 50% of irradiated spheroids (SCDjoJor xenografts (TCDSQ). 
n.d.: not done. 
Growth delay determination 
Growth delay was expressed as a growth delay constant, g, a parameter which was 
previously used by Evans et al. (49) for the NB-100 and LAN-1 cell lines. In this study 
comparable values results for these cell lines in vitro were found. The g-values for the 
tumor lines grown as xenografts, obtained in this study are not of the same magnitude 
as when grown in vitro as spheroids, but a similar ranking was found. The values 
obtained for NCI-H125 lung adenocarcinoma and BRO melanoma lines is in agreement 
with the clinical incurability of these types of tumors. The g-value obtained for the 
squamous cell carcinoma indicates radiosensitivity equal to that of the neuroblastoma, 
whereas in the clinical situation this tumor type is considered to be relatively 
radioresistant, since when it reaches large dimensions it becomes necrotic because of 
poor blood supply and inadequate oxygenation (134). Small tumors, however, such as 
those used in this study, show favorable responses to radiation treatment (135). In this 
context the growth delay constant as derived in this study would be in agreement with 
this clinical curability. 
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Figure 5.4. Radiation sensitivity of five human tumor cell lines expressed as the time 
period required to obtain a 5-fold increase in spheroid volume (panel A), or to obtain a 
2-fold increase in xenograft volume (panel B). Radiation was applied as single doses. 
Each data point represents the average growth + SE of ten spheroids or five xenografts. 
The drawn line is the best fit for all radiation doses. 
Calculated cell survival 
Spheroids from a number of human tumor lines have been found to be highly sensitive 
to artefactual cell killing during disaggregation (136), making analysis of the survival of 
single cells obtained from spheroids ¡npractical. In addition, such determinations are 
often hampered by low plating efficiencies. In those cell lines where disaggregation is 
possible the survival of clonogenic cells is to be preferred since this renders the best 
indication of radiosensitivity (137). However, back-extrapolation of regrowth curves and 
subsequent determination of Do-values have been shown to be comparable with those 
obtained from disaggregated spheroids of human melanomas (42). The Do-values of the 
cell lines used in this study and obtained by the method of Wheldon et al. (48) indicated 
that the least sensitive cell lines would be the melanoma (D0= 3.6 Gy) and the lung 
adenocarcinoma (Dor 2.6 Gy). The other three lines would be of comparable sensitivity 
(Do= 1 Gy). Recently it has been shown that parameters such as the survival at 2 Gy 
give a more accurate indication of radiosensitivity (23). In the cell lines studied here the 
2 Gy gave practically no growth delay, and for this reason was omitted. 
TCD50 and SCDjQ analysis 
The TCD50 and SCDjo values for the two clinically sensitive tumor types are lower than 
those for the two types considered to be of limited radiocurability clinically. Local 
tumor control following radiation treatment has occasionally been observed for human 
tumor xenografts, but has not often been used as an endpoint. TCD50 values have been 
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reported to be lower than expected from calculations using in vitro survival data ( 138), 
which were initially attributed to a lower number of clonogenic cells in vivo than 
estimated in vitro, perhaps as a result of radiation-induced vascular damage. An immune 
response by the host was also implicated. Since this latter factor was ruled out in this 
study, the conclusion must be, contrary to Rofstad (138), that local control, as 
expressed by TCD50, can be representative for tumor cure in humans. 
In their study on the radiosensitivity of spheroids initiated from human melanoma 
xenograft lines, Rofstad et al. (45) derived SCDsQ-values in the range from 3.6 to 6.6 
Gy. The value of 5.6 Gy found for the BRO melanoma cell line in this study is well 
within this range. However, if compared with the SCDso-values for the other cell lines 
it is the lowest of all, and in contrast with the other two parameters, it would indicate 
the highest radiosensitivity. In determining the growth of spheroids we are not 
measuring radiation sensitivity in the strict sense, but rather radiation responsiveness, 
that is, the complex interaction of cell killing, repair, and repopulation (139). As 
Durand and Sutherland (137) pointed out, cells that were not inactivated by radiation 
may not be in a position to proliferate and contribute to growth. In their view this is 
the major draw-back of the SCDjo-assay. Alternatively, radiation-inactivated cells may 
not have been broken down and removed completely at the time the required relative 
volume increase was achieved, that is, these cells may have contributed to the volume 
of the irradiated spheroids and xenografts. The low number of regrowing spheroids of 
melanoma BRO in the cure experiment, as opposed to the low growth delay constant, 
may reflect a large fraction of cells which survived the radiation treatment, but died of 
other reasons before they were able to initiate regrowth. In their study on Nail 
melanoma cell line Pourreau-Schneider and Malaise (38) also found a discrepancy 
between cure and regrowth delay as endpoints of radiation responsiveness. They argued 
that metabolic waste could contribute to the increase in volume even after sterilizing 
doses. In a recent review Mueller-Klieser (29) pointed out that spheroids may reflect the 
intrinsic radiosensitivity of the tumor cells as well as the influence of a 'tumor-like' 
microenvironment of this sensitivity. In this view the differences in radiosensitivity 
observed in our investigation might be attributable to cell line specific differences in 
spheroid oxygenation, energy metabolism, pH and possibly growth rate. Moreover, in 
later studies (Chapters 8 and 9) the cure dose for BRO spheroids was much higher, and 
more in agreement with the clinical incurability of its parent tumor type. 
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Figure 5.5. Tumor control as expressed by the percentage of cured spheroids (panel A) 
and xenografts (panel B) of five human tumor cell lines as a function of radiation dose, 
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The differences in doses required to cure spheroids and xenografts of the same cell 
line can be explained by the fact that in xenografts there are far more cells to be killed. 
Also, the presence of hypoxic cells, which require a higher dose to be sterilized, in 
xenografts can contribute to this difference. A similar difference between spheroids and 
xenografts was also observed in the magnitudes of the respective growth delay 
constants. 
Comparisons of parameters 
In spheroids there was a poor correlation between SCD50 with growth delay constant and 
Do-values (-0.16 and -0.24, respectively). The correlation between Ц) and growth delay 
is very high: -0.88. Since both parameters are obtained from data of spheroid volume, 
this is not surprising. When data of the BRO melanoma line were omitted the first two 
correlations increased to -.092 and 0.73, respectively. 
There is also a clear relation between the radiosensitivity and the growth rates of the 
spheroids: the most sensitive are the most rapidly growing cells. This might be a 
tumor-type specific property of the cell line used. To elucidate the contribution of 
growth rate in one type of spheroids, results of further studies are reported in chapter 8. 
In xenografts the rankings of TCD50 values with growth delay constant values 
showed a high correlation: 0.99. There is no clear relation between the radiosensitivity 
and the growth rate of the xenografts. The slowest growing line, HN-1, and the line NB-
100 which grows significantly faster, are equally sensitive. 
Growth delay studies of xenografts following single dose irradiation have been 
carried out at several institutes and include different histological types of tumors, which 
have been summarized by Steel (132). In practically all cases one type of tumor 
histology was studied, and the radiosensitivity was found to be similar to the parent 
type of tumor. The radiation response varied among the xenografts of the same tumor 
type, which was especially so for human melanomas (133). On the other hand, the 
growth delay after irradiation of three lung tumor xenograft lines was recently reported 
to be virtually the same (140). This is one of the First studies using xenografts derived 
from diverse histological types of tumors for determination of radiosensitivity. 
CONCLUSIONS 
The results support the finding that radiosensitivity of human tumor cells can be studied 
in terms of growth of xenografts and spheroids. Growth delay and DQ-values as obtained 
by extrapolation of regrowth curves, can both be used for the evaluation of radiation 
responsiveness of human tumor cells grown as spheroids. The sensitivity established 
from these evaluations parallels the clinical behavior of the studied tumor types. The 
SCDso assay is also applicable, but for reasons not yet clearly understood, the results for 
the melanoma line deviate from the general pattern. 
Growth delay and tumor cure can both be used for the evaluation of radiation 
responsiveness of human tumor cells when grown as xenografts in nude mice. The 
sensitivity established from these evaluations also parallels the clinical behavior of the 
studied tumor types. Moreover, the ranking obtained from the spheroid studies and is the 
same as in the tumor xenograft studies, showing that spheroids indeed reflect tumor 
responses in vivo. Therefore, spheroids are an appropriate model to study radiation 
phenomena in vitro. 
52 
This chapter was based on: 
JHM Schwachöfer, RPMA Crooijmans, JJM van Gasteren, J Hoogenhout, CR Jerusalem, HB 
Kal, AGM Thecuwes: Radiosensitivity of different human tumor cell lines grown as 
multicellular spheroids determined from growth curves and survival data. Int J Radiât Oncol 
Biol Phys 17: 1015-1020, 1989 
and: 
JHM Schwachöfer, J Hoogenhout, HB Kal, J Koedam, HPN van Wezel: Radiosensitivity of 
different human tumor lines grown as xenografts determined from growth curves and survival 
data. In Vivo 4: 253-258, 1990 
Chapter 6 
Repair of sublethal damage in human 
tumor cell lines of different 
radiosensitivity when grown as 
multicellular spheroids 
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Repair of sublethal damage in human tumor cell lines of 
different radiosensitivity when grown as multicellular 
spheroids 
ABSTRACT 
Four cell lines of human origin, obtained from a neuroblastoma (NB-100), a squamous cell 
carcinoma (HN-1), a lung adenocarcinoma (NCI-H125) and a melanoma (BRO), were exposed 
to graded doses (3-11 Gy) of radiation with 18 MV photons. Radiation was applied either as a 
single or as a split dose with an interval of 6 h to determine the extent of sublethal damage 
repair. Treated spheroids regrew at approximately the same growth rate as control spheroids, 
precceded by a static or regression phase. Radiation response was quantified in terms of 
growth delay, expressed as the time needed for treated spheroids to obtain an 8-fold increase 
of the initial volume at the time of irradiation. Data obtained from regrowth delay analysis 
were used to calculate the extent of sublethal damage repair, showing no systematic 
differences between the four cell lines. Repair increased with larger dose fractions in all four 
the cell lines. The capacity to repair sublethal damage as expressed by the fl-value of the LQ-
equation showed that there were no differences between the four cell lines, independent of the 
respective radiosensitivities. Our results with different human tumor cell lines grown as 
spheroids show that differences in radiosensitivity are not caused by differences in repair 
capacity, but by intrinsic cellular radiosensitivity. 
INTRODUCTION 
Radiotherapy is used with curative intent in cancers such as neuroblastoma and 
squamous cell carcinoma of the head and neck, whereas the nature of treatment in 
melanoma and non-small cell lung cancer is mainly of a palliative nature. However, 
many series show that up to 10%-15% of patients with lung cancer and melanoma may 
be long-term survivors after radical irradiation for inoperable tumors. This suggests that 
radiotherapy has a potential for the local control of these tumors, although factors to 
treatment failure or success have not been clearly defined. 
Several authors have claimed that the differences in intrinsic radiosensitivity among 
human tumor cell lines are too small to account for the differences in radiation response 
observed among tumors in the clinic (141). However, interest in cellular radiosensitivity 
was increased since the studies of Deacon et al. (44) and Fértil & Malaise (43) showed 
survival curve characteristics to be correlated with clinical radiocurability. Some of the 
factors thought to be responsible for the clinical variability of tumor responses can be 
studied at the cellular level, for example, the intrinsic radiosensitivity of human tumor 
cells in culture (43), the capacity for repair of sublethal and potentially lethal damage 
(142,143), and the radiation response when grown as multicellular spheroids (28,75). 
It is generally accepted that a difference in sparing effect between normal and 
tumorous tissues due to fractionated irradiation may offer a therapeutic advantage, 
provided that tumor cells are less likely to be spared. This chapter presents the results of 
studies on the response of spheroids, derived from four tumor cell lines of human 
origin, to single-dose as compared to split-dose irradiation to determine the extent of 
sublethal damage repair. Two cell lines, NCI-H125 lung adenocarcinoma and BRO 
melanoma, clinically considered to be of limited radiocurability were compared with two 
cell lines, squamous cell carcinoma of the tongue HN-1 and NB-100 neuroblastoma, 
considered to be of moderate and high radiocurability, respectively. 
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RESULTS 
Using the various techniques described in chapter 3, the following results were obtained. 
Spheroid growth curves 
The growth curves of control and irradiated spheroids of NB-100 are shown in Figure 
6.1A and B. The first part of the control growth curve is exponential, with a volume 
doubling time of 1.7 days. The growth curves for irradiated spheroids show a delay, or a 
regression phase, before resuming growth with volume doubling times close to control 
values. The lateral displacement (growth delay) of the growth curves after irradiation is 
proportional to the dose. 
Growth curves after irradiation of NC1-H125 lung adenocarcinoma spheroids are 
shown in Figure 6.2A and B. Volume doubling time during exponential growth phase 
was 3.7 days. A dose-dependent retardation in volume increase was observed in the 
irradiated spheroids at low single doses (panel a). At higher doses a dose-dependent 
regression of spheroid size was exhibited, after which growth proceeded at a rate 
comparable to that of untreated controls. The split-dose (panel b) irradiated spheroids 
showed a similar pattern, but the degree of response was less pronounced when 
compared with the single doses of equal total dose. 
Growth delay as a function of the total dose for both single-dose and split-dose 
groups are shown in Figures 6.3A and В for the responsive tumor types NB-100 and 
HN-1, respectively. Specific growth delay as a function of total dose for both single-
dose and split-dose groups are shown in Figures 6.4A and В for the unresponsive tumor 
types BRO and NCI-H125, respectively. Specific growth delay defined as time to obtain 
an 8-fold of the volume at the time of irradiation - time of control spheroids/volume 
doubling time of untreated control spheroids. There is an obvious difference in growth 
delay after single and split-dose irradiation, indicating repair of sublethal damage in all 
four the tumor cell lines. 
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Figure 6.1. Growth curves of neuroblastoma spheroids (NB-100) with single doses 
(panel A), and split doses (panel В) of 18 MV X rays. Expressed is volume/initial 
volume as a function of time after treatment. Each point represents the average volume 
of at least ten spheroids. Bars represent standard errors. 
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Figure 6.2. Growth curves for lung adenocarcinoma spheroids (NCI-H125) with 
single doses (panel A), and split doses (panel B) of 18 MV X rays. Expressed is 
volume/initial volume as a function of time after treatment. Each point represents the 
average volume of at least ten spheroids. Bars represent standard errors. 
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Figure 6.3. Growth delay (time to obtain an 8-fold of the volume at the time of 
irradiation - time of control spheroids) of treated spheroids as a function of total dose for 
neuroblastoma NB-100 (panel A) and squamous cell carcinoma line HN-1 (panel B) 
irradiated with single and split doses of 18 MVX rays. 
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Quantification of sublethal damage repair 
A "dose repaired" was calculated from the growth delay curves shown in Figures 6.3 and 
6.4. In Table 6.1 the dose repaired calculated for the four tumor cell lines is shown for 
the employed fraction doses. There is an increase in sparing effect with increasing 
fraction doses for all four cell lines. On the whole, the dose repaired at comparable 
fraction doses is not significantly different. 
When repair data were analyzed with the LQ-model (144), the repair ratio, RR, 
defined as the ratio of surviving fractions obtained after a total dose D, given in either a 
single or in a split-dose regimen with fraction dose d, is determined by the β component 
in lnRR= 2ßD2. Recently it has been proposed that the ß-value may be used as a 
comparative measure of cellular recovery proficiency (91). Analogeous to the 
determination of the RR of the surviving fractions, the repair ratio of growth delays was 
deduced using the data presented in Figures 6.3 and 6.4. Results shown in Figure 6.5 
indicate that the β components of all four cell lines are not significantly different. 
specific growth delay specific growth delay 
Figure 6.4. Specific growth delay as a function of total dose for melanoma BRO 
(panel A) and lung adenocarcinoma line NCI-H125 (panel B) irradiated with single and 
split doses of 18 MV X rays. 
DISCUSSION 
When compared to single radiation doses, the in vitro growth delay of multicellular 
spheroids from four human tumor cell lines was clearly lower when radiation doses were 
split in two equal fractions spaced by a 6-hour interval. Split-dose recovery was 
calculated from the growth delay data (Figs. 6.3 and 6.4) on an iso-effect basis (144) and 
expressed as dose repaired (Table 6.1). Several reports on the single-dose radiosensitivity 
of human tumor cells in culture (43) or as spheroids (45,48,49) reveal great 
heterogeneity in the in vitro radiosensitivity of human tumor cells, even for the same 
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type of tumor. Split-dose data for tumor cell lines show the same heterogeneity for 
repair of radiation damage (145) when irradiated as monolayers. Wheldon et al. (80) 
showed an absence of a sparing effect for neuroblastoma cells grown as spheroids and 
irradiated with total doses of 0.5 to 3.5 Gy. This study, however, shows repair of 
sublethal damage in spheroids of a human neuroblastoma and three other tumor cell 
lines, although in a dose range higher than that used by Wheldon et al (80). The dose 
related repair capacity is well within the range seen in monolayer cultures (145). 
Several authors have proposed that a systematic difference may exist in the repair 
capacities of radioresistant and radiosensitive cell lines, and between cells of tumor cell 
lines and of normal tissues. The maximum recovery ratios calculated from the growth 
delay data (Figs. 6.3 and 6.4) were well below 2. This is lower than reported for normal 
cell lines (146) and early-reacting tissues such as skin (147). This would mean that the 
tumor cell lines used in this study were less competent for repair of sublethal damage 
than normal tissues. These results suggest that repair of sublethal damage may not 
contribute significantly to the clinical resistance to radiation of tumor such as 
melanoma and lung tumor. 
When the recovery ratios calculated from the growth delay values were plotted as a 
function of the square of the fraction dose, the slope of the line represents the ß-value 
from the linear-quadratic equation (91). Although the LQ-equation describes cellular 
survival, it has been shown by Wheldon and co-workers (48) that estimates of cell 
survival can be obtained from regrowth curves of spheroids. Therefore, it seemed not 
inappropriate to apply the LQ-equation to growth delay data. The data for BRO 
melanoma spheroids did not fit well, but the data for the other three cell lines gave a 
good fit, with slopes that were small. Hence, the ß-value as represented by this slope 
would be low (ß= 0.052 Gy"2, 0.038-0.062, 95% confidence limits). 
Tabic 6.1. Dose related repair capacity as expressed by dose repaired for four human tumor 
cell lines grown as multicellular tumor spheroids, calculated from growth delay curves. 
Fraction 
dose 
(Gy) 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
5.5 
NB-100 
dose repaired 
(Gy) 
0.2 
0.8 
1.2 
1.6 
HN-1 
dose repaired 
(Gy) 
0.6 
1.0 
1.1 
0.9 
1.2 
BRO 
dose repaired 
(Gy) 
0.3 
0.9 
1.0 
1.0 
NCI-H125 
dose repaired 
(Gy) 
0.1 
0.6 
1.0 
1.2 
2.0 
Recently, Steel and Peacock (148) used the ß-values from various human tumor cells 
irradiated as monolayer cultures. These ß-values were deduced from recovery ratios 
obtained in split-dose experiments using the same equation as in this study. These 
authors also concluded that there were no differences in repair proficiency of 
radiosensitive and radioresistant cell lines. Using Thames' model for complete repair 
(149), the results of the split-dose experiments were re-analysed using the cure fractions 
obtained after irradiation. Due to the low number of cures, especially in the split-dose 
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groups, there are very large confidence intervals. However, the analysis shows 
comparable ß-values for the four cell lines, with the exception of NCI-H125, where the 
number of responding spheroids for analysis were so low that no confidence limits could 
be calculated. Disregarding the limited confidence of data, they do show, however, that 
the cell lines differ in their α-values, and consequently, have different α/β-ratios. This 
implies that these cells probably have different responses to fractionated radiation 
regimens. This point will be further elucidated in the next chapter. The results from this 
re-analysing also shows that the method of obtaining ß-values by plotting the recovery 
ratios (148) is an appropriate one. 
In RR 
0.8 η 
Figure 6.5. Recovery ratio (RR) calculated from growth delay values, plotted as 
function of squares of radiation fraction dose, for four cell lines grown as spheroids. 
Slope of the two parallel lines represents the β component of the LQ-equation. 
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Table б.2.Parameters of the linear quadratic equation for four human 
tumor cell lines grown as spheroids derived from Thames' model for complete repair. 
Cell line σ/β (Gy) α (Gy1) β (Gy2) 
NB-100 
HN-1 
BRO 
NCI-H125 
3.2 
7.2 
0.1 
2 0 . 2 
0.16 
0.43 
0.004 
0.27 
0.050 
0.060 
0.040 
0.015 
This is the first report on the repair capacity of human tumor cell lines of different 
radiosensitivity grown as spheroids. Although only four cell lines were used, the results 
substantiate the notion that multicellular spheroids are an appropriate model to study 
radiation phenomena such as sublethal damage repair. 
This chapter was based on: 
JHM Schwachöfer, RPMA Crooijmans, JJM van Gasteren, J Hoogenhout, CR Jerusalem, HB 
Kal, AGM Theeuwes: Repair of sublethal damage in two human tumor cell lines grown as 
multicellular spheroids. Int J Radiât Oncol Biol Phys 17: 591-595, 1989. 
and: 
JHM Schwachöfer, RPMA Crooijmans, J Hoogenhout, HB Kal, AGM Theeuwes: Sublethal 
damage repair in two radioresistant human tumour cell lines irradiated as multicellular 
spheroids. Tumor Biol 12: 207-216, 1991. 
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Repair kinetics of radiation induced damage in two human 
tumor cell lines grown as spheroids and in monolayer 
ABSTRACT 
Cells from two human tumor cell lines were irradiated both as multicellular tumor spheroids 
and in monolayer culture Growth curves of spheroids were used to obtain survival estimates 
by back-extrapolation after split and single dose irradiation Neuroblastoma (NB-100) and 
squamous cell carcinoma (HN-1) single cells from monolayer culture were assessed for repair 
of sublethal damage (SLD) and potentially lethal damage (PLD) The proficiency of cellular 
recovery was compared with the induction and repair of DNA damage It was shown that repair 
of PLD could not contribute to the SLD repair capacity of HN-1 squamous cell carcinoma 
spheroids since this cell line was found to be deficient for this type of repair Even in NB-100 
neuroblastoma spheroids this type of repair did not contribute to SLD repair, although this 
cell Une is capable of PLD repair The HN-1 squamous carcinoma cell line is more proficient 
in SLD repair than NB-100 neuroblastoma, when grown as spheroids, which is consistent 
with the clinical radiocurabihty of the tumor types of origin This shows the feasibility of 
the method used by Moore et al (22), thus allowing compansons between monolayer cells 
and spheroids, in those instances where no disaggregation of spheroids into single cell 
suspensions is possible 
When specific growth delay was used to determine the repair rate of SLD in spheroids of the 
NB-100 and HN-1 cell line, it was found that growth delay was not sensitive enough to 
discriminate between the different tune intervals Spheroid cure however, showed that at iso-
effcctive cure levels the NB-100 spheroids repaired SLD within 1 h, whereas the HN-1 
spheroids required more than 4 h to complete repair When the NB-100 spheroids where 
irradiated with a higher total dose (10 Gy), it was found that the repair was significantly 
slower, and comparable to HN-1 spheroids Using the same doses of X-rays as employed for 
the spheroids, in exponential monolayer cultures the two cell lines showed comparable repair 
rates The repair rate was approximately the same in spheroids and monolayers 
In plateau phase cells it was found that NB-100 showed virtually no SLD repair, whereas the 
HN-1 ceUs did repair SLD PLD however, was repaired by NB-100 cells but not by HN-1 cells 
These findings correlate well with the identic dose-response curves for DNA damage directly 
after irradiation, and the different extents of DNA damage remaining after repair as determined 
by the Fluonmetric Analysis of DNA Unwinding The DNA repair did correlate with SLD 
repair, but not with PLD repair This showed that the FADU method as developed for human 
lymphocytes, is also appUcable for human tumor cell lines 
INTRODUCTION 
Several authors have proposed that a systematic difference may exist in the repair 
capacities of radioresistant and radiosensitive cell lines, and between cells of tumor cell 
lines and of normal tissues (145,150). In clinical practice, a therapeutic advantage might 
be gained through the use of fractionated radiation schemes by which means normal 
tissues should be preferentially spared (144,151 ) 
The response of cultured cells to ionizing radiation can be described by a survival 
curve (152). The enhancement in survival that occurs when a radiation dose is split into 
two or more fractions is interpreted as being due to sublethal damage (SLD) repair 
(57,76). Potentially lethal damage (PLD) is operationally defined as damage which, if 
unrepaired, is lethal. It has been extensively studied by many investigators using a 
variety of experimental conditions (75,150,153,154). Both SLD and PLD are believed 
to play important roles in the response of tumors to radiation therapy. 
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With ionizing radiation the total dose of energy deposited per unit mass can be 
measured with great accuracy. However, the major problem is the assignment of 
biological significance to any particular radiation induced lesion, since model studies 
have indicated that a myriad of lesions, chemically distinct, can be produced (155). Until 
now the relationship between induction and repair of radiation damage in DNA and cell 
killing has not been fully determined. 
The biological basis of tumor resistance in vivo is the subject of intensive study. 
Recently, it has been suggested that inherent radioresistance and the repair of X-ray 
induced damage may play an important role in the sterilization of some tumors by 
radiation treatment (156). Most studies on the molecular mechanisms underlying 
radiosensitivity and/or repair of radiation induced DNA damage in mammalian cells have 
focussed on the repair of strand breaks, because DNA strand breaks are believed to be the 
primary, radiation induced lethal lesion (157). Radiosensitivity may be defined by the 
DQ, whereas Dq is a reflection of the cells' ability to accumulate sublethal damage 
(57,158). In the more contemporary Linear Quadratic model (144) the α-component of 
the LQ equation is thought to represent the intrinsic radiosensitivity, and the β 
component is regarded as a measure of the repair capacity. There are several mechanisms 
by which cell radiosensitivity can be affected, including changes in the initial number of 
DNA lesions induced by the radiation or alterations in the residual frequency of lesions 
left after repair has been completed. DNA strand breaks can be detected with acceptable 
reliability based on the observation that the rate of unwinding of the two DNA strands 
in alkali solution is related to the covalent length of the strands (159,160). A procedure 
has been reported for the detection of DNA strand breaks in white blood cells (93,161), 
which has been used in the experiments reported upon in this chapter. 
Only limited data exist on the sublethal damage repair capacity of human tumor cells 
grown as spheroids (80). With studies using volume changes in spheroids we are not 
measuring radiation sensitivity in the strict sense, but rather radiation response, i.e. the 
complex interaction of cell killing, repopulation, repair of SLD, and possibly repair of 
PLD. Since we have studied the repair of SLD in four human tumor cell lines when 
grown as spheroids (Chapter 6), it was important to elucidate a possible contribution of 
PLD repair in the observed SLD repair. 
In this chapter the repair of SLD in spheroids derived from two human tumor cell 
lines is reported upon, using growth delay, spheroid cure, and survival estimates 
obtained by back-extrapolation of growth curves. These findings are compared with 
repair of SLD and PLD in the respective monolayer cells, as well as with the repair of 
DNA damage in these cells after irradiation. 
RESULTS 
Using the various materials and methods described in chapter 3, the following results 
were obtained. 
Figure 7.1, panels A and В show the survival curves derived by back-extrapolation 
of growth curves of NB-100 and HN-1, respectively. The correlation coefficients for the 
best common slope fit were 0.96 and 0.83 for NB-100 and HN-1, respectively. There is 
an increased survival for spheroids that were treated with split doses, indicating SLD 
repair. For doses smaller than 4 Gy no data points were derived since these doses were 
not applied to spheroids. The multitarget parameters of the curves are summarized in 
Table 7.1. 
In Figure 7.1, panels С and D the survival fractions are shown as a function of 
radiation dose for exponential monolayer cells of NB-100 and HN-1, respectively. Cells 
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Figure 7.1. X-ray survival curves for NB-100 neuroblastoma and HN-1 squamous cell 
carcinoma cells. In panels A to D cells were irradiated with single doses (drawn lines) 
and split doses (dashed lines) with interval times of six hours. Panels A and B: survival 
curves obtained from estimates of cell survival derived by back-extrapolation of growth 
curves. Panels С and D: survival curves for exponential monolayer cells. In panels E 
and F plateau phase monolayer cells were irradiated with single doses with direct plating 
(drawn lines) or after 24-hour delay period (dashed lines), respectively. Bars indicate 
standard enrors. 
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were in log phase with 70-80% of cells proliferating as measured by flow cytometry. 
Here too, the differential survival for split-dose irradiation indicated SLD repair. 
In panels E and F of Figure 7.1 the survived curves are depicted for the two cell lines 
after single dose irradiation of plateau phase cells that were replated either directly or 
after a 24-h delay period. For NB-100 cells (panel E) there is an increase in survival if 
cells were allowed for 24 h recovery, indicating repair of PLD. For HN-1 cells (panel F) 
virtually no increase in survival can be noted for irradiated cells given 24 h delay before 
plating. Apparently no repair of PLD has occurred in these cells. The multitarget 
parameters derived from these curves are summarized in Table 7.1. Only 7-11% of cells 
were still in log phase as determined by flow cytometric analysis of КІ67 staining 
(142). The plating efficiency in the monolayer experiments ranged from 6 to 9% with 
no changes attributable to culture conditions. 
Table 7.1. Multitarget parameters from survival curves of irradiated spheroids and 
monolayer culture cells from human tumor cell lines NB-100 (neuroblastoma) and HN-1 
(squamous cell carcinoma). 
Do(Gy) Dq(Gy) Ñ 
+ SD + SD + SD 
SPHEROIDS 
NB-100 
HN-1 
MONOLAYERS 
NB-100 exponential 
HN-1 exponential 
NB-100 plateau phase 
HN-1 plateau phase 
0.80 
1.00 
0 .85 
0 .90 
0 .85 
0.80 
+ 
+ 
+ 
+ 
+ 
+ 
0.05 
0 .08 
0.12 
0.10 
0.07 
0.07 
4 .0 + 0.3 
3.9 + 0.4 
1.7 + 0.2 
4 .2 + 0.4 
1.3 + 0.2 
2 .5 + 0.3 
120 
44 
7 
1800 
4 
30 
+ 
+ 
+ 
+ 
+ 
+ 
12 
7 
0 .8 
90 
0.6 
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The radiosensitivity, as expressed by DQ, is comparable between spheroids and both 
exponential and plateau phase monolayer cells in both cell lines. For HN-1 there is a 
small difference between the DQ'S of spheroids and plateau phase cells. Also, there is no 
real difference between either exponential and plateau phase monolayer cells of the two 
cell lines. The Do-value for HN-1 spheroids is higher than for the NB-100 spheroids. 
For HN-1 monolayer cells the Dq-value is substantially higher them for NB-100 
monolayer cells, reflecting a higher capacity to accumulate sublethal damage (138). 
A "dose repaired" was calculated from the survival data in Figure 7.1. The dose 
related repair capacity, as expressed by this dose repaired in shown in Figure 7.2, panel 
A, for NB-100 neuroblastoma cell line. The absolute values of the dose repaired is lower 
for spheroids than for exponential monolayer cells. In panel В the results of similar 
calculations are shown for HN-1 squamous cell carcinoma cell line. For this cell line 
the differences in dose repaired for the two growth conditions is less pronounced. 
When repair data were analysed with the linear quadratic model (124), the recovery 
ratios for NB-100 and HN-1 tumor cells were deduced from the spheroid and monolayer 
survival curves. Results from this analysis are shown in Figure 7.3, panels A and B, for 
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Figure 7.2. Dose repaired as a function of total dose, calculated on an iso-effect basis 
from survival curves for NB-100 (panel A), spheroids (dots) and exponential monolayer 
cells (circles), and HN-1 (panel B), spheroids (closed rectangles) and exponential 
monolayer cells (open rectangles). 
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Figure 7.3. Recovery ratio (RR) calculated from survival data, plotted as function of 
squares of radiation fraction dose for NB-100 (panel A) and HN-1 (panel B). Symbols as 
in Figure 7.2. 
NB-100 and HN-1 cells, respectively. For NB-100 spheroids a good fit could be obtained 
(R= 0.93), this fit was less good for exponential monolayer cells (R= 0.69). For HN-1 a 
satisfactory fit could be obtained for both growth conditions (R= 0.96). The ß-values 
calculated from the recovery ratios for NB-100 and HN-1 cells are shown in Table 7.2. 
The values are all of the same magnitude, with the exception of the value for NB-100 
exponential monolayer cells. However, the fit for the recovery ratios from these cells 
was less good (R= 0.69) than for the other groups (R > 0.90). 
Growth curves of control and irradiated spheroids of the NB-100 cell line are shown 
in Figure 7.4, panel A. The control growth curve is exponential, with a volume 
doubling time (T¿) of 2.3 days. The growth curve for the spheroids that were irradiated 
with a 7 Gy single dose showed a regression phase before resuming growth with a 
volume doubling time comparable to that of control spheroids. Growth curves for the 
spheroids that were irradiated with two doses of 3.5 Gy, divided by a time period of 1, 2, 
or 4 h, showed a static phase before returning to a growth curve with doubling times 
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equal to control value. No significant differences in growth curves obtained with the 
various time intervals between doses were observed. 
Table 7.2. Values for the ß-component from the linear quadratic equation for spheroids and 
monolayer cells of two human tumor cell lines. 
NB-100 
spheroids 
exponential monolayer 
HN-1 
spheroids 
exponential monolayer 
mean 
0.04 
0.02 
0.04 
0.04 
Ρ (Gy2) 
+ 
+ 
+ 
+ 
(SD) 
0.01 
0.02 
0.01 
0.01 
Figure 7.4, panel В shows the growth curves of HN-1 spheroids after similar 
irradiations. Т^ is 2.1 days, and the total dose employed for these spheroids is 6 Gy. The 
delay in growth is most pronounced in single-dose irradiated spheroids. No signifcant 
difference in growth delay obtained after the 1,2, and 4 interval period for split-dose 
irradiated spheroids was observed (Table 7.3). For NB-100 and HN-1 spheroids, specific 
growth delays were 5.0 and 2.6 for single-dose treatment and about 4.1 and 1.5 for split-
dose treatment, respectively. 
RELATIVE VOLUME 
RELATIVE VOLUUE 
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Figure 7.4. Growth curves of NB-100 neuroblastoma (panel A) spheroids after a 
single dose of 7 Gy and 2 χ 3.5 Gy split dose irradiation with 18 MV X rays. Split 
doses were administered with interval times of 1, 2, and 4 h. Growth curves of HN-1 
squamous cell carcinoma spheroids after a single dose of 6 Gy and 2x3 Gy split dose 
irradiation are shown in panel B. Expressed is volume/initial volume as function of 
time after treatment. Each point represents the average + SE of at least 12 spheroids. 
70 
Table 7.3. Specific growth delay in neuroblastoma cell line NB-100 and squamous 
carcinoma cell line HN-1 spheroids after single and split-dose irradiations. 
NB-
dose (Gy), 
interval 
1 x 7 
2 χ 3.5, 1 h 
2 χ 3.5, 2 h 
2 χ 3.5, 4 h 
100 
specific growth 
delay (+ SD) 
5.0 + 0.3 
4.1 + 0.2 
4.1 + 0.2 
4.3 + 0.2 
dose (Gy), 
interval 
1 x 6 
2 x 3, 1 h 
2 x 3, 2 h 
2 x 3 , 4 h 
HN-1 
specific growth 
delay (+ SD) 
2.6 + 0.4 
1.0 + 0.6 
1.7 + 1.0 
1.5 + 0.5 
The percentage of surviving spheroids was plotted in Figure 7.5 as a function of interval 
time between two dose fractions. The 0-h interval period represented the single dose 
irradiation. For NB-100 spheroids the surviving fraction did not increase anymore after 
the 1 h interval period, indicating that repair was completed within this time span. At a 
single dose of 6 Gy the proportion cured HN-1 spheroids was comparable to the 7 Gy 
single dose in NB-100 spheroids (about 40%). In HN-1 spheroids the surviving fraction 
increased with increasing interval time between dose fractions, indicating a slower rate 
of repair than in NB-100. When a total dose of 10 Gy was employed for NB-100 
spheroids, a repair rate was observed similar to that in HN-1 spheroids. 
SURVIVING FRACTION (%) 
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Figure 7.5. Surviving fraction expressed in percentage of irradiated spheroids of NB-
100 neuroblastoma (dots: 7 Gy; circles: 10 Gy, total dose) and HN-1 squamous cell 
carcinoma (rectangles: 6 Gy, total dose). Total doses were administered in two equal 
fractions separated by different time intervals. 
Surviving fractions for NB-100 and HN-1 exponential and plateau phase monolayer cells 
after split-dose treatments are shown in Figure 7.6, panels A and B, respectively. The 
exponential monolayer cells from both cell lines showed comparable repair rates, the 
surviving fraction for NB-100 being lower than for HN-1 cells due to the higher dose 
employed. The plateau phase cells of HN-1 clearly showed split dose recovery , whereas 
virtually no repair was observed in NB-100 plateau phase cells. 
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Panel С of Figure 7.6 shows the repair kinetics of potentially lethal damage (PLD) 
after a 4 Gy radiation dose for both cell lines. HN-1 exhibited lower repair of PLD than 
NB-100 cells, in agreement with the results shown in Figure 1, panels E and F. 
Surviving ІгіСІІОЛ (Ъ) Surviving fraction (%) Чптлчд fracbon M 
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Figure 7.6. Comparison of cellular radiation repair kinetics in human tumor cells 
from neuroblastoma cell line NB-100 (dots) and HN-1 squamous cell carcinoma 
(squares). For sublethal damage repair kinetics in exponential monolayer cells (panel A) 
various time intervals between split doses were used. In panel В the split dose recovery 
in plateau phase cells is depicted. For potentially lethal damage repair kinetics (panel C) 
various time delays for replating after irradiation were used. Each point represents the 
average of six determinations in two separate experiments. Error bars indicate standard 
errors. 
Figure 7.7, panel A shows the dose-response curve of DNA strand breaks in cells from 
human neuroblastoma cell line NB-100 following X-irradiation. Q D values were 
determined as described in Chapter 3. The relationship between QD, reflecting the level 
of radiation-induced strand breaks, and the dose was linear over the low dose range of 0.5 
to 5 Gy. At higher doses, the dose-response curve was not linear. In panel В the results 
of similar determinations are shown for HN-1 squamous cell carcinoma cells. 
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Figure 7.7. Dose response curves of DNA strand breaks in human tumor cells of 
neuroblastoma cell line NB-100 (panel A) and squamous cell carcinoma cell line HN-1 
(panel B). Irradiation with 18 MV X-rays was performed at 0° С with a dose rate of 2 
Gy/min. Each measuring point represents the average of six to nine independent 
experiments. Standard deviation bars were smaller than symbol size. 
The repair process of the X-ray induced strand breaks was studied by incubating control 
or irradiated cells (4 Gy) in culture medium at 37° С for different periods before 
fluorimetrie analysis of DNA unwinding (FADU). Results were expressed as percentage 
of initial damage remaining after various time periods. Figure 7.8, panel A shows the 
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results for NB-100 neuroblastoma cells. The damage was gradually repaired in a period 
of 15-20 minutes, before a plateau was reached, leaving approximately 50% of the 
damage unrepaired. Panel В shows the results obtained with HN-1 squamous carcinoma 
cells. Repair of \)ΝΑ damage was at a maximum after approximately 20 minutes when 
a plateau was reached, leaving about 25% of the initial damage unrepaired. 
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Figure 7.8. In vitro repair kinetics of DNA strand breaks after irradiation of human 
tumor cells of neuroblastoma cell line NB-100 (panel A) and squamous cell carcinoma 
line HN-1 (panel B) with a dose of 4 Cy. Irradiation was performed at 0° С and cells 
were subsequently kept at 373 С for various time intervals before FADU assay. Each 
point represents the average of four to six independent experiments. Bars indicate 
standard deviation. 
DISCUSSION 
Split-dose data for tumor cells, when irradiated as monolayers, reveal great heterogeneity 
with regard to the repair of radiation damage (145), even for the same type of tumor 
origin. Using low radiation doses (0.5-3.0 Gy) Wheldon et al. (80) showed the absence 
of a sparing effect for neuroblastoma cells grown as spheroids, whereas in the present 
study, repair of SUD, as expressed by the differential survival after split-dose irradiation, 
was apparent in spheroids from two human tumor cell lines, one of which was a 
neuroblastoma. It remains uncertain whether this is related to the higher (4.0-9.0 Gy) 
doses employed. From NB-100 neuroblastoma spheroid growth curves obtained by other 
investigators (49) a Од- аіие of 0.81 Gy was calculated by Moore et al. (42). The Dg-
value was 0.80 Gy (Table 7.1) in this study. This value is also consistent with the 
Findings from Deacon et al. (47), who reported a Dg-value of 0.90 Gy for neuroblastoma 
cells irradiated under oxic conditions. Unfortunately, no comparative spheroid data from 
studies on squamous cell carcinoma of the head and neck region are available. The 
radiosensitivity of the HN-1 spheroids, as expressed by the Dg-value of 1.0 Gy (Table 
7.1) estimated from the SRU survival curve seems low for a squamous cell carcinoma, 
however, it is comparable to that for the monolayer culture cells from the same cell 
line. 
The value for Dq is somewhat higher for HN-1 cells than for NB-100 cells, when 
grown as monolayers, indicative of a higher capacity to accumulate sublethal damage. 
The radiation dose that is actually repaired as expressed by the dose repaired, is higher 
for HN-1 spheroids than for NB-100 spheroids. This finding is consistent with the 
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difference in clinical radiocurability of the tumor types of origin. It is not clear whether 
the equal Dq-values for spheroids of the two cell lines, derived by back-extrapolation of 
growth curves, is due to actual equal shoulder regions in the survival curves, or is an 
arefactual finding caused by the method used. The low responsiveness at doses lower 
than 4 Gy, would cause higher estimates of survival fraction, and hence to a broad 
shoulder in the survival curve. By using the dose repaired as a measure of the amount of 
SLD that is actually repaired, problems regarding shoulder width and SLD accumulation 
can be circumvented. 
Since volume changes in spheroids represent radiation responsiveness rather than 
radiosensitivity in the strict sense, contribution of potentially lethal damage (PLD) 
repair in the measured SLD repair is theoretically possible. It is unlikely that PLD 
repair contributed to the higher repaired dose in HN-1 cells, since this cell line seems to 
be deficient in this respect. In spheroids of human tumor cell lines, the contribution of 
PLD is difficult to determine since difficulties are encountered in obtaining single cell 
suspensions with disaggregation (34,136). There is, however, no reason to assume that 
PLD repair, absent in plateau phase monolayer cells, will appear when tumor cells are 
grown as spheroids. 
Wheldon and co-workers (48) have shown that cell survival estimates can be 
obtained by back-extrapolation of regrowth curves of spheroids after irradiation. 
Therefore, it seemed not inappropriate to analyse curves obtained with this method in 
terms of the LQ-equation. Consistent with the findings described in Chapter 6, the 
repair capacity as expressed by β (the slope of the fitted line) is similar for NB-100 and 
HN-1 spheroids (0.04 Gy2). Therefore, the differences in the dose repaired seemed to be 
determined by the intrinsic radiosensitivity, as expressed by the α-components of the 
LQ equation, and not by a post-irradiation process (75). Recently, Steel and Peacock 
(148) have shown in 17 tumor cell lines that the α-component of the linear-quadratic 
equation was indicative of the intrinsic radiosensitivity. This is consistent with the 
findings presented here, and the different clinical radiocurability of neuroblastoma and 
squamous cell carcinoma. 
When the recovery ratios were used to determine the repair capacities of spheroids 
and monolayer cells, it was found that the slopes of the fitted lines (ß's) showed little 
differences (Table 7.2). Both in HN-1 spheroids and exponential monolayer cells the ß-
value approximates 0.04 Gy2. This value was also derived for the NB-100 spheroids, 
but the monolayer cells showed a lower value (0.02 Gy2). However, the line fit from 
which this value was derived was less good (R= 0.69), which was also expressed by the 
standard deviation of 0.02 in the Q-value. Apparently the capacity to repair sublethal 
damage, as expressed by β-values, does not alter when cells from these two cell lines are 
grown as spheroids. 
Using specific growth delay calculated from the spheroid growth curves after single-
dose irradiation and split-dose irradiation with increasing interval time (Table 7.3), no 
differences between the two cell lines were observed with regard to repair rate. In these 
spheroids the endpoint of spheroid cure was more suitable to compare the repair rate of 
SLD. When proportion cured spheroids was used at an iso-effect level (60% surviving 
spheroids), the NB-100 neuroblastoma cell line seemed to be more proficient in 
repairing SLD. However, at higher spheroid cure fractions, i.e. at larger total dose, the 
shape of the curve resembled that of the HN-1 spheroids. Thus, the results from 
monolayer and spheroid irradiation are in agreement, since at the same radiation doses 
exponential monolayer cells of the two cell lines showed comparable repair rates (Figure 
7.6A). Plateau phase monolayer cells of the two cell lines differed with regard to repair 
rates for SLD. Whereas in NB-100 cells virtually no SLD repair was apparent, HN-1 
plateau phase cells clearly exhibited a sparing effect of split-dose irradiation. In regard to 
repair of PLD in plateau phase cells, the two cell lines also differed, but for this type of 
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repair the ΗΝ-1 cells were deficient, as also established from the survival curves in 
Figure 7.IF. NB-100 cells did show repair of PLD. 
There is a large body of evidence suggesting that DNA strand breaks, and especially 
DNA double strand breaks, are the molecular lesions responsible for radiation-induced 
toxicity (163,164). Furthermore, studies with DNA repair inhibitors and certain 
radiation sensitive cell mutants suggest that the repair of DNA double strand breaks 
underlies the phenomena of SLD repair and in some cases PLD repair (163,164,165). 
Surprisingly, the results from the DNA repair measurements in plateau phase cells from 
both cell lines are in good agreement with the repair of SLD, whereas the repair of PLD 
showed opposite results. These results suggest that DNA strand-break repair is not an 
important factor in PLD repair, but only in SLD repair, for the two cell lines studied 
here. 
The FADU method developed by Bimboim and Jevcak (93) to measure DNA strand 
breaks in human lymphocytes is applicable for human tumor cells as well. With this 
method the physical separation of renatured and denatured DNA is not required, and 
advantage is taken of the different quantum yield in fluorescence of ethidium bromide 
when intercalated in renatured or denatured DNA (166). The method was also used by 
Thierry et al. (161) for studying DNA damage and repair in human lymphocytes. 
Using the FADU method it was possible to demonstrate that the dose-response 
relationship obtained for two human tumor cell lines showed a comparable relationship 
over the range of 0 to 10 Gy (Fig. 7.7). Both cell lines showed the same linear 
relationship for 0-5 Gy, indicating equal radiosensitivity for both cell lines, the slope 
of the linear part of the curves being 5.6. This slope is lower than the values reported 
by Thierry et al. (161) who found a slope of about 12. The lower steepness of the slope 
of the dose-response curve in our study as compared to that of human lymphocytes, may 
be interpreted as a lower radiosensitivity of the tumor cells. 
Under the alkaline denaturing conditions specified by Bimboim and Jevcak (93), the 
relationship Qu and dose was not linear for doses above 5 Gy. If one assumes that X-
radiation induced randomly distributed breaks along the DNA molecule and that 
denaturation at each break site proceeded at a constant rate, regardless of the size of 
duplex DNA between breaks, then small duplex DNA portions (as are generated under 
high doses of X-rays) will separate completely under the usual alkali conditions. This 
will result in an underestimation of the number of DNA breaks at high doses. 
The cellular radiosensitivity of these two cell lines has been shown to be comparable 
(Table 7.1), which is in line with the observed similarity between the dose-response 
relationship for the DNA damage directly after irradiation. However, in this study the 
DNA repair kinetics after a single dose of 4 Gy was shown to be significantly different 
(Fig. 7.8). In NB-100 about 50% of the initial damage remained after 60 minutes, 
whereas in HN-1 squamous carcinoma cells only about 25% of the initial damage 
remained after this time period. This is in good agreement with the results from the 
clonogenic assay after split and single-dose irradiation of plateau phase cells, but in 
contrast to the results from the clonogenic assay after delayed plating. 
Although the FADU method does not differentiate between double strand and single 
strand breaks, it provides a measure of the damage remaining after rejoining of DNA 
strands (161). Several authors have suggested that the level of damage remaining post-
irradiation (unrepairable damage) may be the critical variable for survival (167,168). The 
findings presented here support the idea that DNA strand-break repair influences the 
survival of cells after irradiation. The level of radiation induced DNA damage is 
comparable in both cell types (Fig. 7.7), the DNA damage remaining after repair is 
different (Fig. 7.8). This correlates with differences in cell survival in the two cell types 
after irradiation with a dose of 4 Gy (Fig. 7.6), which contradicts the findings from 
Sweigert et al. (169), who reported for two murine tumor cell lines that cell survival did 
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not correlate with the repair rates of DNA strand breaks as detected with a DNA elution 
assay. Recently, Tanigher et al. (170) reported the fluorometric methods, such as 
FADU, preferable to elution methods, since these are more restricted in the range of 
DNA alterations detected. 
CONCLUSIONS 
Using the spheroid model and the method of analysis as used by Moore et al. (42) it was 
possible to determine the extent of SLD repair. For the cell lines used in the present 
study it was shown that repair of PLD cannot contribute to the SLD repair capacity of 
HN-1 squamous cell carcinoma spheroids since this cell line was found to be deficient 
for this type of repair. Even in NB-100 neuroblastoma spheroids this type of repair did 
not contribute to SLD repair, although this cell line is capable of PLD repair. The HN-
1 squamous carcinoma cell line is more proficient in SLD repair than NB-100 
neuroblastoma, when grown as spheroids, which is consistent with the clinical 
radiocurability of the tumor types of origin. This shows the feasibility of the method 
used by Moore et al. (42), thus allowing comparisons between monolayer cells and 
spheroids, in those instances where no disaggregation of spheroids into single cell 
suspensions is possible. 
When specific growth delay was used to determine the repair rate of SLD in 
spheroids of the NB-100 and HN-1 cell lines, it was found that growth delay was not 
sensitive enough to discriminate between the different time intervals. Spheroid cure 
however, showed that at iso-effective cure levels the NB-100 spheroids repaired SLD 
within 1 h, whereas the HN-1 spheroids required more than 4 h to complete repair. 
When the NB-100 spheroids where irradiated with a higher total dose (10 Gy), it was 
found that the repair was significantly slower, and comparable to HN-1 spheroids. Using 
the same doses of X-rays as employed for the spheroids, in exponential monolayer 
cultures, the two cell lines showed comparable repair rates. The repair rate was 
approximately the same in spheroids and monolayers. 
In plateau phase cells it was found that NB-100 showed virtually no SLD repair, 
whereas the HN-1 cells did repair SLD. PLD however, was repaired by NB-100 cells but 
not by HN-1 cells. These findings correlate well with the identic dose-response curves 
for DNA damage directly after irradiation, and the different extents of DNA damage 
remaining after repair. The DNA repair did correlate with SLD repair, but not with PLD 
repair. This showed that the FADU method as developed for human lymphocytes, is 
also applicable for human tumor cell lines. 
Most importantly, it follows from these experiments that in studying SLD repair in 
spheroids the repair properties of the monolayer cells are not confounding the results of 
such determinations. 
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Radiosensitivity and sublethal damage repair in human 
melanoma spheroids influenced by growth rate 
ABSTRACT 
The radiosensitivity of human melanoma cell line BRO was investigated using the 
multicellular tumor spheroid system By adding different concentrations of bovine serum to 
the tissue culture medium two different growth rates could be obtained Spheroids (200-250 
μιη) were irradiated with graded single doses of X-rays (2-8 Gy) The radiation response was 
quantified using specific growth delay, clonogemc cell survival, and spheroid cure 
The three assays showed a growth rate dependent radiation response At both growth rates the 
spheroid growth fraction and critical cell number were of comparable magnitude There also 
was a strong correlation between the radiation response of spheroid regenerating units and 
clonogemc cells from dispersed spheroids 
Cell survival curves indicated a decreased ability to accumulate sublethal damage in fast 
growing spheroids For this reason a second series of expenments were performed, 
irradiating two groups of spheroids which differed in their growth rates, with single and split 
doses (3-11 Gy) of X-rays Again a growth rate dependent radiosensitivity was shown by 
growth delay and spheroid cure Slow growing spheroids exhibited a larger repair of sublethal 
damage as expressed by the dose repaired, calculated on an iso-effect basis from the growth 
delay data The proportion cured spheroids showed a larger sparing effect of split-dose 
irradiation for the slow growing spheroids 
From this study it appears that the intrinsic radiosensitivity of human melanoma BRO cells 
in spheroids is modulated by intratumoral conditions These condiuons also influence the 
capacity to repair sublethal damage Even if differences in sublethal damage repair do not 
fully explain differences in radioresponsiveness, the results indicate that the use of 
fractionated regimens in fast growing tumors best exploits the differential repair capacities 
of normal and tumorous tissues 
I N T R O D U C T I O N 
Human melanomas are generally considered to be clinically radioresistant tumors (171). 
However, in vitro cell survival curves for human melanoma cell lines do not differ from 
those of other human tumor cell lines, with the exception of a somewhat larger 
shoulder, and do not explain the clinical radioresistance. It is therefore important to 
establish whether the observed clinical resistance of melanomas to radiotherapy is caused 
by intrinsic cellular properties or by tumor constitution. The radiosensitivity of human 
neuroblastoma and melanoma has been investigated using the spheroid system. These 
studies showed the intrinsic radiosensitivity to be correlated with growth rate of 
spheroids, which in tum depended on the tumor type (49). In chapter 5 a correlation was 
already noticed between growth rate of spheroids and radiosensitivity. The growth rate of 
spheroids from tumor cell lines can be manipulated by tissue culture conditions and 
additives (115). In chapter 4 it was observed that in BRO melanoma spheroids addition 
of bovine serum enhanced the growth rate significantly. 
In this chapter, the influence of different concentrations of fetal bovine serum added 
to the tissue culture medium of BRO melanoma spheroids, on growth rate and radiation 
responses is described. In the first series of experiments, spheroids were irradiated at a 
diameter of 250 μιη with graded single doses of X-rays (2-8 Gy). Radiation response 
was quantified in terms of specific growth delay, clonogenic cell survival, and spheroid 
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cure. In a second series of experiments two groups of spheroids were irradiated with both 
single and split doses (3-11 Gy) of X-rays. 
RESULTS 
Using the various materials and methods described in chapter 3, the following results 
were obtained. 
In one group of spheroids an average volume doubling time was obtained of 4.6 
days. A second group attained a volume doubling time of 3.0 days. For reasons of 
clarity the former group was termed 'slow growing spheroids', and the latter 'fast 
growing spheroids'. 
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Fi gure 8.1. Specific growth delay as a 
function of radiation dose for X-ray 
irradiated spheroids ofBRO human 
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Figure 8.2. X-ray survival curve for 
BRO human melanoma cells from 
dispersed spheroids afìer single-dose 
(2-8 Gy) irradiation. Rectangles: slow 
growing spheroids; circles: fast 
growing spheroids. 
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Figure 8.1 shows the specific growth delay (time to obtain 8-fold volume increase 
divided by volume doubling time of untreated controls). A growth rate dependence is 
apparent for this type of human tumor spheroids, i.e. fast growing spheroids show a 
larger growth delay than slow growing spheroids, indicating higher radiosensitivity. 
The response to irradiation under aerobic conditions of single cells taken from 
dispersed spheroids, is illustrated in Figure 8.2. Survival curves have been computed 
using the multi-target equation (172). Multitarget parameters for slow growing 
spheroids are: Ц)= 1.9 + 0.2 Gy, Dq= 2.4 + 0.1 Gy, N= 4.6, and for the fast growing 
spheroids: D(j= 1.2 + 0.3 Gy, Dq= 0.9 + 0.1 Gy, N=2.1. The D 0 and Dq values for the 
two types of spheroids differ, thus indicating different radiation sensitivities and different 
capacities to accumulate sublethal damage, respectively. 
Figure 8.3 shows the surviving cell fraction in relation to the specific growth delay 
from Figure 8.1. For the slow growing spheroids there was a good correlation (R= 
0.87); for the fast growing spheroids this was less clear (R= 0.51). 
Specific growlh delay 
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Figure 8.3. Specific growth delay in relation to surviving fraction in spheroids with 
two growth rates. Rectangles: slow growing spheroids; circles: fast growing spheroids. 
Spheroid cure was judged by the absence of growth during the observation period. 
Figure 8.4 shows the relationship of cure probability as a function of dose for spheroids 
with different growth rates. SCD50 for slow growing spheroids is 7.9 Gy (7.4-9.1 Gy; 
95% confidence limits), and for fast growing spheroids 6.7 Gy (6.2-7.2 Gy; 95% 
confidence limits). The difference between the two SCDSQ'S was statistically significant 
as determined by the method of Litchfield and Wilcoxon (90). 
Figure 8.5 shows the DNA histograms from slow (panel A) and fast growing 
spheroids (panel B). The percentages of cells in each cell cycle phase for each type of 
spheroids did not differ appreciably. The cell number per spheroid was counted in a 
hemocytometer after 40 to 48 spheroids were trypsinized and mixed by vigorous 
pipetting. Slow growing spheroids contained 1145 +_ 59 cells per spheroid, and fast 
growing spheroids 1833 + 119. 
The cell plating efficiencies were 5.3% and 8.2%, respectively. The clonogenic cell 
number in fast growing spheroids was higher, 150, than in slow growing spheroids, 60. 
The larger number of clonogenic cells in the fast growing spheroids obviously did not 
influence the cell cycle distribution. 
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Figure 8.4. Cure-dose relationship for 
spheroids growing with two different 
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Figure 8.5. DNA distributions of 
cells obtained from dispersed spheroids 
that grew at two different growth 
rates. Panel A: slow growing 
spheroids; panel B: fast growing 
spheroids. 
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Figure 8.6. Growth curves for slow growing spheroids of human melanoma cell line 
BRO, irradiated with single (panel A) or split (panel B) doses of X-rays (3-11 Gy). 
Expressed is volume/initial volume as a function of time after treatment. Each point 
represents the average ± SD of at least 10 spheroids. 
In the second series of experiments the volume doubling times obtained were 2.2 and 
1.2 days for slow and fast growing spheroids, respectively. Figure 8.6 shows the growth 
curves of spheroids irradiated with single (panel A) and split (panel B) doses of X-rays 
(3-11 Gy) growing at a volume doubling time of 2.2 days. Figure 8.7 shows growth 
curves of spheroids irradiated when growing at a volume doubling time of 1.2 days. 
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Growth curves for control spheroids of both groups are exponential in shape. Similar 
responses to radiation were observed in both groups: a dose dependent retardation in 
growth, or a dose dependent lag period, in which the size remained constant, followed by 
resumption of normal growth, and a dose dependent reduction in size less than the 
original volume, followed by either a resumption of growth at the rate of control 
spheroids, or no regrowth at all. 
The response to radiation is more pronounced in the fast growing spheroids than in 
the slow growing spheroids. This is expressed by the distance between the curve for 
control spheroids and the curves of the 3 and 5 Gy irradiated spheroids, which is larger 
for the fast growing spheroids. The difference in response to radiation is also clearly 
expressed by the 9 Gy total dose response of spheroids from both groups. Whereas the 
slow growing spheroids are capable of resuming growth (even after the 11 Gy dosis), 
the fast growing spheroids show no regrowth after 9 Gy single dose during the 5 week 
post-irradiation observation period. 
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Figure 8.7. Growth curves for fast growing spheroids of human melanoma cell line 
BRO, irradiated with single (panel A) or split (panel B) doses of X-rays (3-11 Gy). 
Expressed is volume/initial volume as a function of time after treatment. Each point 
represents the average ± SD of at least 10 spheroids. 
The growth delay calculated from the growth curves of the spheroids (Figs 8.6 and 8.7) 
is shown in Figure 8.8 (panel A; slow growing spheroids, panel B; fast growing 
spheroids). After split-dose irradiation, the growth delay is significantly lower than after 
single doses, indicating repair of sublethal damage in spheroids growing at different 
growth rates. 
Differences in radiosensitivity cannot be deduced from the growth delay data, since a 
different growth delay endpoint had to be chosen for both groups. However, on an iso-
effect level a 'dose repaired' could be calculated and compared for the two growth rate 
groups. Figure 8.9 shows the dose repaired as a function of total dose. The dose repaired 
at low doses (3-5 Gy) seems to be larger for slow growing spheroids (circles) than for 
fast growing spheroids (dots). At doses in excess of 7 Gy this difference is less clear, 
although for the fast growing spheroids the sparing effect in growth delay at 11 Gy total 
dose could not be calculated due to the high cure rate. 
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Figure 8.10 illustrates the recovery ratio, RR, calculated from the data presented in 
Figure 8.8 as a function of the square of the fraction dose. Data points from both 
experimental groups could be Fitted by the same line. 
Figure 8.11 shows the results of the probit analysis of the proportion cured 
spheroids after single and split-dose irradiation as a function of total dose for slow 
growing (panel A) and fast growing (panel B) spheroids. The single dose necessary to 
sterilize 50% of the spheroids is significantly larger for the slow growing spheroids: 9.7 
Gy (9.0-10.6 Gy; 95% confidence limits), than for the fast growing spheroids: 6.7 Gy 
(6.2-7.2 Gy; 95% confidence limits). Also, the distance between the curves for single 
and split dose irradiation is larger for slow growing spheroids than for the fast growing 
spheroids. This is an indication for a larger sparing effect of split-dose irradiation in 
slow growing spheroids. 
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Figure 8.8. Growth delay as a function of total radiation dose for X-ray irradiated 
human melanoma cell line growing either as slow growing spheroids (panel A), or as 
fast growing spheroids (panel B). Circles: single dose; dots: split dose. 
DISCUSSION 
In this work the aim was to determine whether factors other than the intrinsic cellular 
radiosensitivity can contribute to the response of human melanoma multicellular 
spheroids to radiation. To do this, spheroid response has been assessed using the 
endpoints growth delay, cell survival, and spheroid cure. All three assays reveal for this 
type of spheroids a growth rate dependent response to radiation. 
The characteristic growth response of spheroids to cytotoxic treatment is growth 
delay followed by regrowth at a rate similar to untreated control (173). This pattern is 
also observed in BRO human melanoma spheroids growing at two different growth 
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rates. When the specific growth delay (SGD) was calculated at values other than 8 times 
initial treatment volume, and when comparisons were made between the two growth 
rates the conclusions remain the same, that is, fast growing spheroids are more sensitive 
than slow growing spheroids from the same cell line when the assay is by growth delay. 
This is further emphasized when the assays of SGD and cell survival are compared as in 
Figure 8.3. For the two types of spheroids there is an apparent relationship between cell 
survival and SGD. A linear regression analysis gives correlation coefficients of 0.87 for 
slow growing and 0.51 for fast growing spheroids. Theoretically, if cell survival and 
growth delay are well correlated, then a decade of cell kill required 3.3 doublings of the 
surviving cells for growth to the original treatment volume. The results for BRO 
melanoma spheroids are in reasonable agreement with the theoretical prediction 
(l/slope= 3.1, cf. theoretical value of 3.3). This indicates that, at least for slow 
growing spheroids, both these endpoints are equivalent. A similar conclusion was 
reached by Pourreau-Schneider and Malaise (38) when comparing cell survival and LD50 
assays of radiation response of human melanoma Nai l spheroids. However, the 
expected intercept in Figure 8.3 should be unity. This is not the case and may be due to 
the fact that cells suffer an increasing amount of cell cycle delay as a function of 
radiation dose. This would lead to a non-linear relationship of SGD and cell survival, 
with a tendency for values of SGD to be larger than expected. 
When cure was used as an endpoint, fast growing spheroids were found to be more 
sensitive than slow growing spheroids, that is, they had a significantly lower SCD50 A 
relationship between tumor control and the radiosensitivity of its component cells has 
been derived by combining an equation for a one-hit multitarget model (174) with a cure 
probability derived from the Poisson distribution (175). In animal tumors, difficulties in 
estimating the number of clonogenic cells in solid tumors have made it impossible to 
establish a fully quantitative relationship between these parameters (136). However, 
these difficulties could theoretically be overcome by using multicellular tumor spheroids 
in vitro where survival curves and cure-dose curves could be obtained in the same dose 
range and the number of clonogenic cells could be determined by colony formation. 
Durand ( 176) used V79 and Pourreau-Schneider and Malaise (38) used human melanoma 
Nal 1 spheroids to examine this relationship. They found that the presence or absence of 
one surviving clonogenic cell could determine succes or failure in controlling spheroid 
growth. 
In the human melanoma BRO cell line used here, the cellular radiosensitivity of 
250-μηι spheroids was different when spheroids grew at different growth rates. In BRO 
monolayer cells, adding different concentrations of serum to the culture medium, 
resulted in different cell cycle distribution of cells (data not shown). Apparently, 
intratumor structure in spheroids influences the growth behavior and radiosensitivity of 
BRO melanoma cells. When setting up a quantitative relationship for BRO cells the 
qualities to describe cellular radiosensitivity were equated by ( 177): P= exp(-N/p), where 
Ρ is the cure probability obtained from Figure 8.4, N is the number of surviving 
clonogenic cells per spheroid, taken from Figure 8.2, and ρ is the critical cell number. 
The value of ρ calculated for cells in BRO melanoma spheroids growing with different 
growth rates was approximately equal to 2.5 for slow growing spheroids, and 2.7 for 
fast growing spheroids. This value is of the same magnitude as for 250-μπι HMV-I 
human melanoma spheroids (40). 
The term, "critical cell number", in a slightly different form with similar meanings 
was originally used by Cohen and Cohen (178) in animal experiments. Other terms 
were "the chance for a single cell to repopulate" (179), and the "tumour rescuing cells" 
(175), or "spheroid regenerating units" (48). In animal tumors Cohen and Cohen (178) 
showed that host animal cells with immunological activity resulted in an increase of the 
critical cell number. In the present work with spheroids the critical cell number was 
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equal in spheroids with different growth rates. Here, spheroids in the absence of "host 
animals'' could not have immune reactions to account for the cell number larger than 1. 
It is suggested that when spheroid cure occurs, the surviving fraction of clonogenic cells 
would be 10"1 to IO-2 (see Figure 8.2). In other words, each surviving clonogenic cell 
in the spheroid would be in the neighborhood or enclosed by 90 to 99% of dying or dead 
cells. This imposes a difficult set of conditions in which a clonogenic cell may not be 
able to repopulate the spheroid. The critical cell number (p) could be considered as the 
probability for one clonogenic cell to outgrow or the chance for one clonogenic cell to 
repopulate (179). In this study the critical cell number is approximately equal for 
spheroids growing with two different growth rates. This contradicts the observed 
differences in radiosensitivity between the two types of spheroids. Fast growing 
spheroids contain more cells, 1833, than slow growing spheroids, 1145. The number of 
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Figure 8.9. Dose repaired as a function 
of total dose, calculated on an iso-effect 
basis from growth delay curves for BRO 
human melanoma spheroids. Circles: 
slow growing spheroids; dots: fast growing 
spheroids. 
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Figure 8.10. Recovery ratio (RR) 
as calculated from the growth delay 
values as presented in Figure 8.8, 
expressed as a function of the squares 
of fraction dose for BRO melanoma 
spheroids growing at two growth 
rates. Circles: slow growing 
spheroids; dots: fast growing 
spheroids. 
clonogenic cells in fast growing spheroids, 150, is 2.5 times higher than in slow 
growing spheroids, 60. The number of cells in the different cell cycle phases is not 
different (see Figure 8.5). Also, experiments using КІ67, a monoclonal antibody that, 
like BrdU, selectively binds to proliferating cells (162), have shown equal labelling. 
Since КІ67 has been shown to give a good indication of growth fraction in tumor 
xenografts (180), we conclude that the two groups of spheroids have equal growth 
fractions. The equal growth fraction implies that the cell cycle time in fast growing 
spheroids is lower than in slow growing spheroids (117). The cell cycle time for the 
clonogenic cells might even be shorter than for the rest of the cells (181). Kubota et al. 
(177) showed that cell populations from different regions from a spheroid had similar 
cell cycle distributions, but highly different radiosensitivities. The number of 
clonogenic cells in these populations was the same. 
Although the relative cell number may not be usable for this type of spheroid to 
explain the observed differences in radiosensitivity when spheroids grow with different 
growth rates, the response of the critical cell number to radiation may give insight into 
the different radiosensitivities. The critical cell number, or spheroid regenerating units, 
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SRU, (175) can be obtained by back-extrapolation of regrowth curves (48). Using this 
method survival estimates were obtained. Figure 8.12 shows the relationship between 
the surviving fractions of clonogenic cells and the surviving fraction SRU. There is a 
strong correlation for slow growing (R= 0.98) and fast growing spheroids (R= 0.87). 
This indicates that the conclusion regarding the different radiosensitivities of the two 
groups of spheroids are substantiated by this analysis. The back-extrapolation method 
using the derived DQ-values could, in those cases where determination of clonogenic cell 
survival is impossible, give insight into the relative radiosensitivities of spheroids. 
The survival curves for clonogenic cells give a clear indication of different capacities 
to accumulate sublethal damage in the two groups of spheroids. For this reason single 
and split-dose irradiations were performed in two groups of BRO spheroids that grew at 
different volume doubling times. The earlier results were replicated with regard to the 
different radiosensitivities of the two groups of spheroids when the assay was by growth 
delay. The response to radiation is more pronounced in the fast growing spheroids, 
which is clearly illustrated by the growth curves after 9 Gy single dose, i.e. fast 
growing spheroids did not regrow after this dose during the 5-week observation period, 
whereas the slow growing spheroids were able to regrow after a single dose of 11 Gy. 
Although flow cytometric analysis had shown that there were no differences in cell cycle 
distribution between the two groups of spheroids, the period during which the growth is 
continued after irradiation is not equal between the two groups. This may be caused by a 
different number of cells in spheroids from both groups that are able to conclude cell 
division after radiation treatment, thus contributing to volume increase. 
Cure probability Cure probability 
• о 
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Figure 8.11. Cure-dose curves from probit analysis for slow growing (panel A) and 
fast growing (panel B) spheroids from BRO human melanoma. Closed symbols: single 
dose irradiation; open symbols: split dose irradiation. 
Different radiosensitivity of spheroids growing with different growth rates was again 
also emphasized by the cure studies where 50% of the fast growing spheroids was 
sterilized by 6.7 Gy, whereas in the slow growing group 9.7 Gy was necessary to reach 
50% control. 
Differences in sublethal damage (SLD) repair between the two groups with different 
growth rates, were observed when growth delay was used to calculate a "dose repaired" 
(Fig. 8.9). This dose repaired is a measure of the amount of radiation that is actually 
repaired. At low doses (3-5 Gy) the dose repaired was larger for slow growing spheroids 
than for the fast growing spheroids. At the 11 Gy dose no calculation could be 
performed since even after split dose application all spheroids were cured. Only at the 9 
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Gy radiation dose the repaired dose was larger for fast growing than for slow growing 
spheroids. This is probably due to the calculation method of this value from the fitted 
curves (Fig. 8.8). As can be seen in Figure 8.8, panel B, the Tit for the split-dose points 
might well be closer to the single-dose line, since the distance between the two lines in 
this region is determined by only two dose points per line. In that case the dose repaired 
for the doses smaller than 9 Gy would be unaltered, but at 9 Gy the dose repaired would 
than be smaller. 
The plot of the recovery ratio (Fig. 8.10) showed that the dose points from both 
experimental groups could be fitted by the same line. Therefore, the ß-value from the 
LQ-equation (144) as expressed by the slope of the fitted line (91) is equal for both 
groups of spheroids. Contrary to the observations of Deschevanne and Malaise (182), in 
BRO spheroids the different radiosensitivity is not determined by different ß-values, but 
seems to be caused by the intrinsic radiosensitivity expressed by the α-value. The higher 
dose repaired in slow growing spheroids as compared to fast growing spheroids may in 
part be attributable to a longer cell cycle time, thus allowing more time for repair of 
potentially lethal damage. 
Surviving fraclion clonogens 
Figure 8.12. Surviving fraction of clonogens in relation to surviving fraction SRU 
in spheroids with two growth rates. Ractangles: slow growing spheroids; circles: fast 
growing spheroids. 
It seems that in these tumor cells there is a difference between the repair capacity as 
expressed by the β-value of the LQ-equation, and the radiation dose that is actually 
repaired, as expressed by the dose repaired. As stated by Steel and co-workers (82) the 
split-dose recovery reflects the incidence of repairable lesions rather than the recovery 
capacity as the β-value does. 
A difference in the split-dose recovery for spheroids growing at two different growth 
rates can also be deduced from the proportion cured spheroids. Apart from the different 
SCDso-values calculated from the probit curves, there is a difference in distance between 
the single dose curves and those for split-dose irradiation. Slow growing spheroids show 
a greater distance, i.e. a larger split-dose recovery, than the fast growing spheroids. 
Since there was no difference in cell cycle distribution between the two groups of 
spheroids, it seems plausible that differences induced by the nutrient availability are 
responsible for the observed difference in SLD repair. For V79 mammalian cells it was 
shown that the capacity to repair sublethal damage is dependent on energy status of 
cells, i.e. availability of ATP (183). It seems logical that the higher growth rate, and 
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the shorter cell cycle time, may cause a depletion of available ATP in fast growing 
spheroids which in turn leads to decreased repair of SLD. 
Rofstad and co-workers have intensively studied the radiosensitivity of human 
melanoma cells grown as spheroids (184) and as xenografts (185). Differences in 
radiosensitivity in five melanoma lines were reported, and good correlations were found 
between radiation responses in xenografts and spheroids (184,185), and for the different 
endpoints used for studying radiosensitivity (184). However, they failed to observe the 
relation between growth rate and radiosensitivity, spheroids growing with the largest 
volume doubling times were the least sensitive (184). 
In clinical practice fast growing tumors are considered to be more resistant to 
radiation treatment than slow growing tumors. Radiation therapy is given in multiple 
small fractions over a period of several weeks, and this treatment scheme has a higher 
therapeutic ratio than several large doses given in a limited time span. Using V79 
spheroids, Durand (77) has shown that proliferation during fractionated irradiation is a 
major determinant of the outcome of treatment. Taken together with these findings, the 
results presented in this chapter may indicate that fast growing tumors are not so much 
more resistant to radiotherapy, but that sterilized areas are rapidly repopulated by 
surviving cells. The finding that fast growing tumor cells are less proficient at repair of 
SLD makes them more amenable to fractionated treatment than slow growing tumor 
cells. Large fractions would seem to be indicated since only a small proportion would be 
repaired by fast growing cells. This is also the conclusion of Bentzen et al (186), who 
showed that large doses per fraction were the most effective in human melanoma. This 
effectiveness of large fraction doses was attributable to low α/β-ratios for malignant 
melanoma, which was also observed for BRO melanoma spheroids (Chapter 6). 
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ABSTRACT 
Clinical investigations have shown that the histological type of human tumor has an 
important predictive value for its radiocurabihty The use of uniform fractionation schemes 
raises the question about the magnitude of the contribution of sublethal damage (SLD) repair 
in the differential radiocurabihty of tumors In the literature no data were available on SLD 
repair in spheroids of either human squamous cell carcinoma (SCC) of the head and neck, nor 
human melanoma Therefore, cells of a SCC cell line, HN-1, and a melanoma line, BRO, were 
irradiated with single and split doses of X-rays Irradiation was performed at varying 
diameters to study the influence of size on the radioresponsiveness and SLD repair Radiation 
response was quantified using growth delay spheroid cure, and, for the melanoma spheroids, 
survival estimates deduced from back-extrapolated growth curves Repair of sublethal damage 
was described by the repaired dose 
In good agreement with other investigators it was found that radiosensitivity, as expressed 
by spheroid cure, decreased with increasing spheroid diameter in BRO melanoma In HN-1 
SCC spheroids however, the radiosensitivity increased with spheroid diameter Survival 
curve parameters for BRO melanoma indicated thai cellular survival was equal in spheroids of 
different diameters The critical cell number, denved from the cure probability and cell 
survival estimates, increased with increasing diameter, but not proportional to the spheroid 
volume This indicates that larger BRO spheroids are less responsive to irradiation due to 
other factors than cellular sensitivity Hypoxia as a possible explanation for the 
observations in HN-1 and BRO could be excluded on results from other studies The repair as 
expressed by the dose repaired was equal for differently sized HN-1 spheroids The smallest 
(200 μιη) BRO spheroids showed a larger dose repaired than the 330 ц т and 440 μια 
spheroids 
To further elucidate the repair capacity of HN-1 spheroids, fractionated radiation regimens 
were employed Regimens were calculated with the LQ-equation to be iso-effective All 
regimens were given in both once and twice daily radiation sessions Using specific growth 
delay (SGD) to quantify radiation response after one to five fractions, it was found that repair 
capacity was equal in HN-1 spheroids of different sizes, as had been indicated by the split-
dose experiments For small HN-1 spheroids the SGD was smaller in once daily fractionation 
regimens than when radiation was administered in twice daily sessions In large spheroids the 
advantage of accelerated fractionation was not observed If spheroids from this SCC bne may 
be regarded as a relevant model system for their m vivo counterparts, the results of these 
expenments may indicate that accelerated fractionation of treatment is advantageous for 
small lesions, but not for larger tumors From the spht-dose and fractionated irradiation 
experiments the conclusion is that differences in repair capacity for SLD cannot be the 
determining factor m the different radioresponsiveness of small and large spheroids It is 
assumed that mtratumor conditions influence radiosensitivity by mechanisms that are as yet 
unknown 
I N T R O D U C T I O N 
Intercellular contact has been shown to be a potent modifier of the repair capacity of 
irradiated mammalian cells (54,78), and, consequently, considerably influences cellular 
responses to multifraction irradiation. In 1973, Durand and Sutherland demonstrated that 
mammalian cells cultured in vitro as three-dimensionally growing multicellular tumor 
spheroids may become more radioresistant than monolayers. Chinese hamster V79 cells, 
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when grown for 1 day as spheroids, displayed an increased resistance to ionizing 
radiation, which was explained as a contact effect. This was primarily a shoulder-
modifying effect, which resulted in an increase in the D q -value of the survival curve by 
1-3 Gy (54,187). The reduced radiosensitivity was attributed to the three-dimensional 
contact of cells within the spheroid and thus denoted "contact resistance" or "contact 
effect" (CE). The CE has since been reported in rodent tumors (188) and human tumor 
xenografts (189). The increased radioresistance of spheroid cells is independent of the 
proliferative status of the cells (53). 
When cultured under conditions as in spheroids, cells display an enhanced ability to 
accumulate sublethal radiation damage (SLD). In addition, it was shown, using split-
dose regimens of low-linear-energy-transfer radiation, that cells from spheroids can repair 
SLD more efficiently when grown as spheroids (28). 
No data are available on SLD repair in human tumor spheroids of different diameters. 
In the present study spheroids from two human tumor cell lines, squamous cell 
carcinoma of the tongue (HN-1), and a melanoma (BRO), were irradiated at increasing 
diameters. Radiosensitivity and SLD repair were determined at 130 ц т and 350 pm 
(HN-1), and 200 μηι, 330 μιη, and 440 μιη (BRO) were determined using growth delay 
and spheroid cure. 
Weichselbaum et al. (75) however, showed that the response of tumor cells in vitro 
to treatment with fractionated radiation can differ considerably from that predicted on the 
basis of split-dose recovery. In clinical practice, a course of radiation therapy is given in 
multiple small fractions over a time period of several weeks, and this treatment scheme 
has a higher therapeutic ratio than several large doses given in a limited time span. It 
has been suggested that SLD repair accounts for tumor cell recovery after each dose in 
clinical radiotherapy (158). Since the proliferation rate is high, especially in squamous 
cell carcinomas of the tongue (190), repopulation by surviving clonogenic cells during 
treatment may be the cause of poor treatment results (191). Therefore, experiments were 
performed on HN-1 spheroids of two diameters (160 μηι and 460 pm), comparing a 
twice daily fractionation regimen with a conventional regimen, i.e. one fraction a day. 
All regimens were calculated to be iso-efective for radiation damage to early responding 
normal tissues, considered to be dose-limiting in this type of tumor, using the LQ-
equation(144). 
RESULTS 
Using the various methods and materials described in chapter 3, the following results 
were obtained. 
Figure 9.1 shows growth curves of BRO melanoma spheroids irradiated with single 
(A) and split (B) doses of X-rays at a diameter of 200 pm. Figure 9.2 shows growth 
curves of BRO spheroids irradiated at 330 pm. In a similar manner Figure 9.3 shows 
the growth curves for spheroids irradiated at a diameter of 440 μιη. The most striking 
difference between responses of spheroids with the three different diameters is the 
absence of regrowth in the 330 μηι and 440 μπι spheroids after a single dose of 11 Gy, 
whereas the 200 pm spheroids did regrow during the same time span after the same 
dose. 
The specific growth delay calculated from the growth curves of spheroids in Figures 
9.1, 9.2 and 9.3 are shown in Figure 9.4, panels A, B, and C, respectively. After split-
dose irradiation, the growth delay is significantly lower than after single doses, 
indicating repair of sublethal damage. Although specific growth delay was used, 
absolute values of growth delay cannot be intercompared for radiosensitivity of BRO 
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spheroids irradiated at different diameters, since the criterium for this endpoint was 
different for the 200 μιη (8 times volume increase), or the 330 μτη and 440 μιη 
spheroids (4 times volume increase). For the 330 μιη and 440 μιη spheroids the same 
criterium could be used, showing the 440 μιη spheroids to be less sensitive to 
irradiation, i.e. lower specific growth delay values. 
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Figure 9.1. Growth curves of BRO human melanoma spheroids irradiated with single 
(panel A) and split (panel B) doses of X-rays at a diameter of 200 μπι. Expressed is 
volume/initial volume as a function of time after treatment Each point represents the 
average + SD of at least 10 spheroids. 
re lat ive vo lume -
100 V o l 
relative volume -
100 Vo 
-¿ . „„„o , / · * -»« 
Э 30/Jin spheroids 
split dost 
Figure 9.2. Growth curves of BRO human melanoma spheroids irradiated with single 
(panel A) and split (panel B) doses of X-rays at a diameter of 330 μm. Expressed is 
volume/initial volume as a function of time after treatment. Each point represents the 
average ± SD of at least 10 spheroids. 
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Figure 9.3. Growth curves of BRO human melanoma spheroids irradiated with single 
(panel A) and split (panel B) doses of X-rays at a diameter of 440 μm. Expressed is 
volume/initial volume as a function of time after treatment Each point represents the 
average + SD of at least 10 spheroids. 
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Figure 9.4. Growth delay as a function of total radiation dose for BRO human 
melanoma cell line irradiated either as 200 цт (panel A), 330 μm (panel B, or as 440 
цт (panel C) spheroids. Dots: single dose irradiation; circles: split dose irradiation. 
Figure 9.5 shows the growth curves of HN-1 squamous cell carcinoma spheroids 
irradiated with single (A) and split (B) doses of X-rays at a diameter of 130 \im. Figure 
9.6 shows growth curves of spheroids irradiated at 350 μτα. A static phase of the growth 
was reached after doses in excess of 6 Gy (130 μτη spheroids) and 4 Gy (350 μιη 
spheroids). The lower dose in the 350 μπι spheroids already induced a static phase in 
spheroid regrowth curves, indicating a greater radiosensitivity as compared to the 130 
μπι spheroids. 
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Figure 9.5. Growth curves ofHN-l 
squamous cell carcinoma spheroids 
irradiated at a diameter of 130 pm with 
(panel A) single and (panel B) split doses 
of X-rays. Expressed is volume/initial 
volume as a function of time after 
treatment. Each point represents the 
average + SD of at ¡east 12 spheroids. 
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Figure 9.6. Growth curves of HN-1 
squamous cell carcinoma spheroids 
irradiated at a diameter of 350 μm 
with (panel A) single and (panel B) 
split doses of X-rays. Expressed is 
volume/initial volume as a function 
ottime after treatment. Each point 
represents the average ± SD of at least 
12 spheroids. 
The growth delay calculated from the growth curves of the HN-1 spheroids (Figs 9.5 and 
9.6) is shown in Figure 9.7 panels A and B. In this type of spheroids the growth delay 
after split-dose irradiation is significantly lower than after single doses, indicating repair 
of SIX) in spheroids of both diameters. 
The dose repaired calculated from the growth delay curves for both types of spheroids 
irradiated at different diameters is shown in Figure 9.8. Expressed is the dose repaired as 
a function of total radiation dose. The dose repaired is significantly larger in BRO 
spheroids irradiated at a diameter of 200 μηι than at the diamaters of 330 and 440 μιη. 
The dose repaired is larger in 440 ц т spheroids than in 330 μιη spheroids. For HN-1 
spheroids this is less clear; at the 5 and 6 Gy doses the repaired dose is larger for the 130 
μιη spheroids, but at the 7 and 8 Gy doses the picture is reversed. 
Figure 9.9 illustarates the results of the probit analysis of the proportion cured 
spheroids after single dose irradiation as a function of total radiation dose. Panels A and 
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В show the results for BRO and HN-1 spheroids, respectively. The SCD^-values (95% 
confidence limits) for BRO were 8.6 Gy (7.8-9.3 Gy), 9.2 (8.6-9.9 Gy), and 9.9 (9.5-
10.2 Gy), for the 200 μιη, 330 μτη, and 440 μτη spheroids respectively. For the HN-1 
spheroids the values were 7.8 Gy (7.4- 8.5 Gy) and 6.9 Gy (6.1-7.2 Gy) for the 130 
μτη, and 350 μιη spheroids, respectively. 
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Figure 9.7. Growth delay as function of total dose for irradiated spheroids of 
squamous carcinoma cell line HN-1. Single (dots) and split (circles) doses were 
administered to spheroids with a diameter of 130 μ/η (panel A) and 350 pm (panel B). 
HN-1 spheroids of two diameters (160 and 460 pm) were irradiated according to different 
fractionation schemes, which were calculated with the LQ-equation to be iso-effective 
for early-responding normal tissues (assuming an α/ß-value of 10 Gy). The details of 
these schedules are given in Table 9.1. 
The average time taken to reach an eight-fold increase in volume for 160 μτη 
spheroids, and a four-fold increase in volume for 460 μτη spheroids is presented in 
tabular form in Table 9.1. 
DISCUSSION 
This study was performed to determine whether tumor cells derived from a human 
melanoma and a human squamous carcinoma cell line show size-dependent differences in 
radiosensitivity, and whether these differences could be correlated to sublethal damage 
(SLD) repair. Clinically, curability of malignant tumors is related both to local control 
and the development of metastatic disease. Here, radiocurability is defined in terms of 
the ease of local control. In determining the growth of spheroids after irradiation we are 
not measuring radiosensitivity in the strict sense, but rather radiation responsiveness, 
that is, the complex interaction of cell killing, repair and repopulation (139). As Durand 
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and Sutherland (137) pointed out, cell that were not inactivated by radiation may not be 
in a position to proliferate and contribute to growth. In their view this is the major 
draw-back of the use of growth delay and SCDjo assays. On the other hand, they 
admitted that these convenient measures with long-term analysis can lead to reasonable 
estimates of cell viability ( 137). In a recent review Mueller-Klieser (29) pointed out that 
spheroids may reflect the intrinsic radiosensitivity of the tumor cells as well as the 
influence of a "tumor-like'' microenvironment on this sensitivity. This 
microenvironment is determined by several factors such as nutrient and oxygen 
deprivation of centrally located cells (37). 
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Figure 9.8. Dose repaired as a function of total dose, calculated on an iso-effect basis 
from growth delay curves for spheroids of different diameters from two cell lines. 
Circles: BRO, 200 цт; dots: BRO, ЗЗОцт; triangles: BRO, 400pm; closed squares: 
HN-1, 130 μm; open squares: HN-1, 350 цт (panel B). 
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Figure 9.9. Cure-dose curves from probit analysis for (panel A) BRO melanoma 
spheroids and (panel B) HN-1 squamous cell carcinoma spheroids. Panel A: circles: 200 
μη spheroids; dots: 330 цт spheroids; rectangles: 440 цт spheroids. Panel B: closed 
squares: 130 μm spheroids; open squares: 350 цт spheroids. 
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In this study it was found that large BRO melanoma spheroids are less sensitive to 
irradiation, i.e. show a larger SCDjo-value (Fig. 9.9). This is in agreement with the 
results obtained by Kuwashima et al. (40), who reported higher cure doses and higher 
cell survival in human melanoma spheroids with increasing diameters. Estimates of 
cellular survival after irradiation of spheroids can be obtained by back-extrapolation of 
regrowth curves (48). In the previous chapter it was shown that for BRO melanoma 
spheroids a very close correlation exists between estimates of spheroid regenerating 
units (SRU) obtained by this method and clonogenic cell survival. Figure 9.10 shows 
the survival curves obtained with this method for the spheroids used in the present 
study. The data were fitted to a single-hit multitarget model (172), showing no 
significant differences in sensitivity as expressed by the Do-values. Do-values (+ SD) 
were 1.7 Gy (0.2), 1.6 Gy (0.2), and 1.6 Gy (0.1) for the 200-μπι, 330-pm, and 440-
μτη spheroids respectively. This indicates that radiosensitivity of BRO melanoma cells 
was not altered when growing in spheroids of different diameters. 
Using the same equation as described in chapter 8, the cellular radiosensitivity of 
BRO cells is equated by (177): p= -N/lnP, where Ρ is the cure probability obtained from 
Figure 9.9, N is the surviving fraction taken from Figure 9.10, and ρ is the critical cell 
number. The value of ρ calculated for cells in BRO melanoma spheroids irradiated at 
different diameters increased with increasing spheroid diameter: 1.9 for 200-μπι 
spheroids, 2.2 for 330-цт and 3.2 for 440-μιη spheroids. The values for the 200-цт 
and ЗЗО-μιη spheroids are of the same magnitude as for 250-μπι HMV-I human 
melanoma spheroids (40). 
The difference in volume between 200-μιη and 330-μπι spheroids represents a factor 
4.5 increase in cell number. Analysis of the critical cell number shows that an equal 
minimal number of surviving cells is required to regrow, i.e. the critical cell number did 
not increase proportional to the number of cells present in a spheroid. In a relative sense 
this implies that cells in larger spheroids become less sensitive to radiation. 
The decrease in radiosensitivity of BRO spheroids did not seem to be due to an 
increased ability to repair SLD. On the contrary, the amount of radiation that was 
repaired was significantly lower in 330-μπι and 440-μιη spheroids (Fig. 9.8). When the 
growth delay was calculated at values other than 8x for the 200 μπι spheroids and 4x for 
330-μιη and 440-μπι spheroids, and comparisons were made between the different sizes, 
the conclusions remain the same, i.e. large spheroids are more resistant to radiation but 
show less repair of SLD than do 200-μ m spheroids. 
Irradiation of human tumor cells of a squamous carcinoma cell line HN-1 growing as 
spheroids of different diameters show a similar picture, although less clear. 
Nevertheless, for this cell type too, it seems that the repair of SLD is lower in the 
larger spheroids. The reported increase in ability to repair SLD in cells growing as 
spheroids of increasing diameter (8,34) was not observed in the human tumor cells 
under consideration here. It is not clear whether this is a unique property of human 
tumor cells when grown as spheroids, as opposed to the murine cell lines used by 
Sutherland and co-workers (28,54). 
Cells of spheroids derived from a number of human tumor lines have been found to 
be highly sensitive to artefactual cell killing during disaggregation, making analysis of 
survival of single cells obtained from spheroids impractical (34). In addition, such 
determinations are often hampered by low plating efficiencies (136), as is also the case 
with HN-1 spheroids. The fact that after disaggregation of HN-1 spheroids the plating 
efficiency of cells was too low for analysis of clonogenic survival prevented analysis of 
cure rate in terms of critical cell number. The low clonogenic cell number in itself 
indicates that the critical cell number in HN-1 spheroids must be low. 
Table 9.1. Tune to obtain an eight-fold volume increase for spheroids from squamous cell 
carcinoma cell line HN-1, irradiated at a diameter of 160 |im (A), and time to obtain a four­
fold volume increase for spheroids from squamous cell carcinoma cell line HN-1, irradiated at 
a diameter of 460 ц т (В). Total doses were calculated with the linear quadratic equation to be 
iso-effective for early-responding normal tissues (α/β= 10 Gy). 
Number of 
fractions 
A) 
control 
Dose per 
fraction 
(Gy) 
0 
5.0 
2.91 
2.05 
1.62 
1.32 
2.91 
2.05 
1.62 
1.32 
Overall treatment 
time 00 
0 
0 
2 4 
4 8 
7 2 
96 
8 
2 4 
32 
4 8 
Total 
dose 
(Gy) 
0 
5.0 
5.82 
6.15 
6.48 
6.60 
5.82 
6.15 
6.48 
6.60 
Time to obtain required 
volume increase (day) with 
(95% 
6.0 
12.7 
14.3 
11.9 
9.4 
9.5 
15.6 
14.4 
13.0 
13.3 
confidence limits) 
(5.7 - 6.3) 
(11.5 - 14.1) 
(13.2 - 15.3) 
(10.8 - 13.0) 
(8.9 - 10.0) 
(8.7 - 10.4) 
(14.8 - 16.6) 
(13.3 - 15.6) 
(12.1 - 14.0) 
(12.4 - 14.2) 
B) 
control 
1 
2 
3 
4 
5 
2 
3 
4 
5 
0 
5.0 
2.91 
2.05 
1.62 
1.32 
2.91 
2.05 
1.62 
1.32 
0 
0 
24 
4 8 
7 2 
9 6 
8 
24 
32 
4 8 
0 
5.0 
5.82 
6.15 
6.48 
6.60 
5.82 
6.15 
6.48 
6.60 
10.5 
23.1 
22.1 
21.0 
21.9 
21.6 
23.1 
21.6 
23.7 
2 2 . 8 
(9.7 11.3) 
(21.8 - 24 6) 
(20.8 - 23.6) 
(20.2 - 21.8) 
(21.0 - 23.1) 
(20.8 - 22.5) 
(21.6 - 24.8) 
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In contrast with the results of Kuwashima et al. (40), who found an increasing SCDJQ 
with increasing diameter for HMV-I melanoma spheroids, and the results presented in 
this chapter for BRO melanoma spheroids, the HN-1 squamous cell carcinoma cells 
growing as spheroids show 350-μπι spheroids to be more sensitive than 130-цт 
spheroids. 
A plausible reason for a decreasing radiosensitivity in BRO spheroids would be a 
modifying influence of hypoxia in larger spheroids. However, hypoxia is not the 
concluding factor in the observed difference in radiosensitivity of small and large 
spheroids, since direct oxygen tension measurements with micro-electrodes have not 
shown hypoxic regions in BRO spheroids of this size (chapter 11). Moreover, in HN-1 
spheroids there were also no hypoxic regions, but the relation between diameter and 
radiosensitivity was reversed as compared to BRO spheroids. It seems that factors that 
are as yet unknown influence the radiosensitivity of human tumor cells in spheroids of 
different diameters, and this influence can be different in different types of tumor cells. 
In the clinic large tumors are less curable by radiation treatment than small tumors. 
Several factors may be responsible for this phenomenon which evolves during tumor 
growth. The increase in cell number can hardly account for the important clinical 
radioresistance of large tumors, which is more likely due to other factors, possibly the 
appearance of radioresistant mutants (192). Also, large tumors may differ from small 
tumors not only with regard to changes occuring during the tumor growth, but also in 
the intrinsic cell characteristics which could govern the tumor more directly than size 
and stage (192). 
If spheroids may be considered a relevant in vitro model for human tumors, the 
results from the present study of melanoma spheroids may be interpreted as indicating 
that although larger tumors need higher total doses to be sterilized, the decreased ability 
of SLD repair offers an advantage of fractionation. Results from clinical studies also 
point in that direction (186), showing especially promising results for large dose per 
fraction schemes. 
When radiation was applied to small HN-1 spheroids (160 μιη) in daily sessions 
larger volumes were observed after 4 weeks than after a single dose. It was assumed 
previously that total doses selected on basis of the LQ-model would yield iso-effective 
levels. The known high proliferation rate of squamous cell carcinoma (191) was 
probably responsible for repopulation of those parts of the spheroid in which cells were 
sterilized by radiation, rendering treatment less effective. If the same regimens were 
given in twice-daily sessions the effect was equal to that of the single dose treatment. 
The specific growth delay (SGD) for small spheroids was larger for the twice daily 
regimen than for the once daily scheme (Table 9.1 A). Repopulation is obviously less 
pronounced in this regimen, hence more growth delay was obtained with the twice daily 
regimen. For both regimens there weis a decrease in SGD with decreasing fraction dose, 
which stabilized, and even slightly increased, in the 5 fraction treatments. Although 
indicative, these differences were not statistically significant. It is not clear whether the 
observed increase in SGD would have continued with further fractionation. 
In large HN-1 spheroids (460 μιη) a different response pattern was observed. Once 
daily irradiation schemes resulted in equal growth delay values as the 5 Gy single dose 
(Table 9. IB). Here too, repopulation eventually decreased the effectiveness of treatment. 
Contrary to the results with small spheroids, there was no significant difference in SGD 
values for the once and twice daily irradiation schemes (Table 9.IB). 
Comparing HN-1 spheroids of two different diameters using a fractionation regimen, 
it can be concluded that there is an equal repair when twice daily regimens are used: at 
both diameters of spheroids all fractionated regimens are iso-effective to the single dose. 
If repair capacity in the spheroids was a function of volume, i.e., having different α/β -
ratios, one of the two groups would not show iso-effective responses to the single dose. 
Using a once daily regimen the response patterns are comparable in the two diameter 
groups, but in this regimen the fractionated radiation curves were different from the 
single dose response. Only in the 160-μιη group the difference was signifcant. This 
may be due to one of the major disadvantages of the linear-quadratic equation we used; 
the absence of a time factor (193). For the twice daily schemes the choice of an α/β-
ratio of 10 Gy seemed correct, and in consistency with reported values for tumors (194). 
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Figure 9 . 1 0 . X-ray survival curves for BRO human melanoma cells of spheroid 
regenerating units (SRU) obtained from back extrapolation of regrowth curves of 
spheroids after single (dots) and split (circles) doses of X-rays. Radiation administered at 
200 pm (panel A), 330 pm (panel B), and 440 pm (panel C). 
If spheroids from this squamous cell carcinoma cell line may be regarded as a relevant 
model system for their in vivo counterparts, than the results from the present study 
might indicate that accelerated fractionation of treatment is advantageous for small 
lesions. However, adopting such a procedure would result in increased toxicity for early-
responding tissues (190). In view of the size of the lesion the toxicity may be confined 
to a small area. 
This study also shows that even small differences in size (160 and 460 μτη) may 
influence the outcome of fractionated treatments. 
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Chapter 10 
Effectiveness of platinum compounds in 
the chemotherapy of squamous cell 
carcinoma grown as spheroids, and their 
inhibition of sublethal damage repair 
Effectiveness of platinum compounds in the chemotherapy 
of squamous cell carcinoma grown as spheroids, and their 
inhibition of sublethal damage repair 
ABSTRACT 
The ability of cisplatin and carboplatin to inhibit spheroid growth was compared The 
activities of cisplatin and carboplatin were also compared in an antimetabolic assay for their 
ability to inhibit [ H]-thymidine incorporation in multicellular spheroids The spheroids 
were denved from squamous cell carcinoma line HN-1, originally denved from a tumor of the 
tongue To produce equal levels of growth delay in spheroids, carboplatin was required at 
concentrations approximately 16 times that of cisplatin Carboplatin also required much 
longer incubation penods to produce equivalent growth delay and proportions of cured 
spheroids Reflecting the initial response to chemotherapy, the antimetabolic assay showed 
that carboplatin was required at higher concentrations and longer exposure tunes to produce 
equal inhibition of the nucleotide precursor thymidine These findings are in good agreement 
with preliminary findings from clinical trials, supporting a role for carboplatin in the 
treatment of squamous cell carcinoma of the head and neck, since total free-drug exposure of 
patients to carboplatin may be up to 16-fold greater than with cisplatin, and the clinical side 
effects of carboplatin have been shown to be well tolerated 
Clinical protocols have been designed to combine platinum based drugs and radiation in the 
treatment of cancer The rationale for this approach has been developed from preclinical 
studies demonstrating that platinum compounds can potentiate the cytotoxic effects of 
radiation towards cells In the second part of the present chapter spheroids denved from 
squamous cell caranoma line HN-1, have been used to study the effects of both cisplatin and 
carboplatin when administered pnor to, concurrently, and after radiation treatment To study 
the influence of both platin compounds on sublethal damage (SLD) repair, single and split 
doses of radiation were appbed Growth delay served as endpoint Both cisplatin (2 Mg/ml) 
and carboplatin (20 Mg/ml) had no potentiating effect when administered 24 h prior to 
irradiation When administered 3 h after completion of irradiation procedures, growth delay 
after single and split doses were enhanced to the same extent The Drug Enhancement Ratio 
(DER) for cisplatin was larger (1 5) than for carboplatin (1 2) Because both single and split 
doses were enhanced by the same factor, there was no effect in SLD repair when expressed as 
dose repaired When platin compounds were present in the target cells at the time of 
irradiation, especially the split-dose radiation response was strongly enhanced, DER 3 9 for 
cisplatin and 3 2 for carboplatin SLD repair was totally repressed This study shows that 
platin compounds can potentiate radiation by different mechanisms, showing that the 
sequence of the two modalities is important Moreover, these results may in part explain the 
heterogeneous outcomes of trials combining platinum compounds and radiation 
INTRODUCTION 
Cisplatin has become an important clinical chemotherapeutic agent because of its 
relatively broad antitumor spectrum (195). However, its usefulness is limited by severe 
side-effects; renal toxicity, nausea, vomiting and ototoxicity (196). 
Second-generation platinum complexes such as carboplatin have entered clinical 
trials (197,198). Since carboplatin has the same active intermediate as cisplatin, it is 
probable that carboplatin has a similar dose-response relationship in human tumors. 
Carboplatin's lack of neurotoxicity and nephrotoxicity (199) may facilitate use of 
platinum compounds in higher doses in patients with platinum responsive tumors. 
Among the most effective cytotoxic agents in head and neck cancer are cisplatin and 
methotrexate. Single-agent experience with both drugs in patients with recurrent disease 
indicates that response rates range from 25% to 30% (200). Cisplatin-containing 
combinations have not shown a clear advantage over single-agent treatment for patients 
with recurrent disease. Preliminary data from carboplatin treatment of patients with 
advanced head and neck tumors show good acceptance of side-effects and similar tumor 
responses as with cisplatin (201) 
The discovery of antitumor activity for cisplatin (202) and its subsequent clinical 
application was soon followed by an investigation of cisplatin combined with radiation 
delivered to mice bearing P338 leukemia. This combined treatment resulted in an 
increase in the expected life span (203). Also, it was discovered that cisplatin increased 
radiosensitivity in E. coli cells (204). Subsequently cisplatin was tested with radiation 
in several murine tumors, where a probable synergy of response was observed (205). 
This investigation was based on the rationale of radiation sensitization. 
The mechanism of radiation potentiation is difficult to determine, since cisplatin 
exposed to cells, either before or after irradiation, can increase radiation sensitivity 
(206,207). A small degree of potentiation was seen in the absence but not in the 
presence of oxygen when cisplatin was tested in V79 (208) and HeLa (209) cells. In H4 
cells, oxic potentiation by cisplatin decreased the shoulder in the survival curve, whereas 
hypoxic potentiation largely led to a change in the slope of the dose-response curve 
(210). The mechanism of cisplatin potentiation of radiosensitivity is most often 
investigated as the inhibition of potentially lethal damage repair (PLDR)(153) or 
sublethal damage repair (SLDRX57). In tissue culture, such experiments are usually 
carried out in the presence of oxygen. An inconsistent pattern of potentiation by 
cisplatin of radiation response, either by PLDR or SLDR, was observed (211). 
Clinical trials have integrated cisplatin with radiation rather independently of 
modality sequencing. As was elegantly shown by Lelieveld et al. (212) and Tanabe et al. 
(213) in tumor xenografts, the combined effect of cisplatin and radiation is maximal 
when cisplatin is given close in time to radiation fractions. Inhibition of SLD repair by 
cisplatin is suggested to be the most reasonable mechanism to explain the radiation 
potentiation. 
In this study the effectiveness of cisplatin and carboplatin was compared, using the 
human squamous cell carcinoma cell line HN-1, when grown as spheroids. In many 
respects, spheroids provide a more realistic in vitro tumor model than do monolayers 
(37). Spheroids resemble micrometastases during the avascular phase of their growth and 
display "contact resistance" to drug and radiation treatment (37). Spheroids may therefore 
provide an appropriate in vitro model for experimental chemotherapeutic studies on the 
effectiveness of different agents. 
The effectiveness of cisplatin and its analogue carboplatin were compared using the 
growth inhibition of spheroids and the proportions of cured spheroids caused by both 
agents. As a measure of the initial response to chemotherapy an antimetabolic assay 
was used. To test the hypothesis that inhibition of SLD repair is the mechanism of 
radiation potentiation of platinum compounds, we compared the effectiveness of 
cisplatin and carboplatin for their ability to inhibit SLDR when human tumor cells 
were cultured as spheroids. Iso-effective doses of cisplatin and carboplatin that were 
established in the first part of the study, were administered to spheroids from HN-1 
squamous cell carcinoma of the tongue either 24 hours before, during, or three hours 
after radiation treatment. As a measure of radiation response, growth delay and the 
proportion of cured spheroids was used. 
RESULTS 
Using the various materials and methods as described in chapter 3, the following results 
were obtained. 
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Figure 10.1. Growth curves of HN-1 squamous cell carcinoma spheroids after 
treatment with cisplatin for 1 h. Control spheroids: dots. Panel A: circles: 0.01 μg/ml; 
closed squares: 0.1 μβ/πιΐ; open squares: 1.0 ц§/т1. Panel B: open triangles: 5 ug/ml; 
closed triangles: 10 μΕ/πύ; diamonds: 15 μg/ml. Expressed is volume/Initial volume as 
a function of time after treatment. Each point represents the average ± SD of at ¡east 12 
spheroids. 
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Figure 10.2. Growth curves of HN-1 squamous cell carcinoma spheroids after 
treatment with carboplatin for 1 h (panel A) and 24 h (panel B). Untreated controls: 
dots; 5 μg/ml: circles; 10 μg/ml: closed squares; 20 μ§/ιη1: open squares. Expressed is 
volume/initial volume as a function of time after treatment. Each point represents the 
average ± SD of at least 12 spheroids. 
Figure 10.1 shows the growth curves for HN-1 squamous cell carcinoma spheroids after 
treatment with cisplatin for 1 hour, either with low doses (panel A) or high doses (panel 
B). The curve for untreated control spheroids is exponential in shape with a volume 
doubling time of approximately 3.7 days. In the low dose range there was no significant 
difference between 0.01 μg/ml (circles), 0.1 pg/ml (dots), and 1.0 μg/ml (open squares). 
In the high dose range there was a marked difference between the S μg/ml (open 
triangles), 10 μ§/τη1 (closed triangles), and IS μg/ml (open diamonds). There was a 
progressive increase in the time period before growth was resumed. In the 15 \xg/m\ 
treatment group no regrowth was exhibited during the S-week observation period. If 
treatment in the high dose group was prolonged for more than 1 hour no regrowth 
occurred in any of the treatment groups. 
Figure 10.2 shows the growth curves for HN-1 spheroids after treatment with 
carboplatin. Since there was no growth inhibition in the low dose range, only the 
results obtained in the high dose range are shown. After 1 h treatment (panel A) with 
carboplatin, only the 20 pg/ml treated spheroids (open squares) were clearly inhibited in 
their growth. The growth inhibition was more pronounced after 24 h treatment (panel 
B), when the 5 tig/mi and 10 )xg/m\ treated spheroids were also inhibited in their 
growth. Table 10.1 summarizes the specific growth detey values for the various 
treatment times and concentrations. 
Table 10.1. Specific growth delay (SGD) in squamous cell carcinoma spheroids after 
treatment with graded doses of either cisplatin or carboplatin for various exposure times. 
dose 
(ЦБ/тІ) 
0.01 
0.1 
1.0 
0.01 
0.1 
1.0 
0.01 
0.1 
1.0 
5 
10 
15 
Cisplatin 
exposure 
time (h) 
1 
1 
1 
4 
4 
4 
2 4 
2 4 
2 4 
1 
1 
1 
SGD 
0.60 
0.60 
0.27 
0.18 
0.18 
2.49 
0.18 
0.64 
6.84 
7.80 
12.43 
CO 
dose 
(Цб/ті) 
5 
10 
20 
5 
10 
2 0 
5 
10 
2 0 
Carboplatin 
exposure 
time (h) 
1 
1 
1 
4 
4 
4 
2 4 
2 4 
2 4 
SGD 
-0.20 
0.17 
1.17 
0.03 
0.77 
3.70 
5.03 
10.70 
13.10 
Figure 10.3 shows the proportion of cured HN-1 spheroids after teatment with graded 
doses of cisplatin (panel A) and carboplatin (panel B). Both treatments were performed 
within the high dose range. However, cisplatin was applied for a period of 1 h, whereas 
treatment with carboplatin lasted 24 h. The SCDjo-values for cisplatin and carboplatin 
were 10.4 μπι/ιηΐ (7.7-12.3 μg/ml, 95% confidence limits) and 12.2 μg/nll (9.8-15.8 
μg/ml, 95% confidence limits), respectively. The difference in SCDso-values was not 
significant as determined by the methods described by Litchfield and Wilcoxon (90). 
The incorporation of [^l-thymidine in HN-1 spheroid cells is illustrated in Figure 
10.4. Cisplatin treatment (panel A) for 1 h (closed bars) showed a decreased 
incorporation of [3H]-thymidine at a level of approximately 95% of control. Treatment 
periods of 4 h gave a decrease of incorporation to about 25% at 1.0 μg/ml (shaded bars). 
After 24 h treatment (striped bars) this decrease was even more pronounced (10%). 
по 
Carboplatin treatment (panel В) also inhibited the incorporation of pH]-thymidine. 
For 1 h (closed bars) and 4 h (shaded bars) incubation period there was a gradual decrease 
in incorporation with increasing dose. A similar result was obtained with the 24 h 
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Figure 10.3. Cure-dose relationship curves from probit analysis for spheroids treated 
with (panel A) 2 ц^ті cisplatin and (panel B) 20 ц^ті carboplatin. At 50% cure the 
95% confidence intervals are shown. 
treatment time (striped bars), but a larger decrease in incorporation was brought about 
by this incubation with carboplatin. 
Figure 10.5 shows the correlation between the growth delay values and the [3H]-
thymidine incorporation. The correlation coefficient for the drawn line was 0.74. 
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Figure 10.4. l3H]-thymidine incorporation in HN-1 squamous cell carcinoma 
spheroids after treatment with (panel A) cisplatin and (panel B) carboplatin. 
Incorporation after treatment expressed as percentage of untreated control values. 
Figure 10.6 shows growth curves of spheroids irradiated with single and split doses of X 
rays (2-6 Gy). When no combination with platin compounds was employed (panel A), 
after an initial increase in volume, a static phase in the growth of spheroids was reached 
after a single 4 Gy and a 6 Gy split dose. A decrease in volume to approximately the 
volume at the time of treatment was exhibited by the single 6 Gy irradiated spheroids. 
Panel A also shows the growth curves for spheroids treated with either 2 pg/ml 
cisplatin or 20 Mg/ml carboplatin alone. These curves did not differ significantly from 
each other and from the control curve. 
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Figure 10.5. Correlation between specific growth delay (SGD) values and pH]-
thymidine incorporation after treatment with cisplatin and carboplatin. 
When cisplatin was present at the time of irradiation (panel B), a similar response 
pattern for the single dose irradiated spheroids was observed as in the spheroids where no 
platin compounds were used. The growth of spheroids after split doses of radiation was 
fundamentally different from that after no combination treatment. The 4 and 6 Gy split 
dose treated spheroids diminished in volume even below the size at treatment 
When cisplatin was added after irradiation procedures were complete, a growth pattern 
was observed intermediate between those described for no combination and concurrent 
combination treatment. After 6 Gy total doses the spheroid volume declined below 
treatment volumes before regrowth occurred, whereas the 2 Gy total dose treated 
spheroids showed a minor displacement of the growth curves. 
When cisplatin was added 24 h before radiation was applied (growth curves not 
shown), curves were obtained that showed virtually no deviation from those after 
irradiation without platin compounds. 
Figure 10.6. Growth curves ofHN-l spheroids (250 μιη) irradiated with single and 
split doses of X-rays or treated for 1 h with 20 μβ/ηηί carboplatin or 2 pg/ml cisplatin 
(panel A), or combination of irradiation and 1 h cisplatin treatment concurrently (panel 
B), or 3 b after completion of irradiation procedures (panel C). 
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Figure 10.7. Growth delay as function of total radiation dose for spheroids of 
squamous carcinoma line HN-1. Single (closed symbols) and split (open symbols) doses 
administered to spheroids without platinum compounds (panel A), concurrently with 2 
pg/ml cisplatin (panel B), or prior to cisplatin treatment (panel C). 
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Figure 10.8. Growth delay as function of total radiation dose for spheroids of 
squamous carcinoma line HN-1. Single (closed symbols) and split (open symbols) doses 
administered to spheroids without platinum compounds (panel A), concurrently with 20 
μg/ml carboplatin (panel B), or prior to carboplatin treatment (panel C). 
The growth delay calculated from the growth curves of the spheroids (Fig. 10.6) are 
shown in Figure 10.7. After split-dose irradiation, the growth delay is significantly 
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lower than after single doses, indicating repair of sublethal damage in these spheroids, 
when no cytostatic drug was used (panel A). When cisplatin was present at the time of 
irradiation (panel B), the picture reversed, i.e. growth delay after split doses was larger 
than after single doses. Obviously, there is no indication of repair of sublethal damage. 
When cisplatin was added 3 h after irradiation procedures were completed, the growth 
delay (panel C)was larger than when no cytotoxic drug was used. The growth delay was 
more pronounced after single dose irradiation than after split doses, indicating repair of 
sublethal damage. 
The use of carboplatin produced a similar pattern to cisplatin, Figure 10.8 shows the 
growth delay calculated from curves obtained after single and split dose irradiation 
(growth curves not shown). However, all growth delay values were lower for 
combination with carboplatin than after treatment combined with cisplatin. 
Table 10.2. Dose related repair capacity as expressed by dose repaired after irradiation of 
HN-1 squamous cell carcinoma spheroids either with or without platin compounds. Dose 
repaired calculated on an iso-effect basis from the growth delay data. 
Total dose (Gy) Dose repaired + SD (Gy) 
no platinum pre-treated post-treated 
cisplatin carboplatin cisplatin carboplatin 
2 
4 
6 
0.7 + 0 . 2 
0.8 + 0.3 
1.3 + 0 . 3 
0.6 + 0 . 2 
0.8 + 0.2 
1.2 + 0 . 3 
0.6 + 0 . 2 
0.9 + 0.3 
1.3 + 0 . 2 
0.8 + 0 . 2 
0.9 + 0.3 
1.1 + 0 . 2 
0.6 + 0 . 2 
0.7 + 0.2 
1.3 + 0 . 3 
A dose repaired was calculated from regrowth delay in spheroids. Table 10.2 lists the 
dose repaired as a function of total dose. The dose related repair capacity was not 
different when spheroids were irradiated either in the absence of platinum compounds, or 
when those were present 24 h before and 3 h after irradiation procedures. No difference 
was found between cisplatin and carboplatin. However, this iso-effect method produced 
negative values when applied to the data of spheroids irradiated in the presence of 
platinum compounds. Negative values are biologically meaningless and must be 
interpreted as the total absence of split dose recovery. 
When the DER was calculated from the growth delay data a new picture emerged. 
Table 10.3 lists the DER values calculated from the growth delays. When drugs were 
present during irradiation, DER was higher for cisplatin (1.2) than for carboplatin (1.0). 
Split doses gave the most pronounced DER values; 3.92 for cisplatin and 3.19 for 
carboplatin. When pre-treatment with platin compounds was performed, the DER values 
did not differ from 1.0 for either cisplatin or carboplatin. Posttreatment with cisplatin 
gave equal DER values for split and single dose treatment (1.5). In the case of 
carboplatin post-treatment the DER values were also equal for single and split dese 
irradiation (1.2), but lower than for cisplatin. 
DISCUSSION 
The results obtained from the growth delay studies with HN-1 squamous cell carcinoma 
spheroids suggest that at iso-effect levels carboplatin concentration is approximately 16 
times higher than cisplatin concentration (Table 10.1). This suggests that at equivalent 
concentrations carboplatin is about 16 times less toxic than cisplatin to tumor cells in 
spheroids. 
Predictions of the relative therapeutic effectiveness of these drugs can only be made 
if information on their relative toxicity for normal tissues in clinically tolerable doses is 
taken into account. The recommended maximal single-agent doses for cisplatin and 
carboplatin are 100 and 400 mg/m2, respectively (214). Together with pharmacokinetic 
differences between the drugs, e.g. clearance rates and protein binding, these doses result 
in the AUC (area under the concentration-time curve) values for the two drugs: cisplatin, 
5 μιη/ Pt h/ml and carboplatin 80 μg/Pt h/ml (214). These values are for free platinum. 
Thus carboplatin has an AUC of 16 times that of cisplatin. This means that although 
carboplatin is 16 times less effective in spheroids, an equal effect in patients can be 
reached by the 16 times higher doses attainable. 
The growth delay results with HN-1 spheroids in this study showed that carboplatin 
and cisplatin were iso-effective only when carboplatin was present at concentrations 16 
times that of cisplatin, or when incubation was for longer periods in carboplatin than in 
cisplatin. This phenomenon was shown most clearly in Figure 10.3, where both 
cisplatin and carboplatin exhibited a similar proportion of cured spheroids. The SCD50-
values for both drugs were not significantly different. However, the exposure time in 
carboplatin was 24 times that of the cisplatin exposure time. 
The antimetabolic assay used here has confirmed its specificity in reproducing 
human tumor cell sensitivity to drugs. This assay has been shown to predict with great 
accuracy the chemosensitivity and resistance of tumor biopsies (215) and tumor 
xenografts (103). The highest inhibition by cisplatin in incorporation of the radioactive 
nucleotide precursor [^J-thymidine was observed at the concentration of 1 pg/ml. This 
inhibition was more pronounced with increasing incubation time. Carboplatin inhibited 
the pH]-thymidine incorporation to similar levels, at concentrations 10 to 20 times 
higher than the cisplatin concentrations. Whereas the 1-h incubation period gave no 
marked inhibition for carboplatin and only little inhibition for cisplatin, the 4-h 
incubation period showed a dose dependent inhibition of PHl-thymidine incorporation. 
At 24-h incubation periods this dose dependency is even more pronounced. Equal levels 
of inhibition were obtained for the 24-h incubation of cisplatin and carboplatin when 
their concentrations were 1 pg/ml and 20 Mg/ml, respectively. 
The differences between the drug effects in this assay are of the same magnitude as in 
the growth delay and spheroid cure studies. The correlation between the growth delay and 
metabolic assay is clearly present, but should be further substantiated. As shown in 
Figure 10.5, the correlation between the two assays is more qualitative than quantitatve, 
i.e. high incorporation correlates with low growth delay, and low incorporation with 
high growth delay. 
The growth delay assay and the antimetabolic assay give insight into the 
mechanisms of the two drugs at different levels. Whereas the growth delay and cure 
endpoints give an overall response to treatment, as in the clinical situation, the 
antimetabolic assay reflects the initial response to chemotherapy, as does a clonogenic 
assay. 
The advantage of a clonogenic assay is that it is an accepted endpoint for determining 
cell survival. The human tumor stem cell assay has been used extensively for drug and 
radiation testing, and has the advantage that cloning of cells in soft agar is indicative of 
malignant cell growth. The stringent requirements of clonogenic assays, however, 
cannot usually be met in cultures from spheroids (136). The primary problem is setting 
up an assay such that all colonies arise from single cells; a signifcant number of 
colonies arising from a clump of more than one cell results in an artificially high 
estimate of cell survival (217). Cells used for spheroid formation are proficient in the 
capacity of aggregation (30). Other problems with clonogenic assays that must be 
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considered include the potential dependence of plating efficiency on cell seeding density, 
a non-linear relationship between cell number and colony formation (218), very low 
plating efficiencies (136) and the problem of abortive colonies large enough to be 
counted as survivors (217). Taking these considerations into account, the antimetabolic 
assay as used in this study was preferred. 
As shown by the results from this study, there seemed to be good agreement 
between the inhibitory effects of the two drugs on nucleotide precursor incorporation and 
the overall effects on the growth of spheroids. It thus seems feasible to study drug 
effects on spheroids using this quick and simple technique. 
There have been numerous clinical reports of protocols that combine platinum-based 
drugs and radiation in the treatment of cancer (reviewed in 211). The rationale for the 
design of these clinical protocols has developed from the results of preclinical studies 
demonstrating that platinum compounds potentiate the cytotoxic effects of radiation 
towards cells both in culture and in transplantable tumor models. 
The mechanism responsible for this potentiation are unknown, but supra-additive 
effects, when they have been observed, have been attributed to two interactions: 1) 
radiosensitization of either hypoxic or oxic cells, and 2) inhibition of recovery of cells 
from radiation induced potentially or sublethal damage. In the HN-1 spheroids used in 
the present study repair of PUD is not likely to contribute since this cell line is deficient 
in this respect (chapter 7). Also, hypoxic potentiation can be excluded since direct 
oxygen tension measurements have not shown hypoxia in this type of spheroids 
(chapter 11). 
Platinum compounds form adducts with cellular DNA, but it has not yet been 
proven which adduct type is responsible for the observed antitumor effects. The 
formation of DNA adducts is a fast process, as is the half-life of adducts, approximately 
3.5 h (218). 
During a 24-h period after 1-hour exposure to platinum compounds, most of the 
DNA adducts would have disappeared, giving little effect on the spheroid growth, as is 
demonstrated by the growth curves in Figure 10.6, panel A. This might explain the 
total absence of an additive effect when cisplatin or carboplatin when given 24 h before 
irradiation (Table 10.3). Also, no effect on sublethal damage repair would be observed 
(Table 10.2). 
Table 10.3. Drug enhancement ratio calculated from growth delay data of spheroids 
irradiated when either cisplatin or carboplatin were administered before, during or after 
irradiation for 1 h. 
Platin compound: 
Cisplatin: 2 μg/ml 
single doses 
split doses 
Carboplatin: 20 μg/ml 
single doses 
split doses 
pre-treated 
1.0 
1.1 
1.0 
1.0 
Drug enhancement ratio 
concurrently 
1.2 
3.9 
1.0 
3.3 
post-treated 
1.5 
1.5 
1.2 
1.2 
By adding cisplatin and carboplatin 3 h prior to radiation treatment, the drugs could have 
intercalated with the DNA, and would be present when radiation was applied. The 
carboplatin enhancement of single radiation doses was only fractionally higher than for 
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carboplatin pre-treatment, for cisplatin the enhancement was somewhat more (1.2). The 
enhancement ratio was in excess of 3 for both cisplatin and carboplatin when radiation 
was split in two equal fractions spaced by 6 h. These results indicate repression of the 
sublethal damage repair in HN-1 spheroids by platinum compounds. By using only two 
(split) doses of radiation, a possible disturbance in the results induced by regrowth 
between fractions can be excluded. Inhibition of SLD repair has also been reported for 
human cervical carcinoma cells, HeLa S3 (209). However, for the same type of cells an 
absence of influence of cisplatin on SLD repair has been reported (219). In general, an 
inconsistent pattern of potentiation effects of cisplatin has been observed (211). So far 
no radiation modifying effects in human tumor cells in vitro have been reported. In V79 
Chinese hamster fibroblast cells similar potentiating effects for carboplatin have been 
reported as for cisplatin (220). 
A possible reason for this inconsistency may be indicated by this study. Post-
treatment with cisplatin and carboplatin gave an enhancement in growth delay and 
proportion cured spheroids after single as well as after split doses, which indicates that a 
radiation modifying effect can be achieved that is not induced through sublethal damage 
repair. Moreover, the dose repaired (Table 10.2) was not altered in post and pretreated 
spheroids, as compared to spheroids irradiated in the absence of cytostatic drugs. The 
time at which platin compounds are added to the cells is clearly relevant for the 
explanation of an observed effect. 
The post-irradiation enhancement by platinum compounds would most likely be 
explained by inhibition of potentially lethal damage repair. However, the HN-1 cell line 
does not exhibit this type of repair (40). Therefore, the mechanism of this enhancement 
is not likely to be explained by inhibition of PLD repair. 
Clinical trials have revealed that the efficacious integration of cisplatin with 
radiation is rather independent of particular sequence. If the phenomena observed in this 
study can also occur in clinical practice, this sequence insensitivity can be explained. 
During a course of radiation treatment combined with platin compounds, enhancement 
can be achieved by the post-irradiation process. The largest enhancement would then be 
expected when platin compounds are present in the target cells at the time of irradiation. 
As was shown by Lelieveld et al. (212) and Tanabe et al. (213), the combined effect of 
cisplatin and radiation in a murine tumor model is maximal when cisplatin is given 
close in time to radiation fractions. In patient treatment, a careful timing of drug 
administration would thus be mandatoiy. 
The underlying mechanisms of radiation potentiation will be difficult to study in 
patients or in animal models. Platinum compounds could be bound to blood proteins 
which would increase their half-life. The spheroid system seems more suitable for this 
type of study, since repeated removal of tissue culture medium is possible. The results 
from such studies can than be extrapolated to the clinical situation. 
With regard to the clinical situation, it is important to note that carboplatin and 
cisplatin gave similar effects. For equal effects, however, at least ten times higher 
concentrations of carboplatin have to be used. The recommended maximal single-agent 
dose for cisplatin and carboplatin are 100 and 400 mg/m2, respectively (214). Together 
with pharmacokinetic differences between the drugs, e.g. clearance rates and protein 
binding, these doses result in 16 times higher AUC (area under the concentration-time 
curve) for carboplatin than for cisplatin (214). Although carboplatin is less effective in 
tumor cells, as is also shown in the present study, a much higher dose can be achieved 
in patients. Carboplatin's lack of neurotoxicity and nephrotoxicity (194) may facilitate 
use of platinum compounds in higher doses in patients with platinum-responsive 
tumors. Our results with the squamous cell carcinoma cell line HN-1 showed that 
carboplatin might be a promising replacement for cisplatin in squamous cell carcinoma 
of the head and neck. In combination with radiotherapy an enhancement effect equal to 
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cisplatin can be achieved. Special care should be taken to ensure that platinum 
compounds are present in the target cells at the moment of irradiation. 
This chapter was based on: 
JHM Schwachöfer, RPMA Crooijmans, J Hoogenhout, HB Kal, AGM Theeuwes: 
Effectiveness of cis-platin and carboplatin in the chemotherapy of squamous cell carcinoma 
grown as multicellular spheroids. Anticancer Res 10: 805-812, 1990. 
and: 
JHM Schwachöfer, RPMA Crooijmans, J Hoogenhout, HB Kal, AGM Theeuwes: 
Effectiveness in inhibition of repair of recovery of cell survival by cisplatin and carboplatin: 
influence of treatment sequence. Int J Radiât Oncol Biol Phys 20: 1235-1242, 1991. 

Chapter 11 
The relation between oxygen and radiation 
response in multicellular tumor spheroids 
of human tumor cell lines 
120 
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multicellular tumor spheroids of human tumor cell lines 
ABSTRACT 
Multicellular spheroids of cells from human neuroblastoma cell line NB-100 and malignant 
melanoma cell line BRO were irradiated. It was shown that for studying radiation sensitivity 
of large spheroids growth delay was not a suitable endpoint. Spheroid cure doses, however, 
indicated that radiosensitivity of differently sized spheroids was not significantly different. 
Clonogen-survival studies showed that the cellular radiosensitivity in both cell lines 
increased with increasing diameter. Polarographic microelectrode measurements of oxygen 
tension inside spheroids showed a marked difference between the two tumor types. In both 
types of spheroids the central oxygen tension decreased with larger diameters, but more in 
neuroblastoma spheroids (lowest value 10 Torr) than in the melanoma spheroids (lowest 
value 20 Torr) where an increase in central ρθ2 was observed in spheroids of more than 1000 
μτη diameter. Cellular oxygen consumption was constant across spheroids, indicating that all 
cells were in the same physiological state. The consumption rate was governed by the 
spheroid diameter, i.e. larger spheroids had lower oxygen consumption. Although in the 
neuroblastoma spheroids oxygen tensions were measured where radiobiologically hypoxic 
cells exist, the radiation studies did not indicate a radioresistant cell population. The low 
oxygen consumption in large spheroids may imply that cells are shifting towards a state of 
low metabolic activity, but with no radiorcsislance, or that cells are committed to cell death. 
The latter might explain the increased radiosensitivity at large spheroid diameters. The 
results from the present study show the need for more studies on human tumor spheroids to 
clarify these phenomena. 
The NB-100 neuroblastoma spheroids were irradiated with doses of 5 and 10 Gy y-rays and 
subsequently the oxygen tension was measured 1 and 5 h after irradiation. A reoxygenation 
effect could not be observed, either after single doses or after split-dose irradiation. The 
results from these experiments indicate that reoxygenation is a process eluding 
Polarographie measurements, or that no dramatic changes in oxygen tension are to be 
expected shortly after high single doses or early in a fractionation scheme. 
I N T R O D U C T I O N 
The existence of hypoxic cells in malignant tumors that are resistant to radiation 
treatment is a major problem in radiotherapy. In studying the susceptibility of cancer 
cells to various treatment modalities, evidence has been provided that oxygen plays a 
major role in controlling the metabolic and cell cycle state of these tumor cells, thus 
modifying the responsiveness of the cells to therapy (37,221). Several investigators 
have measured oxygen tension distributions in spheroids with 02-sens i t ive 
microelectrodes (95,222,223). The distribution of oxygen inside multicellular spheroids 
and the oxygen consumption rate is of considerable interest, since it is possible to 
determine whether these factors influence the radioresistance of tumor cells (66). 
Clinically, hypoxic cells in tumors are thought to reoxygenate during a fractionated 
radiation scheme, rendering previously hypoxic cells amenable for radiation. 
Demonstration of the presence of radiation-resistant hypoxic cells in experimental 
tumors (14,50) and in murine spheroids (62) has been performed with indirect techniques 
by studying the radiation response of cells under well-defined oxygen conditions. 
It has been shown that the oxygen deprivation in the centre of a spheroid results 
from the oxygen consumption by the outer rim of viable cell layers (65,224). The 
relative respiration rate of the viable cells thus influences the number of hypoxic cells 
and hence the radiation response of the spheroids. 
In the present study spheroids from two human tumor cell lines were compared with 
regard to their oxygen tension profiles, and the cellular radiosensitivity, at different 
spheroid diameters. Estimates of oxygen consumption were deduced from oxygen 
tension profiles using the model described by Grossmann (86). Changes in oxygen 
tension after irradiation were monitored after several time intervals. 
RESULTS 
Employing the various materials and methods described in chapter 3, the following 
results were obtained. 
Figure 11.1, panel A, shows growth curves for NB-100 neuroblastoma spheroids 
irradiated at 250 μιη diameter. A dose-dependent growth delay was exhibited. However, 
when irradiations were performed at larger diameters (450 μιη: panel B; 750 μιη: panel 
C), it became increasingly difficult to determine a criterium of growth delay for 
quantifying radiation response. 
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Figure 11.1. Growth curves of NB-100 neuroblastoma spheroids irradiated at a 
diameter of 250 pm (panel A), 450 цт (panel B), and 750 μm (panel C) with single 
doses of X-rays. Dots: untreated control; circles: 3 Gy; closed rectangles: 5 Gy; open 
rectangles: 7 Gy; triangles: 9 Gy. 
The percentage cured spheroids was used to determine the dose at which 50% of 
irradiated spheroids was sterilized. The results from probit analysis of these data for NB-
100 spheroids are shown in Figure 11.2. The calculated SCD50-values at different 
diameters were: 8.3 Gy (7.8-8.9, 95% confidence interval), 450 μιη; 8.9 Gy (8.4-9.8), 
630 μπι; 9.4 Gy (8.7-11.4), 750 μπι. For BRO melanoma spheroids higher SCDJQ-
values were calculated: 11.1 Gy, 570 μπι and 11.6 Gy, 750 μιη. The values at different 
diameters were not different as determined with the method of Litchfield and Wilcoxon 
(90), but a tendency seemed present for higher cure doses at larger diameters. Also, the 
earlier observations on differences in cure doses for the two types of spheroids from 
different histology (chapter 5) were confirmed. 
Radiation survival curves for cells from dispersed spheroids that were irradiated in 
vitro are presented in Figure 11.3. The DQ values decreased with increasing spheroid 
diameter in NB-100 (panel A), the Dq-values were virtually unaltered. In BRO spheroids 
(panel B) a similar decrease in DQ was observed, the D.-value also decreased with 
increasing diameter. The results of the radiation studies are summarized in Table 11.1. 
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Figure 11.2. Cure-dose curves from probit analysis for NB-100 neuroblastoma 
spheroids irradiated at three diameters. Dots: 250 μm; circles: 450 μm; rectangles: 750 
μm. At 50% cure the 95% confìdence intervals are shown for 250-μm and 750^m 
spheroids. 
Table 11.1. Survival characteristics and cell numbers for spheroids from two human tumor 
cell lines irradiated at different diameters. 
Cell line 
NB-100 
BRO 
Spheroid 
diameter 
(цт) 
330 
460 
710 
830 
1070 
1170 
330 
530 
780 
1070 
Do (Gy) 
average j 
1.0 
1.0 
0.8 
0.8 
0.65 
0.65 
0.81 
0.51 
0.50 
0.50 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
:SD 
0.1 
0.1 
0.1 
0.2 
0.08 
0.09 
0.09 
0.06 
0.04 
0.06 
Dq(Gy) 
average + 
0.8 
0.8 
1.1 
1.1 
1.0 
1.0 
2.3 
2.3 
1.2 
1.2 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
SD 
0.2 
0.1 
0.1 
0.2 
0.1 
0.2 
0.5 
0.5 
0.3 
0.3 
Cells pet 
average ; 
7,500 
11,500 
62,500 
72,500 
90,000 
92,500 
8,000 
13,500 
51.500 
80,000 
spheroid 
LSD 
+ 700 
+ 1,000 
+ 6,000 
+ 6,000 
+ 9,000 
+ 8,500 
+ 750 
+ 8,500 
+ 5,000 
+ 9,000 
Oxygen tensions were measured in both types of spheroids, and the central рОг was 
plotted as a function of spheroid diameter in Figure 11.4. Both small and large spheroids 
were included in the analysis. NB-100 (panel A) as well as BRO (panel B) spheroids had 
a characteristic pattern that was different between the two cell lines. NB-100 
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neuroblastoma spheroids showed a decrease in central pO^ with increasing spheroid 
diameter, with minimal values of less than 10 Torr at approximately 700 μπι after 
which no further decrease in pOj was observed. The BRO melanoma spheroids showed a 
similar decrease in central oxygen tension values, but in this type of spheroids the 
central pQz values increased after approximately 800 μπι diameter. No pOj values below 
10 Torr were measured. Both patterns of central oxygen tension as a function of 
spheroid diameter have been reported for spheroids from other human tumor cell lines 
(95). 
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Figure 11.3. X-ray survival curves for (panel A) NB-100 neuroblastoma and (panel B) 
BRO melanoma cells from dispersed spheroids after single-dose irradiation. Panel A: 
dots: 330 цт; circles: 460 цт; closed squares: 710 pm; open squares: 830 цт; closed 
diamonds: 1070 цт; open diamonds: ¡170 цт. Panel B: dots: 330 цт; circles: 530 
цт; closed squares: 780 цт; open diamonds: 1070 цт. 
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Figure 11.4. Oxygen tension in center of spheroids as function of spheroid diameter 
measured in two human tumor cell lines: NB-100 neuroblastoma (panel A) and BRO 
melanoma (panel B). 
Oxygen consumption (ml (УЮО g mm) 
2.0-
10-
· * · 
• · · · 
. тл w . 
V 
NB-100 
4h 
200 Д00 600 800 1000 1200 
spheroid diameter (/jm 
Oxygen consumption (ml Ck/IOOg-mm) 
2.0 
10 
В 
κ· ?\ 
• ^ 
BRO 
V
. X - · 
4h 
200 Д00 600 800 1000 1200 
spheroid diameter (yum) 
Figure 11.5. Oxygen consumption in spheroids of two human tumor cell lines 
calculated from oxygen tension measurements as function of spheroid diameter. NB-100 
neuroblastoma (panel A) and BRO melanoma (panel B). 
Using the methods described in Materials and Methods chapter, oxygen consumption 
profiles were calculated from measured pOj profiles inside spheroids. A horizontal 
oxygen consumption profile was found in all spheroids, irrespective of diameter, in both 
types of spheroids (data not shown). These findings indicate a constant oxygen 
consumption throughout the spheroids, as has also been reported for other human cell 
lines (96). In Figure 11.5 the oxygen consumption rate in spheroids was plotted as a 
function of spheroid diameter. Both NB-100 (panel A) and BRO (panel B) showed an 
oxygen consumption of approximately 1.5 ml CV 100 g per min for diameters up to 
600-700 μτη after which the oxygen consumption tapered off. At a diameter of 1000-
1200 μ η the oxygen consumption in NB-100 spheroids seemed to stabilize, whereas 
BRO spheroids showed a further decline. 
Central oxygen tensions were measured in irradiated NB-100 spheroids 1 and S hour 
after a dose of 5 Gy (Figure 11.6, panel A). A total radiation dose was also administered 
in two equal fractions separated by a 6 h interval, and 1 hour after the second fraction the 
oxygen tension was measured. The small dots in the figure represent the values 
measured in unirradiated control spheroids. The majority of the measured values after 
irradiation of spheroids is within the range of control values. The same measurements 
were performed after a total dose of 10 Gy. After this dose (Figure 11.6, panel B) most 
of the measured values were within the normal range. 
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Figure 11.6. Oxygen tension in center of spheroids irradiated with 5 Gy (panel A) and 
10 Gy (panel B) γ-rays. Measurements performed 1 and 5 h after single dose irradiation, 
and 1 h after split dose irradiation (interval between fractions 6h). Small dots demarcate 
normal values. 
DISCUSSION 
Radiation-induced growth delay in small spheroids has been shown to be a suitable 
parameter to differentiate between the radiosensitivity of human tumor cell lines of 
different histology (Chapter 5). As shown in the present study, when spheroids grow to 
very large dimensions, it becomes increasingly difficult to define a growth delay 
criterium to quantify radiation response (Fig. 11.1). 
Spheroid cure, as used in this and other studies (38,176), is a very simple and 
straightforward endpoint. It shows that at large diameters similar differences in 
radiosensitivity exist between NB-100 neuroblastoma and BRO melanoma as reported 
earlier (Chapter 5). It also shows that the SCDso-values were not statistically significant 
at varying spheroid diameter (Fig. 11.2), but there was a biological tendency for higher 
cure doses at larger spheroid dimensions. However, the major liability of the spheroid 
cure technique is the requirement that any surviving cell, even when deep within the 
spheroid, must proliferate and divide to contribute to spheroid volume increase. 
Surviving cells may not be able to do so, just as cells in xenografts that are too far 
away from a blood vessel. Another problem is that this method does not discriminate 
between single and multiple cells contributing to spheroid volume. 
A more appropriate method for analyzing the response of spheroids is to isolate 
monodispersed cells and the subsequent analysis of clonogenic cell survival. However, 
since it is well known that the survival of cells from murine spheroids is critically 
dependent upon trypsin concentration, and trypsinization time, spheroid cells in this 
study were subjected to varying concentrations of trypsin for increasing time periods. 
Plating efficiencies of NB-100 and BRO cells was unchanged by the conditions used in 
our study (Table 11.2). 
Table 11.2. Plating efficiency of single cells from dispersed spheroids of two 
human tumor cell lines. Dispersion obtained by trypsinization for increasing 
time and various trypsin concentration. 
Cell line Trypsin concentration Trypsinization time Plating efficiency 
(%) (minute) (%) 
0.10 
0.10 
0.10 
0.25 
0.25 
0.25 
0.50 
0.50 
0.50 
0.10 
0.10 
0.10 
0.25 
0.25 
0.25 
0.50 
0.50 
0.50 
5 
10 
20 
5 
10 
20 
5 
10 
20 
5 
10 
20 
5 
10 
20 
5 
10 
20 
1 1 
12 
14 
12 
11 
11 
15 
12 
14 
33 
37 
29 
38 
34 
31 
29 
32 
37 
In both tumor cell lines it was found that the radiosensitivity increased if spheroid 
diameter increased from 300 μιη to 1100 pm. Also, no difference in radiosensitivity 
between the two cell lines was observed. In most studies where radiosensitivity was 
assessed at different diameters a reversed picture emerged, i.e. radiosensitivity decreased 
with increasing spheroid diameter. This holds true for cell lines from both murine 
(53,187) and human origin (38,40). However, increasing radiosensitivity in squamous 
cell carcinoma spheroids, as assessed by spheroid cure, at larger spheroid diameter has 
been reported previously (Chapter 9). 
Survival curves obtained after irradiation of large spheroids usually exhibit an 
upward tail in the terminal slope, indicative of the presence of a hypoxic cell fraction. In 
the present study no such a tail in the survival curves was observed for both cell lines. 
This does not necessarily imply that no hypoxic cells were present, it does, however, 
indicate that no radioresistant cells were present. Several studies on spheroids from 
human origin have shown that internal, quiescent cells that could be recovered by 
elutriation techniques, were more sensitive to radiation than cells from the outer rim 
(71,72). The percentage of cells that were not in cycle (50%-55%), was approximately 
127 
the same for both types of human tumour spheroids used in our study at diameters in 
excess of 500 μπι. This was determined by labelling with IdU and with the technique of 
Ki-67 labelling (162). 
The Polarographie measurements (Fig. 11.4A) have shown that oxygen tensions 
below 10 Torr exist in NB-100 spheroids, where cells become radiobiologically hypoxic 
(37). In the BRO spheroids such central oxygen tensions were not achieved (Fig. 
11.4B), at diameters larger than approximately 1000 μπι the central pOj even increased. 
This difference between the two cell lines could not be explained by a different number 
of cells that were respirating. At comparable spheroid diameters the two cell lines had 
similar numbers of cells per spheroid (Table 11.1). 
Both the central oxygen tension in a spheroid, and the oxygen tension profile are 
determined by the oxygen consumption of cells in the outer rim (224). Since it is 
possible to deduce oxygen consumption in spheroids from their oxygen tension profiles 
(96), we used this method to find a possible explanation for the differences observed in 
the two cell lines under study. The oxygen consumption was found to be constant 
throughout the spheroids, which implies that the physiological state of all cells is the 
same. As a consequence it seems acceptable to use cells from the total spheroids for 
clonogenic survival determinations. From Figure 11.5 it follows that the spheroid 
diameter governs the oxygen consumption in a spheroid, and that at large diameters the 
oxygen consumption is lower than at small diameters. At diameters of more than 900 
μπι the oxygen consumption in NB-100 seems fractionally higher than for BRO 
spheroids, but this is not significant. 
The decreased oxygen consumption in large spheroids may imply that cells shift 
towards a state of low metabolic activity, from which state they can presumably be 
recruited into the proliferating compartment, or alternatively, shift towards cell death. 
The latter might explain the higher radiosensitivity of cells in large spheroids. Similar 
observations have been reported for the in vivo situation, where a decrease in 
radiosensitivity with increasing distance from the blood vessels was reported for cells of 
the KHT tumour (225). 
In the NB-100 spheroids, oxygen tensions evidently showed that hypoxic cells exist, 
but no radiobiological hypoxia was observed. For tumors in patients it was reported that 
hypoxic binding of misonidazole was expressed in only two of the several types of 
tumors that were investigated. Hypoxia is perhaps a rare event in human tumors, and 
the actual contribution of irradiated hypoxic cells to tumor recurrence remains unclear. 
The results from the present study indicates that accepted hypotheses on hypoxia and 
radiation cannot explain all experimental findings, and that we urgently need more 
studies to clarify these points. 
Studies regarding radiation effects on oxygenation status of spheroids were performed 
on murine cell lines employing clonogenic cell survival of dispersed irradiated 
spheroids. In several publications, the inhibition of the oxygen utilization in peripheral 
cells in spheroids was found to result in reoxygenation of the more centrally located 
cells, with a concomittant increase of radiosensitivity in the central parts (204,206). 
Furthermore, irradiation with doses large enough to sterilize virtually all oxygenated 
cells also resulted in a reoxygenation (65). Considering the survival curves for NB-100 
cells obtained in this study (Fig. 11.3), a 10 Gy dosis would be large enough to sterilize 
virtually all tumor cells. Reoxygenation at low oxygen tensions, however, could not be 
demonstrated in the irradiated spheroids of the neuroblastoma NB-100 line by 
Polarographie measurement of central partial oxygen tensions. The absence of a 
pronounced oxygen tension increase in any of the irradiated spheroids indicates that 
radiobiological reoxygenation might be a subtle process eluding the measurement with 
microelectrodes. In a similar study Nylen et al. (66) measured the oxygen tension in 
spheroids after treatment with fractionated irradiation. No reoxygenation process could 
be established. 
Spheroids are thought to be models for avascular metastases and for tumor cells 
located round blood vessels growing as cords in tumors (88,107). If the absence of an 
effect on oxygen tension after radiation treatment of spheroids may be extrapolated, the 
results from these experiments may indicate that no dramatic changes in oxygen tension 
due to decreased oxygen utilization of damaged tumor cells is to be expected shortly after 
high single-dose irradiation, or early in a fractionation scheme. However, when 
comparisons are made with tumors in v/voitmust not be forgotten that changes in 
oxygen tension may be caused by radiation-induced decrease in blood flow or radiation-
induced clearance of constricted blood vessels, which may give rise to an increased 
oxygen availability. 
In view of the clinical significance of hypoxia in predicting effectivenees of radiation 
treatment of tumors, especially in regard to the number of studies claiming hypoxia to 
be most appropriate explanation for radiation-related effects, without actually measuring 
oxygen, it is mandatory to perform more studies on the relation of oxygen and radiation. 
Although the use of spheroids derived from human tumor cell lines presented disturbing 
findings, the solving of these problems may offer new insight in the relation between 
oxygen and radiation-related effects. 
This chapter was based on: 
JHM Schwachöfer, H Acker, RPMA Crooijmans, JJM van Gasteren, G Holtermann, J 
Hoogenhout, CR Jerusalem, HB Kal: Oxygen tensions in two human tumor cell lines grown 
and irradiated as multicellular spheroids. Anticancer Res. 11: 273-280, 1991. 
and: 
JHM Schwachöfer, H Acker, RPMA Crooijmans, G Holtermann, J Hoogenhout, HB Kal, AGM 
Theeuwes: Radiosensitivity of spheroids from two human tumour cell lines in relation to 
oxygen tension and oxygen consumption. Cancer Therapy and Control (accepted for 
publication) 


Chapter 12 
General discussion 
General discussion 
Although there are several models to study the responses of human tumor cells to 
treatment (2,5,7,8), the use of multicellular spheroids as a model is increasing rapidly. 
However, so far no study has been published that explored the possibilities of predicting 
the spheroid-forming capacity of a given cell line. 
Chapter 4. 
The first objective of this study was to indicate parameters for pridiction of spheroid-
forming capacity of human tumor cell lines. As was shown in chapter 4, the capacity to 
form growing spheroids is not a general property of human tumor cells in culture. Only 
one out of the eleven tested cell lines exhibited growth of spherical aggregates. Of the 
different parameters that were studied for their predictive value for, only the expression 
of the intermediate filament vimentin proved to be indicative of the capacity to 
aggregate. However, vimentin expression was not indicative for the capacity to further 
increase in volume after formation of spherical aggregates. 
The ease with which spheroids can be manipulated is one of the features that 
facilitates the use of this model. The type of tissue culture medium and percentage of 
foetal bovine serum (FBS) infiuence the growth rate of spheroids. However, the use of 
serum precluded control with chemical environment. It was found that spheroids could 
succesfully be propagated in media that were supplemented with Ex-cyte, a substance 
derived from human blood. This substance can be supplied with virtually no variations 
in composition, and this study has shown that the growth-promoting effect is 
comparable to that of Foetal Bovine Serum. In combination with serum-free media this 
opens the possibility to obtain information on specific biological parameters that could 
be masked in serum-supplemented media (113). 
Chapter S. 
Human tumor xenografts are still the standard in radiobiology with regard to the study 
of responses to therapeutic intervention. For this reason the radiosensitivity of the 
tumor cell lines used in this study was compared when grown both as xenografts and as 
spheroids. A direct inter-comparison of the two model systems would best be attained 
by using the same assay for both. The most obvious assay for this purpose would be 
clonogenic survival. However, disaggregation of spheroids and xenografts has a number 
of potential artefacts (136). Especially for spheroids of human origin this is well 
documented (34). In this study the radiosensitivity of tumor cells in spheroids and 
xenografts was ranked based on parameters such as growth delay constant and cure dose. 
The rankings were the same in both model systems, showing that in vitro spheroids 
accurately reflect the radiosensitivity of tumor cells as expressed in viva For spheroids 
survival curves could be obtained by back-extrapolation of regrowth curves. The derived 
parameter of radiosensitivity, DQ, gave a similar ranking as growth delay and cure dose 
in spheroids. These results show that radiosensitivity as determined from survival and 
growth delay data can correlate, if the cellular integrity in maintained. In that way 
survival curves from back-extrapolation reflect radiosensitivity and are not influenced by 
the sensitivity of cells to the disaggregation method employed. 
This study shows that radiosensitivity of human tumor cell lines when grown as 
spheroids can be studied in terms of growth delay and spheroid cure. The correlation 
between histological type of the parent tumor and survival curve parameters as reported 
by Fértil & Malaise (43) and Deacon et al. (44) for monolayer cultures was also found 
for tumor cells grown as spheroids. 
Chapter 6. 
Having established the applicability of the spheroid system, four cell lines were assayed 
for their capacity to repair sublethal damage. Inherent radiosensitivity and repair of 
radiation damage have been postulated to be determinants of radiocurability of human 
tumors (227). Split-dose repair is found in almost all tumor cell lines in which it has 
been sought for. However, only one report existed so far on the sublethal damage repair 
of one human tumor cell line when grown as spheroids (80). In that publication absence 
of split-dose repair was reported, although only low doses had been applied. 
In the present study split-dose irradiations were performed with four human tumor 
cell lines grown as spheroids. Sublethal damage repair (SLDR) was expressed by all 
four cell lines, independent of their radiosensitivity. SLDR was expressed to a similar 
magnitude in a neuroblastoma cell line, a melanoma, a squamous cell carcinoma of the 
tongue, as well as in a lung adenocarcinoma line, i.e. tumor types of different clinical 
radiocurability. These findings are consistent with those of Steel and Peacock (148) 
found in human tumor cells irradiated as monolayers. 
If all tumors were treated equally in the clinic these findings would probably be of 
no clinical importance. The overall effect of many small fractions would be the 
amplification of the dominance of the α-component. The effect of the ß-component 
would then be negligable because repair would be complete. In clinical practice not 
every tumor is treated uni formerly. Regimens employing large doses per fraction have 
been found to be advantageous for the treatment of melanoma (186). The α/β ratio 
reported by Bentzen et al. (186) in their study was low, as in this study for BRO 
melanoma spheroids (Table 6.2). 
Although only four cell lines were used, the results substantiate the notion that 
multicellular spheroids are an appropriate model to study radiation phenomena such as 
sublethal damage repair. 
Chapter 7. 
Inherent to the methodology used to quantify radiation responses (volume changes of 
spheroids) it seemed possible that confounding influences of potentially lethal damage 
repair (PLDR) were included in the measured SLDR. Therefore, the capacities to repair 
these types of damage were investigated in two of the tumor cell lines. 
The diameters of the spheroids used so small that it was unlikely that quiescent 
cells, capable of PLDR, were present. The two cell lines exhibited similar split-dose 
recovery, with slightly higher repaired doses in the HN-1 squamous carcinoma than in 
the NB-100 neuroblastoma cell line. In plateau phase monolayer cultures it was found 
that NB-100 neuroblastoma was capable of PLDR, whereas the HN-1 cell line was 
deficient in this respect. Therefore it is unlikely that PLDR contributes to the measured 
split-dose recovery in the small spheroids. Moreover, plateau phase cells of NB-100 
showed very little SLDR. In conclusion, SLD repair as studied here may be considered 
to be unbiased by other repair types. At the subcellular level radiation induced damage 
and repair can be studied by using the FADU-technique. The differential repair of SLD 
in plateau phase cells of the two cell lines correlated with the repair of DNA damage, as 
determined by this DNA unwinding technique. 
Based on the notion that repair capacity is virtually the same in tumor cells 
regardless of the radiation responsiveness, fractionation schemes can be designed. Only 
if the amount of repair expressed by a tumor is always dependent only on the repair 
capacity, i.e. repair capacity equals repaired dose, regardless of growth conditions, this 
notion holds true. 
Chapter 8. 
Spheroids have been shown to be significantly influenced in their growth rate by the 
percentage foetal bovine serum (chapter 4). This effect was most pronounced in BRO 
melanoma spheroids (Fig. 4.3). Tumor growth delay is the only available endpoint for 
most human tumor spheroids. This endpoint is easy to use in practice, and discriminates 
adequately between the effect of different treatment doses for a given spheroid line. 
However, there is no generally accepted way of analyzing growth delay data in order to 
compare the treatment sensitivity of spheroid lines with different volumetric growth 
rates. Specific growth delay, i.e. actual growth delay divided by the volume doubling 
time of untreated control, has been suggested to be a useful parameter for rankings 
according to treatment sensitivity. Good correlations have been found between specific 
growth delay and cell surviving fractions measured in vitro for human melanoma 
xenografts (133,185). The BRO melanoma spheroids used in this study is one of the 
few human tumor cell lines that permit clonogenic survival determinations of dispersed 
spheroids. Local control as reflected by spheroid cure, specific growth delay and the 
clonogenic survival assay indicated that spheroids that were grown in culture medium 
with a higher percentage (20%) of FBS were more sensitive to radiation than spheroids 
grown in standard (10%) FBS. 
In order to base comparisons of treatment sensitivity on differences in specific 
growth delay, it is a strict prerequisite that the average doubling time of the surviving 
clonogenic cells equals that of the clonogenic cells in untreated spheroids. There is good 
evidence from studies of melanoma xenografts that the doubling time of the clonogenic 
cells is shortened during the repopulation period (228). The regrowth curves of BRO 
melanoma spheroids could be used for back-extrapolation, indicating that treated 
spheroids regrew at the same rate as control spheroids. Moreover, the survival curves 
obtained by this back-extrapolation closely correlated with the clonogenic survival 
curves. Together this indicates an unchanged doubling time of clonogenic cells in treated 
spheroids of this cell line. 
The cell cycle distribution was the same in spheroids growing at different volume 
doubling times, the growth fraction was identical as substantiated by КІ67 labelling, 
and no hypoxia was likely to be present. Influences of variable radiosensitivity in 
different phases of the cell cycle could therefore be excluded. The differential 
radiosensitivity of spheroids growing at different growth rates must thus be induced by 
other mechanisms. Split-dose experiments in the two groups of spheroids indicated that 
the SLD repair capacity was unaltered. However, the amount of damage that was 
actually repaired was different. It is imaginable that the increased metabolic activity 
required for faster volumetric growth in the high FBS group imposes difficult conditions 
for the repair of SLD. Both processes, cell division and repair of radiation induced 
damage, require energy. When the cellular process of division requires increased energy 
levels, it is possible that insufficient energy remains for repair of radiation damage. This 
would be reflected by increased sensitivity to radiation for fast growing spheroids, as 
observed in this study. 
Chapter 9. 
For most experimental tumors there is a correlation between tumor size and response to 
therapy. In addition, it has been established that increasing radioresistance accompanies 
increasing tumor volume. This may result in part from a greater cell depletion being 
necessary to affect local control (186), but a major component is also believed to be the 
establishment and continued expansion of a population of radioresistant hypoxic cells 
(229,230). 
The majority of the experimental studies examining changes in tumor cell 
radiosensitivity have involved assays in which cell survival can be directly measured. As 
pointed out before, for tumor xenografts and for human tumor cell spheroids, regrowth 
delay is usually the only available assay. For comparisons of different growth rates, for 
tumors of different sizes, there is no standardized way of analyzing the data. 
For human tumor xenografts irradiated at different sizes, it was shown that the 
criterium of growth delay influenced to a great extent the outcome of radiosensitivity 
(231). In the present study no comparisons of radiosensitivity were made between 
spheroid diameters; the growth delay after split and single doses of radiation was used for 
calculation of a dose repaired. Calculations of the dose of radiation that was repaired in 
spheroids of different diameter showed equal doses in HN-1 squamous carcinoma 
spheroids, whereas SCDso-values decreased with increasing diameter. Cure doses 
increased with increasing spheroid diameter in BRO melanoma spheroids, which is 
concurrent with literature. The dose repaired, however, was largest in the smallest 
spheroids. Whether the results with HN-1 are merely an exception to a rule remains as 
yet unclear, but the results with the BRO spheroids further substantiate the finding that 
SLD repair is of limited influence in radiosensitivity. 
Since the response to fractionated radiation treatment may deviate from expectations 
based on results from split-dose experiments (75), the HN-1 squamous cell carcinoma 
spheroids of different size were subjected to fractionated treatment. Assuming an α/β 
ratio of 10 Gy, fractionation schemes were designed to be iso-effective to early 
responding tissues. The results showed that the repair capacity derived from split-dose 
experiments were the same as exhibited in fractionation schemes. Furthermore, the 
small spheroids showed a clear advantage of accelerating the irradiation scheme (i.e. 
twice per day irradiations instead of once per day), whereas in large spheroids this 
advantage was not present. 
In a similarly designed study, Wheldon et al. (81) found that responses of 
neuroblastoma spheroids were not uniform after radiation regimens that were calculated 
to be iso-effective for damage to late responding normal tissues (α/β= 3 Gy). When the 
assumed ratio is not correct, as in the study by Wheldon et al., there is no way of 
determining whether this is brought about by a non-isoeffectiveness of the schemes, 
ignoring all other processes that may be different as a function of spheroid size. 
Wheldon and co-workers (81) however, concluded from the observed differences in 
growth delay between radiation schemes that they differed in effectiveness. They 
performed two separate experiments and observed a difference in the number of sterilized 
spheroids between the two experiments, which they attributed to an accidental difference 
in spheroid size (!) in the two experiments. Since both experiments showed the response 
of spheroids to be not iso-effective for late responding tissues, it was impossible to 
draw conclusions on the spheroid-size difference between the experiments. 
From the split-dose and fractionation experiments the conclusion is that differences 
in repair capacity cannot be the determining factor in the different radioresponsiveness of 
small and large spheroids. What is evident, however, is that the relatively small 
differences in size of these spheroids has profound influence on the response to 
treatment. 
The results from experiments with BRO melanoma spheroids irradiated at different 
diameters, or irradiated when grown with different volume doubling times, show that 
determinations of SLD repair must take into account factors such as growth rate. In 
monolayer cultures factors such as 'diameter' can not be simulated, which leaves only 
the spheroid as an in vitro model to study these phenomena. These results also show 
that determinations of SLD repair, and possibly radiosensitivity determinations, in 
monolayer cultures cannot be used for conclusions about tumor responses in the clinic. 
Other factors such as cellular energy metabolism, must be more intensively studied to 
determine the bearance of such factors on radiosensitivity in vitro, and possibly in vivo. 
Chapter 10. 
An even more complex situation arises when radiation is combined with cytostatic 
drugs. In the clinical situation this combination has long since been introduced. 
Although these applications in the clinic evolved empirically, biological rationale was 
slow to follow. In general, an inconsistent pattern of potentiation effects in human 
tumor cells in vitro have been reported. Deducing mechanisms from drug-radiation 
interactions is complicated by the fact that the agents may exert both direct and indirect 
effects. The cytostatic drug Adriamycin can, for example, cause cellular metabolism 
changes such as reduced oxygen utilization (232) which can subsequently result in 
increased tumor oxygenation and marked radiosensitization (233). A further 
complication is that mechanistic studies are difficult to perform, interpret, or control in 
the clinical setting. Concurrent radiotherapy and chemotherapy, in clinical reality, may 
consist of daily doses of each agent in a precisely prescribed and timed sequence, daily 
treatments as convenient, non-daily administration of chemotherapy during the course of 
radiotherapy, or even single administration of drug during the radiotherapy treatment 
schedule. Usually little attention is paid to the crucial question of controlling the timing 
and sequencing of irradiation relative to drug administration. 
These limitations are not, however, a problem in defined laboratorium systems such 
as the spheroid model. Spheroids offer the ability to administer and maintain known, 
effective drug dosages for precise time periods. If spheroids of small diameter are chosen, 
indirect drug effects, such as reoxygenation, can be avoided. 
The results of this study described in Chapter 10 show that the drug-induced effect of 
carboplatin in spheroids reflected by growth delay, cure, and inhibition of [ 3H]-
thymidine incorporation, requires approximately 16 times the dose or exposure time of 
cisplatin incubation. Clinically, carboplatin concentrations are approximately 16 times 
that of cisplatin, administered as dosages that are tolerated with acceptable side-efects 
(180). This again shows that spheroids adequately reflect the phenomena observed in 
clinical practice. 
Together with the results from the split-dose experiments, which show similar 
enhancing effects for carboplatin and cisplatin, these findings indicate that carboplatin 
may be a useful alternative for cisplatin with respect to effectiveness of tumor control. 
In view of the virtual absence of neurotoxicity and nephrotoxicity after carboplatin 
treatment (214) the use of carboplatin instead of cisplatin prevails. 
Although the present data do not address the critical question of normal tissue 
toxicity, I none the less believe that they have relevance for designing clinical 
protocols. This conclusion follows from the recognition that the sequencing of the two 
modalities determines whether or not the obtained effect is maximal. 
Chapter 11. 
Radiation-resistant hypoxic cells have been demonstrated in most rodent tumors, and 
there is limited evidence for their existence in human tumors (234). Different rates and 
extents of reoxygenation, and therefore enhanced sensitization, may occur during 
multifraction radiation therapy. The relation of reoxygenation to changes induced in 
tumor vascularization, inhibition of tumor cell oxygen consumption, possible 
migration of hypoxic cells, or other characteristics of tumor microregions is not clear. 
There are limitations to the use of xenografts to model oxygenation in human tumors. 
First, the stroma of the xenografts is of rodent origin; the growth rate and characteristics 
of the vascular bed therefore will have murine rather than human characteristics. 
Moreover, the host of a xenograft is, of course, a mouse or a rat. To the extent that the 
oxygenation of the tumors depends on the characteristics of the binding and release of 
oxygen by hemoglobin, the blood pressure, the arterial ρθ2 etc., oxygenation of 
xenografts in mice and rats will be of a rodent nature (235). 
In spheroids, the hypoxic state in the central regions of large spheroids is induced by 
the oxygen consumption of outer cells (65,224). Observed reoxygenation in spheroids 
after irradiation is therefore caused by decreased oxygen consumption of the cells in the 
outer rim (224). Theoretically, this decreased oxygen consumption would give rise to 
higher oxygen tensions in the central parts of a spheroid. Surprisingly, in this study no 
137 
increase in central oxygen tensions in spheroids could be observed. Similar observation 
were made by Nylen et al. (66) after protracted irradiation schemes. Durand and Biaglow 
(65,224) observed that in V79 murine spheroids previous irradiation caused increased 
radiosensitivity of previously less sensitive (hypoxic) cells. This may indicate that the 
irradiation, and therefore induction of radiation damage that must be repaired, activates 
previously quiescent cells. This could be a process acting independently of oxygen 
availability. More elaborate experiments are required to answer this question. 
The radiation responses of differently sized spheroids of two human tumor cell lines 
reported in this study deviate from fmdings in spheroids of murine cell lines. Based on 
those studies one might expect to find a radioresistant "tail" in the survival curve of 
large spheroids, due to hypoxic cells. In the human tumor spheroids used in the present 
study there was no indication of the existence of such hypoxic, resistant cells. 
Although in both types of spheroids the oxygen consumption was determined by 
spheroid diameter, it was constant throughout each spheroid, independent of its diameter. 
One would expect a decrease in oxygen consumption in the more centrally located parts 
of the spheroid, close to the necrotic centers that have been established in spheroids of 
both cell lines (chapter 4). 
The relative concentrations of oxygen and nutrients may affect pathways of energy 
metabolism and thereby influence the fraction of quiescent cells and viable rim thickness 
(37). Glucose concentration, for instance, affects the development of central necrosis 
even when oxygen levels are significant (112). Necrotic or prenecrotic materials can 
produce growth inhibitory feedback effects on the proliferating population of cells (36). 
It has been hypothesized that a significant part of this feedback effect results from the 
increased fraction of quiescent cells and cooperative cellular biochemical interactions that 
modulate energy metabolism during spheroid growth (109). 
Since this study is the first where spheroids from human origin were assayed for 
their radiation responses in relation to oxygen tension and oxygen consumption, it 
remains unclear whether the present findings are typical for human tumor spheroids, or 
perhaps present an exception to the general rule. Further studies will have to answer that 
question. 
MAIN CONCLUSIONS 
1) This study shows that there in only one characteristic (expression of the 
intermediate filament vimentin) of human tumor cell lines that predicts the capacity 
to aggregate. It does, however, not predict the capacity of spherical growth. 
2) Multicellular tumor spheroids accurately reflect the radiosensitivity of human 
tumor cell lines grown as xenografts. There is a good correlation between the 
radiosensitivity of spheroids and the clinical radiocurability of the tumor types of 
origin. 
3) The sublethal damage repair capacity of the human tumor cell lines under study was 
equal, irrespective of their radiosensitivity. This is in agreement with similar 
studies on monolayer cultures. 
4) It was shown that SLD repair in spheroids probably has no contribution of repair of 
potentially lethal damage (PLD), and that repair rate of SLD was comparable in 
spheroids and monolayer cells. Also, the repair of SLD was correlated to repair of 
DNA strand breaks, whereas PLD did not correlate to DNA repair. 
5) Capacity to repair sublethal damage as reflected by the ß-component of the linear 
quadratic equation does not predict the amount of radiation damage that is actually 
repaired in spheroids. Modifying factors such as the spheroid growth rate and the 
diameter at which irradiation is performed, have a profound effect on the amount of 
actually repaired damage. 
6) Spheroids correctly reflect the difference in clinical effectiveness of two platinum-
based drugs: carboplatin and cisplatin. In combination with radiation the sequencing 
of platinum compounds and radiotherapy determines whether the effect is optimal. 
The scheme should be such that platinum compound is present in tumor cell at 
time of irradiation. 
7) Spheroids derived from human tumor cell lines show radiation responses and 
oxygen-related phenomena significantly deviate from findings in spheroids of 
murine origin. It is, however, uncertain whether this is due to the human origin of 
the cell lines, or is an exception to a general rule. More work is needed in this area. 
Summary 
Recent years have seen a steady increase in the number of publications where 
multicellular spheroids were used as a model system to simulate the response of tumor 
cells to therapy. Spheroids constitute a three-dimensional in vitro model of intermediate 
complexity between in vitro monolayer cultures and in vivo tumors. Recent evidence 
regarding the tumor type dependent differences in radiosensitivity of human tumor cells 
in vitro as monolayers made it imperative that spheroid studies on the radiation 
responses in vitro should be performed with cell lines of human origin. In Chapter 1 
several in vivo and in vitro models were described. The spheroid model was described in 
more detail in Chapter 2 before outlining the purpose of the present investigations. The 
methods and materials employed in the performance of the various experiments reported 
upon in this thesis are described in Chapter 3. 
Only a limited number of human tumor cell lines are capable of forming growing 
spheroids. In Chapter 4 cellular characteristics of 7 lung and 4 bladder cancer cell lines 
are described with respect to their spheroid forming capacity. Comparisons were made 
with four reference cell lines. Spherical aggregates were formed by one bladder and one 
lung cancer cell lines, of which only the latter exhibited growth. Cellular factors 
influencing the ability of spheroids to increase in volume after spherical aggregation are 
not yet defined. Viability and clonogenicity of cells in aggregates are not the 
determinant of growth capacity. The growth rate of cell lines that exhibited growth as 
spheroids is determined by tissue culture conditions and additives. Type of medium, 
percentage foetal bovine serum and glucose concentration influenced the growth rate of 
spheroids. Spheroids were growth retarded in serum-free medium. Growth enhancement 
could be induced by Ex-Cyte, a substance derived from human blood, thus allowing 
culture of spheroids under defined medium conditions. 
Chapter 5 reports the results of investigations allowing for comparison of the 
radiosensitivities of five human tumor cell lines of different histology when grown both 
as xenografts and as spheroids. It was established that the radiosensitivity in both model 
systems correlates well with the clinical radiosensitivity of the corresponding tumor 
types. Also, the correlation between the radiosensitivities in the two different growth 
conditions was very high, showing that spheroids of these lines correctly reflect the 
radiosensitivity of the tumor xenografts. 
The possible contribution of sublethal damage (SLD) repair in the different 
radiosensitivity of spheroids from four human tumor cell lines was described in Chapter 
6. It was found that the amount of SLD that was repaired , was approximately the same 
in the four cell lines. The repair capacity as expressed by the ß-value of the linear-
quadratic equation showed that there were no differences between the four cell lines, 
independent of the respective radiosensitivities. These results show that differences in 
radiosensitivity of spheroids are caused by intrinsic radiosensitivity and are not 
determined by differences in repair capacity. 
In Chapter 7 the repair kinetics of radiation-induced damage in two tumor cell lines 
grown as spheroids and in monolayer was described. It was shown that SLD repair in 
spheroids probably has no contribution of repair of potentially lethal damage (PLD), and 
that repair rate of SLD was comparable in spheroids and monolayer cells. Also, the 
repair of SLD was correlated to repair of DNA strand breaks, whereas PLD did not 
correlate to DNA repair. 
The radiosensitivity of a human melanoma cell line was investigated using the 
spheroid system (Chapter 8). By manipulation of tissue culture medium, two groups of 
spheroids with different growth rates were obtained. The faster growing group of 
spheroids was significantly more radiosensitive than the slower growing group. The 
slow growing spheroids exhibited a larger repair of SLD. From this study it appears that 
the intrinsic radiosensitivity of one cell line grown as spheroids is modified by 
intratumoral conditions, which also influence the capacity to repair SUD. These results 
indicate that the use of fractionation in fast growing tumor cells best exploits the 
differentia] repair capacities of normal and tumorous tissues. 
When spheroids were irradiated at increasing diameters (Chapter 9), the melanoma 
spheroids had a decreased radiosensitivity with increasing diameter, whereas squamous 
cell carcinoma spheroids had increasing radiosensitivity with increasing spheroid 
diameter. Based on these experiments it is assumed that intratumoral conditions 
influence radiosensitivity by mechanisms that are as yet not fully known. 
Clinical protocols have been designed to combine platinum based drugs and radiation 
in the treatment of cancer. The rationale for this approach has been developed from 
preclinical studies demonstrating that platinum compounds can potentiate the cytotoxic 
effects of radiation towards cells. In Chapter 10 spheroids derived from a squamous 
carcinoma cell line were used to study the effects of both cisplatin and carboplatin when 
administered prior to, concurrently, and after radiation treatment, either applied in single 
doses or as split-dose irradiation. It was shown that platinum compounds can potentiate 
radiation by different mechanisms, showing that the sequence of the two modalities is 
important. Moreover, these results may in part explain the heterogeneous outcomes of 
trials combining platinum compounds and radiation. 
The relation between oxygen and radiation responsiveness (Chapter 11) in 
multicellular spheroids has been extensively studied using murine cell lines. When 
using human tumor spheroids, it was found that radiosensitivity of cells in spheroids 
increased with increasing spheroid diameter, with no signs of radiobiological hypoxia. 
Oxygen tensions, measured with microelectrodes inside the spheroids, revealed values 
low enough for radiobiological hypoxia. It is argued that factors other than oxygen 
alone determine the radiosensitivity of tumor cells grown in differently sized spheroids. 
Reoxygenation after irradiation, a basic radiobiological process, that has extensively 
been reported upon when observed in murine spheroids, could not be observed when the 
oxygen tensions were measured with microelectrodes. This shows that either 
reoxygenation processes elude measurements with microelectrodes, or that increased 
oxygen tensions after irradiation are not to be expected. 
The experiments on oxygen tensions in spheroids show that it is mandatory that 
more studies on the relation of oxygen and radiation response in spheroids are performed 
using tumor cell lines of human origin. 
This study shows that multicellular spheroids derived from human tumor cell lines 
accurately reflect the radiosensitivity of these lines when grown as xenografts. There is a 
good correlation between the radiosensitivity of the spheroids and the clinical 
radiocurability of the tumor types from which the cell lines originate. The repair of 
sublethal damage was of the same magnitude, irrespective of the radiosensitivity. 
Capacity to repair sublethal damage does not predict the amount of damage that is 
actually repaired after irradiation. Modfifying factors, such as spheroid growth rate, 
spheroid size, have a profound effect on the extent of radiation damage repair. Spheroids 
correctly reflect the difference in clinical effectiveness of two platinum-based drugs. 
Modelling of the use of radiotherapy and chemotherapy showed that sequencing of the 
two modalities is crucial. 
In conclusion, multicellular spheroids of human tumor cells can be used as an in vitro 
model for therapy of human cancer. 
Samenvatting 
De laatste jaren is er een gestage toename geweest in het aantal publicaties waarin 
multicellulaire sferoiden werden gebruikt als model systeem om de respons van 
tumorcellen op therapie te simuleren. Sferoiden vormen een drie-dimensionaal in vitro 
model van intermediaire complexiteit tussen in vitro monolaag cultures en in vivo 
tumoren. Recente aanwijzingen in monolaag culturen dat, afhankelijk van het 
histologisch type, verschillen in radiosensitiviteit kunnen worden gemeten, vormden de 
aanleiding soortgelijke studies te verrichten aan sferoiden van humane oorsprong. In 
hoofdstuk 1 wordt een algemeen overzicht gegeven van de in vivo en in vitro modellen 
die binnen de radiobiologie worden gebruikt. Vervolgens wordt in hoofdstuk 2 het 
sferoid model nader beschreven, alvorens de doelstellingen van dit onderzoek te 
schetsen. De materialen en methoden die werden gebruikt bij de verschillende 
experimenten in dit onderzoek worden beschreven in hoofdstuk 3. 
Slechts een klein aantal tumorcellijnen is in staat sferoiden te vormen die in omvang 
toenemen. In hoofdstuk 4 worden de karakteristieken van 7 long- en 4 urineblaastumor-
cellijnen beschreven met betrekking tot het sferoid-vormend vermogen. Een vergelijking 
werd gemaakt met 4 referentiecellijnen. Ronde agregaten werden gevormd door een long-
en een urineblaastumorlijn, waarvan alleen die van de eerste cellijn groeiden. Celfactoren 
die het al dan niet groeien van ronde aggregaten bepalen konden niet worden 
geïdentificeerd. Viabiliteit en clonogeniciteit van cellen in aggregaten zijn niet de 
determinerende factoren voor groeicapaciteit. De groeisnelheid van sferoiden wordt 
bepaald door weefselkweekmedium en toevoegingen daaraan. Het type medium, 
percentage foetaal kalfsserum en glucose concentratie beïnvloeden de groeisnelheid van 
sferoiden. In serum-vrij medium was de groei van sferoiden vertraagd. Groei kon worden 
verbeterd door toevoeging van Ex-cyte aan het medium. Ex-cyte, een substantie bereid 
uit humaan bloed maakt groei van sferoiden onder gedefinieerde mediumcondities 
mogelijk. 
In hoofdstuk 5 worden de resultaten gerapporteerd van studies die de vergelijking 
mogelijk maken tussen sferoiden en xenografts wat betreft stralingsgevoeligheid van vijf 
humane tumorcellijnen van verschillend histologisch type. De gevoeligheid binnen elk 
van de twee modelsystemen correleerde met de klinische behandelingsrespons van het 
tumortype waarvan de cellijn was afgeleid. Tevens bleek dat de gevonden gevoeligheden 
binnen het in vitro model systeem sterk correleerden met de gevoeligheden in het in 
vivo model. Dit toont aan dat sferoiden een getrouwe afspiegeling geven van de 
gevoeligheid van tumor xenografts. 
De mogelijke bijdrage van herstel van subletale schade (SLD) in de verschillende 
stralingsgevoeligheden van sferoiden van vier humane tumorcellijnen wordt beschreven 
in hoofdstuk 6. Vastgesteld werd dat de hoeveelheid SLD die hersteld werd in sferoiden 
ongeveer gelijk was voor deze vier cellijnen. De herstelcapaciteit zoals weergegeven door 
de ß-component van de lineair-quadratische vergelijking, toonde aan dat er geen 
verschillen waren tussen de vier cellijnen, onafhankelijk van hun stralingsgevoeligheid. 
Deze resultaten tonen aan dat verschillen in stralingsgevoeligheid van sferoiden worden 
veroorzaakt door de intrinsieke stralingsgevoeligheid, en niet door verschillen in 
herstelcapaciteit. 
Hoofdstuk 7 beschrijft de herstelkinetiek van stralingsgeinduceerde schade in twee 
humane tumorcellijnen die groeiden als sferoiden en als monolaag cultures. Er werd 
aangetoond dat de hoogte van SLD-herstel in sferoiden waarschijnlijk niet wordt 
beïnvloed door een bijdrage van herstel van potentieel letale schade (PLD). De snelheid 
van SLD-herstel was gelijk in sferoiden en in monolaag cultures, en SLD-herstel bleek 
overeen te komen met het herstel van schade in DNA. 
De stralingsgevoeligheid van een humane melanomacellijn werd bestudeerd in 
sferoiden (hoofdstuk 8). Door beïnvloeding van de samenstelling van het 
weefselkweekmedium konden verschillende groeisnelheden worden verkregen. De snel 
groeiende groep bleek gevoeliger voor bestraling dan de langzaam groeiende groep. De 
langzaam groeiende sferoiden vertoonden een grotere mate van SLD-herstel. Uit deze 
studie blijkt dat de intrinsieke stralingsgevoeligheid van een cellijn wordt beïnvloed door 
intra-tumorale condities, die tevens de SLD-herstelcapaciteit beïnvloeden. Deze 
resultaten tonen aan dat het gebruik van fractionering juist in snel groeiende tumoren het 
best gebruik maakt van het verschil in herstelcapaciteit tussen normale en tumoreuze 
weefsels. 
Wanneer sferoiden van verschillende diameters werden bestraald (hoofdstuk 9), 
vertoonden de BRO-melanoomsferoiden een afname in stralingsgevoeligheid met 
toenemende diameter, terwijl plaveiselcelcarcinoomsferoiden een toenemende 
gevoeligheid voor bestraling vertoonden met toenemende diameter. Op basis van deze 
experimenten wordt aangenomen dat intra-tumorale condities, op een nog onbekende 
wijze, de bestralingsgevoeligheid beïnvloeden. 
Protocollen werden in het verleden ontworpen voor de behandeling van kanker 
waarbij bestraling werd gecombineerd met platinum-houdende stoffen. De rationale voor 
deze aanpak werd ontwikkeld vanuit preklinische studies waarin werd aangetoond dat 
platinum bevattende cytostatica het cytotoxische effect van bestraling voor tumorcellen 
versterkte. In de experimenten beschreven in hoofdstuk 10 werden sferoiden gebruikt van 
plaveiselcelcarcinoom cellijn HN-1 om de effecten van carboplatin en cisplatinum te 
bestuderen wanneer deze werden toegevoegd, voor, tijdens of na de bestraling. Hierbij 
werd straling toegediend in enkelvoudige doses of in twee gelijke fractiedoses. 
Aangetoond kon worden dat platinum bevattende cytostatica het effect van bestraling 
versterken door middel van verschillende mechanismen, waarbij de volgorde van 
behandeling belangrijk is. Deze resultaten kunnen zelfs gedeeltelijk verklaren waarom in 
het verleden ondubbelzinnige uitkomsten bij klinische trials van bestraling en platinum 
bevattende cytostatica werden gevonden. 
De relatie tussen zuurstof en bestralingsrespons (hoofdstuk 11) in multicellulaire 
sferoiden is intensief bestudeerd in sferoiden van cellijnen van de muis. Bij gebruik van 
humane tumorsferoiden, bleek dat de stralingsgevoeligheid van cellen in sferoiden 
toenam met toenemende sferoiddiameter, zonder dat er tekenen waren van 
radiobiologische hypoxic. Zuurstofspanning, gemeten met micro-electroden in sferoiden, 
gaven waarden aan die laag genoeg waren voor het bestaan van radiobiologisch 
hypoxische cellen. De hypothese wordt gepostuleerd dat andere factoren dan zuurstof 
alleen de stralingsgevoeligheid beïnvloeden van sferoiden van verschillende diameter. 
Reoxygenatie na bestraling, een van de fundamentele radiobiologische processen die 
beschreven zijn in de literatuur voor sferoiden van muize cellijnen, werden niet 
waargenomen in húmeme sferoiden wanneer zuurstofspanning werd gemeten met micro-
electroden. Dit toont dat ofwel reoxygenatie een radiobiologisch proces is dat niet met 
micro-electroden kan worden gemeten, of dat een toename in zuurstofspanning niet mag 
worden verwacht na bestraling van sferoiden. 
De experimenten waarbij zuurstofspanningen in sferoiden werden gemeten tonen aan 
dat het noodzakelijk is dat er meer dergelijke studies worden verricht met humane 
sferoiden om de gerezen vragen afdoende te beantwoorden. 
In conclusie, de diverse experimenten beschreven in dit proefschrift, tonen aan dat 
multicellulaire sferoiden van humane tumorcellijnen gebruikt kunnen worden als een in 
vj'iro-model voor therapie van humane tumoren. 
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Stellingen bij bet proefschrift 'Multicellular spheroids of human tumor 
cells as an in vitro model for treatment responses of human tumors' door 
J.H.M. Schwachöfer, Nijmegen, 19 november 1991. 
1) Sferoiden kunnen een belangrijke bijdrage leveren aan de 
vermindering van het aantal gebruikte proefdieren in het 
kankeronderzoek. 
2) Herstel van sublethale schade verklaart niet de verschillende 
stralingsgevoeligheid van humane tumor sferoiden. 
3) De mate waarin de intrinsieke herstelcapaciteit van sublethale schade 
in humane tumor sferoiden tot expressie komt wordt bepaald door 
externe factoren. 
4) Split-dose experimenten geven in sferoiden in gelijke mate een indmk 
weer van sublethale schade herstel als fractioneringsexperimenten. 
5) Een voor de patiënt optimale combinatie van radio- en chemotherapie 
zal zich slecht laten inpassen in de bestaande werktijden van een 
afdeling radiotherapie. 
6) Als je een interessante vraagstelling hebt, moet de eerste vraag zijn of 
je over de materialen beschikt waarmee redelijkerwijs een resultaat 
verwacht mag worden. A. Querido, 1962. 
7) De afhankelijkheid die ziekenhuizen opbouwen door apparatuur en 
voeding te laten sponsoren door het bedrijfsleven beperkt de 
keuzemogelijkheden van de patiënten. 
8) Een dankwoord is niet in staat tot uitdrukking te brengen hoe groot de 
bijdrage van de partner van de promovendus is in het tot stand komen 
van het proefschrift. 
9) Een promotie lijkt meer een stressbestendigheidstest dan een proeve 
van wetenschappelijke kunde. 
10) Men zou aanzienlijk op de kosten van een promotie kunnen besparen 
indien men zou toestaan dat proefschriften niet als boekwerk maar als 
computerprints worden geaccepteerd. 
11) De opvang van ouders na het overlijden van hun baby is sterk voor 
verbetering vatbaar. 
12) Education has produced a vast population able to read, but unable to 
distinguish what is worth reading. CM. Trevelyan, 1876-1961. 



